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ABSTRACT 
Proteins and RNA are the only known biopolymers that have catalytic roles in 
nature, whereas DNA is primarily considered to store and transfer genetic information. 
However, artificial single-stranded DNA has been identified by in vitro selection to 
catalyze several chemical reactions and several of those are of biological relevance. For 
in vitro selection or directed evolution of proteins, direct amplification is not possible, 
and it essential to attach the genotype to the phenotype. For nucleic acids however, the 
functional biopolymer can be readily amplified. DNA has the advantage of being directly 
amplified by polymerases, whereas RNA requires an additional reverse transcription step. 
Moreover, DNA catalysts identified by in vitro selection processes have shown similar 
catalytic proficiency as RNA. DNA has added advantages of low cost of chemical 
synthesis and higher stability. Considering these factors combined, identification of 
artificial DNA catalysts (deoxyribozymes) for chemical reactions is a valuable endeavor 
with long-term implications.  
Protein post-translational modifications (PTMs) are highly important in biological 
processes involving cellular regulation. Additionally, PTMs serve as important 
intermediates or key motifs on natural products and bioactive peptides. The natural 
protein enzymes carrying out the essential modifications may have several shortcomings 
for biotechnological use. Identification of artificial DNA catalysts with ability to perform 
chemoselective post-translation chemical reaction would be highly useful in studying 
biological regulatory processes, performing synthesis and late-stage diversification of 
post-translationally modified peptides, as well as carrying out other important functions 
that natural proteins may not readily solve.  
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My first effort was to identify DNA enzymes with peptide/protein phosphatase 
activity, more specifically dephosphorylation of peptide side chains. Without a catalyst, 
phosphomonoester hydrolysis reactions have exceedingly low spontaneous reaction rates. 
Nature utilizes proficient protein enzymes to perform this challenging reaction with great 
efficiency. Using a known DNA catalyst for the in vitro selection process, new DNA 
catalysts were identified with phosphatase activity. The phosphatase DNA catalysts 
exhibited multiple-turnover activity with phosphotyrosine-containing free peptides and 
were active even in the presence of externally added cell lysate or bovine serum albumin 
(BSA). Furthermore, the best DNA phosphatase functioned with a larger protein 
substrate. This established the fundamental ability of DNA to catalyze dephosphorylation 
of amino acid side chain residues. The study also suggested that phosphatase DNA 
catalysts could perform intracellular phosphatase activity. Hence, these deoxyribozymes 
were functionalized on gold nanoparticles and delivered inside live mammalian cells to 
investigate if they behave as functional protein analogues (or mimics) of recombinantly 
expressed Protein Tyrosine Phosphatase (PTP1B). Separately, efforts were directed 
towards the important goal of identifying sequence-selective phosphatase 
deoxyribozymes. Although three separate efforts were directed towards identifying 
sequence-selective phosphatases deoxyribozymes, we were unsuccessful in 
accomplishing this specific goal of selectivity in the context of peptide sequence 
discrimination. 
Dehydroalanine (Dha) is a non-proteinogenic electrophilic amino acid that serves 
as a synthetic intermediate or product in the biosynthesis of several bioactive cyclic 
peptides such as lantibiotics, thiopeptides and microcystins. DNA enzymes were 
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identified to establish the fundamental catalytic ability to eliminate phosphate from 
phosphoserine (pSer) to form Dha, namely phosphoserine lyase activity. Furthermore, 
DhaDz1 was utilized to achieve chemo-enzymatic synthesis of a cyclic cystathionine-
containing peptide. Based on this initial success, future efforts will be directed to achieve 
sequence-general phosphoserine and phosphotyrosine lyase activity. Separately, 
application of sequence-general lyases in the synthesis of complex lanthipeptides and 
enrichment of phosphopeptides/proteins in phosphoproteomics will be explored.  
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Chapter 1: Introduction to Enzymatic Catalysis and Applications 
1.1 Enzyme Rate Enhancements 
Biologically relevant chemical reactions have extremely slow spontaneous 
reaction rates, including exceedingly high half-lives. The sluggishness typically arises 
because chemical reactions necessitate formation of unfavorable transition states with 
unusual buildup of positive or negative charges. Reactions also require atoms and 
molecules to be brought together in a specific orientation that are often entropically 
unfavorable. However, enzymes achieve tremendous rate enhancements by performing 
these challenging reactions with high rates, chemoselectivity, and stereospecificity. This 
section briefly reviews how nature achieves high rate enhancements or accelerations. 
1.1.1 Proximity and Orientation  
Entropy reduction is a key feature of enzymes. The enzymes bring their substrates 
in a proper spatial orientation for catalysis by minimizing the relative translational and 
rotational motions. More specifically in cases involving ligation-like reactions, enzymes 
provide high effective molarity. Jencks initially proposed that entropy is a major 
contributing factor for high rate accelerations in enzymatic reactions.1 However, Bruice 
later proposed that improvement in rate enhancements arise mainly from enthalpic (∆H) 
rather than entropic (T∆S) contributions, with experimental evidence supporting the 
Nearest Active Conformation theory (NAC).2 Conformational restriction (or NAC) is 
primarily determined by enthalpy, and the contribution of entropy to catalysis was 
originally overestimated.3 Enzymes can present different activated precursors to close 
proximity to improve the reaction rates, but true catalysis is attributed to enthalpy.  
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1.1.2 Electrostatics  
Desolvation occurs when the substrate binds to the enzyme. This may lead to 
change in the local dielectric constant, which in turn increases the electrostatic 
interactions in the active site. Furthermore, certain enzymes may create a protective 
pocket to shield the reactive groups from water to prevent formation of unwanted side 
products. If water itself is a secondary substrate, as in the case of hydrolysis reactions, a 
specific water molecule has to be held in the active site. In all such cases, enzyme has to 
provide substantial electrostatic stabilization for stripping and shielding the substrates/TS 
or the intermediates from the solvent. Electrostatic effects are established to be one of the 
largest contributors of catalysis.4 Charged transition states are stabilized by active-site 
residues in enzymes forming ionic bonds. The stabilization usually come from acidic or 
basic side chains found on the amino acids (lysine, glutamic acid, aspartic acid, arginine) 
or from the metal cofactors such as magnesium or zinc.5 
1.1.3 Catalysis by Preferential Transition State Binding  
Enzymes may have a preferential affinity for the TS over the substrates or the 
products. Earlier known as “strain and distortion”, preferential binding the TS leads to 
fast reaction rates. The enzyme leads to reduction in the free energy of the TS and 
catalysis is achieved. The concept for TS stabilization was initially called strain because 
it was theorized that enzymes strongly restrain the substrate in a specific transition state 
conformation to enable catalysis. However, theoretical studies predict that enzymes are 
too flexible to force conformational strains on the substrates.6 Binding of substrates to the 
enzymes by itself does not lead to better catalysis. The more likely scenario is for the 
enzyme to achieve an induced fit to enable catalysis.7 This concept of catalysis by 
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preferential transition-state binding has been utilized in two major fields; namely 
transition-state inhibitors and catalytic antibodies.  
Transition-state analogues are designed on the premise that they bind stronger to 
enzymes than the actual substrates themselves. Pharmaceutical and medicinal chemists 
have capitalized on this concept by studying transition states using kinetic isotope effects 
(KIE) and computational simulations. Some successful examples involve design of 
methylthioadenosine nucleosidase,8 thermolysin,9 and arginase transition-state 
analogues.10 (Figure 1.1) 
 
Figure 1.1. Transition-state mimics or analogues are successfully used to inhibit enzymes, suggesting that 
enzymes often have preferential binding affinity for transition states over the substrates or the products. 
Examples of inhibitors designed as analogues of transition states or intermediates for a few enzymes are 
listed here. A) Methylthioadenosine nucleosidase inhibitor.8 B) Thermolysin inhibitor.9 C) Arginase 
inhibitor.10 
Separately, Schultz developed catalytic antibodies and abzymes that strongly rely 
on transition-state analogues. Antigens are designed to resemble transition states of 
known chemical reactions. These antigens are used as haptens to develop antibodies that 
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tightly bind to the transition states. The resulting antibodies are then used as catalysts for 
chemical reactions.11 Catalytic antibodies have been explored for therapeutic potential in 
combating weight gain and drug addiction, treating microbial infections, and curing 
genetic diseases. Separately, abzymes have also been utilized for non-therapeutic 
applications such as Diels-Alder reaction and oxidation of water.12-13  
1.1.4 Acid-Base Catalysis 
In several enzymatic reactions such as hydrolysis of peptides/esters, nucleophilic 
addition on carbonyls and phosphoryl transfer reactions, general acid-base catalysis are 
involved. Formation of charged intermediate in chemical reactions is unfavorable and this 
leads to high free energies of the TS. Enzymes can appropriately donate or accept protons 
to enable catalysis.14 Proteins have several amino acid side chains that function as general 
acid/base catalysts such as imidazoles, amines, carboxyls, thiols, aliphatic/aromatic 
hydroxyls, and guanidines ( from arginine) (Figure 1.2). pH can affect the protonation 
state of the enzyme functional groups. pH of the solution also strongly affects the 
catalytic proficiency of the enzymes that function with acid-base catalytic mechanism. 
When both protonation and deprotonation occur synchronously, then the process is called 
concerted acid-base catalysis.  
5 
 
 
Figure 1.2. Protein side chains have functional groups that are capable of general acid-base catalysis. The 
amino acids shown here are typically found at protein enzyme active sites. Their pKa‘s of these amino acids 
are listed as well. 
1.1.5 Metal Ion Catalysis 
Metal ions are often engaged in enzymatic catalysis. They can be used for binding 
and orienting the substrates (such as metal-bound water), assisting with oxidation-
reduction, or electrostatically shielding negative charges. Metalloenzymes usually contain 
tightly bound metal ions at the active site to achieve catalysis (strong Kd).
15 In cases 
where metal ions are loosely bound, the enzymes are called metal-activated enzymes. 
Metal-organic compounds like heme may merely function as prosthetic or signaling 
groups.16 Enzymes such as phosphatases utilize metal-bound hydroxide for attacking the 
phosphomonoester, which lowers the pKa of water.
17 Metalloproteases use metals to 
stabilize the negative charge formed in the tetrahedral oxyanion intermediates.18 
1.2 Nucleic Acid Catalysts  
Until the 1980s, it was thought that nature exclusively used proteins to perform 
catalysis. However, in the 1980s Thomas Cech and Sidney Altman independently 
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discovered that RNA (polymer of ribonucleotides) are enzymatic.19 Following this 
discovery, Breaker and Joyce identified a single-stranded DNA catalyst to cleave RNA.20  
1.2.1 Ribozymes 
RNA molecules that catalyze specific biochemical reactions are called ribozymes 
(ribonucleic acid enzymes). Ribozymes are found in nature or can be artificially 
developed by in vitro selection. Some of the chemical reactions catalyzed by ribozymes 
are DNA/RNA cleavage, DNA/RNA ligation and peptide bond formation.5 In ribosomal 
protein synthesis, ribosomal RNA is a major catalytic subunit that is used to link the 
specific amino acid residues. Ribozymes also perform a variety of important biological 
functions such as RNA splicing, viral replication and tRNA biosynthesis.  
RNA has received a lot of focus in the field of “origin of life”. Ribozymes have 
been discovered in laboratory that can catalyze their own synthesis (self-replication) from 
activated monomers using RNA as the template.21 Further improvements have been made 
to this ribozyme to add up to 20 nucleotides to a primer template.22 Holliger and co-
workers identified ribozyme-catalyzed transcription of an active ribozyme.23  
Several natural ribozymes have been established. RNase P was first identified by Sidney 
Altman. In an independent effort, Thomas Cech identified group I intron. Both Altman 
and Cech were awarded Nobel Prize for their discovery. Since then, other ribozymes 
have been identified that include group II self-splicing intron, hairpin ribozyme, 
hammerhead ribozyme, GIR1 branching ribozyme, glmS ribozyme, HDV ribozyme, 
twister family ribozyme, and VS ribozyme.19  
Artificial ribozymes have received substantial attention as potential therapeutic 
agents. RNA sequences have been targeted for sequence-specific cleavage.24 Another 
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popular application includes biosensing.25 RNA-based enzymes however have low 
stability (easily degraded both in vitro and in vivo), which is a major challenge in 
ribozyme therapy. Ribozymes have been explored as oligonucleotide therapeutics to 
target HIV RNA gene,26 and hepatitis C viral RNA.27 
1.2.2 Deoxyribozymes 
DNA molecules that catalyze specific biochemical reactions are called 
deoxyribozymes (deoxyribonucleic acid enzymes). As of 2016, no natural DNA 
enzymes have been found in nature. DNA is widely regarded to store and carry genetic 
information. However, Breaker and Joyce identified the first artificial DNA catalyst to 
cleave a rA substrate embedded in a DNA.20 Some of the DNA-catalyzed reactions 
include transesterification of RNA, hydrolysis of DNA and RNA, DNA phosphorylation, 
DNA adenylation, and DNA deglycosylation.28 More recently, DNA catalysts have been 
identified to modify peptides and proteins.29  
1.2.3 Functional Groups in Nucleic Acids for Catalysis 
Proteins are armed with a diverse set of functional groups that enable general 
acid-base catalysis. As mentioned earlier, proteins also have functional groups like 
amine, hydroxyls, thiols, and carboxylates that can have hard-hard or soft-soft 
interactions with metal cations resulting in either metal-assisted protein catalysis or 
metalloenzyme catalysis.  
Nucleic acids however have four nucleobases with primary or secondary 
heterocyclic (aryl) amines that have pKa values over 9, whereas the pKa  of protonated N7 
position of adenine/guanine and N3 position of cytosine is less than 4.30 The RNA 2′-OH 
is predicted to have pKa of the range 12.5-13 whereas DNA lacks any hydroxyl groups.
31 
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The phosphodiester pKa value lies close to 2 (Figure 1.3A). Additionally the 
phosphodiester is also known to have strong affinity with divalent metal cations like 
Mg2+.  
Although nucleic acids do not possess the necessary functional groups to match 
the catalytic repertoire of proteins, they do have substantial catalytic prowess. Initially, 
ribozymes were predicted to be obligatory metalloenzymes.32 However, biochemical and 
structural studies indicate that both ribozymes and deoxyribozymes are capable of 
performing general acid-base catalysis as well even with functional groups having pKa’s 
well outside the physiological pH range.33-35 (Figure 1.3B) 
 
Figure 1.3. A) pKa of functional groups found in nucleic acids are listed here. The green values represent 
protonated form of the nitrogen. B) Mechanistic evidence for general acid-base catalysis mediated by 
nucleobases in the hairpin ribozyme (figure from reference 35). 
1.3 DNA Catalysts 
DNA encompasses several features that make it an exceptional choice of 
biopolymer for performing in vitro selection to identify and discover new biocatalysts. 
DNA is readily synthesized by solid-phase synthesis. Caruthers and co-workers 
developed phosphoramidite chemistry that is highly efficient in comparison to the 
iterative amide coupling chemistry. Because DNA lacks the 2′-OH group, additional 
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protection/deprotection strategies are not required unlike the case of RNA where silyl 
ether protection strategy is typically utilized for the 2′-OH group protection. Furthermore, 
DNA is less prone to degradation whereas RNA is readily broken down by RNases or 
acidic/basic conditions.  
A typical procedure for the identification of DNA catalysts begins with the 
synthesis of the DNA pool. This is achieved by solid-phase synthesis where nucleoside 
phosphoramidites (dA, dG, dC, dT) are mixed in a specific ratio to allow each nucleotide 
an equal coupling opportunity at every iterative synthetic step. DNA sequences with 
fixed length are synthesized. Fixed sequence portions flank the random nucleotide region 
at both the 5′ and 3′ ends. These fixed regions enable downstream PCR amplification. 
Substrates are covalently attached to the DNA sequences in the pool such that every 
sequence now has a covalently attached substrate. Metal cation cofactors are provided to 
enable the catalysis. Catalytically active DNA sequences perform chemical reaction on 
the covalently linked substrate. A chemoselective technique is required to separate and 
isolate the covalently attached product from the initial substrate. This chemoselective 
separation of the product in turn isolates the covalently attached catalytically active DNA 
sequence. This is typically done by a size-based separation using denaturing 
polyacrylamide gel electrophoresis (PAGE). PCR is utilized to amplify the catalytically 
active DNA. After iteratively performing this entire process over several rounds, active 
DNA sequences are enriched, screened, sequenced and characterized for catalysis. 
1.3.1 DNA-Templated Synthesis vs. DNA Catalysis 
DNA-templated synthesis (DTS) or nucleic acid-templated chemistry is a 
chemical technology developed by David Lynn and co-workers (further popularized by 
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David Liu) to achieved controlled synthesis of chemical compounds.36 Oligonucleotides 
are connected through chemical linkages to synthetic small-molecule precursors. These 
synthetic precursors are brought to close spatial proximity after the oligonucleotides are 
hybridized. Because of high effective molarity, the synthetic precursors react to form the 
product. The generality of DTS has been used as a basis for evolving non-natural small 
molecules,37 as well discovering an additional repertoire of chemical reactions among a 
wide range of substrates.36 In addition, DTS has also been used as a display technique to 
identify enzyme inhibitors.38,39 Szostak utilized templated-directed nucleic acid copying 
to provide hypotheses about origin of life.40  
It is important to note the important difference between true enzymatic rate 
enhancement and the rate increase achieved by high effective molarity. Classic 
experiments by Bruice suggest that true catalysis primarily have enthalpic than entropic 
contributions. NACs are not determined by brining synthetic precursors to proximity. 
This is more evident in cleavage reactions like phosphodiester, phosphomonoester and 
amide bond hydrolyses where water is the secondary substrate. In spite of water being in 
high abundance, 55 M, reaction does not occur without aid from an external catalyst or an 
enzyme. Even for reactions involving phosphorylation and DNA/RNA polymerization, 
saturating the reaction solution with high amount of secondary substrates such as NTPs 
or dNTPs need not necessarily accomplish a templated chemical reaction. Enzymes need 
to achieve improved reaction rates by providing high enthalpic contributions that DTS 
does not solve. Additionally, enzymes often perform unfavorable chemistry in the 
presence of other kinetically or thermodynamically favorable competing pathways. 
Although DTS increases reaction rate by bringing synthetic precursors to proximity, it is 
11 
 
important to draw the crucial distinction between true enzymatic catalysis by 
deoxyribozymes and DTS. 
1.3.2 Nucleic Acid vs. Non-nucleic Acid Substrates 
Previous selection processes to identify DNA (or RNA) catalysts were mainly 
directed towards chemical reactions encompassing nucleic acid substrates. Using such 
substrates for in vitro selection is a rational and conservative effort. Nucleic acid 
substrates have the propensity to engage in canonical and non-canonical base pairing with 
DNA/RNA oligonucleotides. Such interactions include Watson-Crick and wobble base 
pairs. Non-canonical interaction such as edge-to-edge base pairs are also predicted to be 
important for structural organization of the RNA/DNA molecules.41  
The first deoxyribozyme identified in 1994 cleaved a RNA linkage in a full DNA 
substrate. Following that, the Silverman laboratory has been one of the pioneers in 
developing DNA catalysts for different chemical reactions.28,29,42 One of such efforts was 
directed towards RNA ligation. DNA-catalyzed syntheses of linear and branched RNA 
have been successfully achieved.42 These DNA catalysts have been used in a few studies 
as important chemical biology tools.43-46 Additionally, DNA catalysts have also been 
identified for phosphodiester hydrolysis in both DNA and RNA.47,48 Even though 
phosphodiester hydrolysis has a half-life (t1/2) of approximately 30 million years, 
49 and 
kinetically favorable competing reactions such as RNA transesterification has a half-life 
of 10 years,50 DNA is capable of achieving site-specific phosphodiester hydrolysis 
(Figure 1.4).  
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Figure 1.4. Reactions catalyzed by DNA involving nucleic acid substrates. A) RNA ligation (figure from 
reference 29). B) Phosphodiester hydrolysis in RNA (figure from reference 42). 
More recently, efforts have been directed to identify DNA catalysts that modify 
peptides and small molecules (with non-nucleotide character). Extending DNA catalysis 
to small-molecule substrates with non-nucleotide character can be challenging because of 
the lack of Watson-Crick base pairing or zero potential to form canonical or non-
canonical interactions. However, DNA catalysis has been achieved with Diels-Alder 
reaction for efficient carbon-carbon bond formation.51 DNA also has the ability to 
catalyze covalent modification of protein side chains.52,53 Chemoselective modifications 
of peptide or protein side chains have tremendous biological implications that 
conventional chemical methods do not entirely solve. Fundamental ability of DNA 
catalysts to modify peptide side chains like tyrosine and serine has been established.53,54 
Hence efforts can be directed to seek DNA catalysts for other protein modifications. 
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Identifying DNA catalysts that perform cleavage reactions like protease activity, and 
post-translation modifications (PTMs) such as phosphatase, and kinase activities would 
be a huge advancement to the chemical and biological research. There is a major impetus 
to seek deoxyribozymes that function with non-nucleic acid substrates in addition to the 
conventional nucleic acid substrates. 
1.3.3 Phosphoryl Transfer Reactions 
Phosphoryl groups are constructs made of phosphoric acid. The conjugate base of 
phosphoric acid is an inorganic phosphate. Phosphoric acid has three acidic protons with 
pKa values of 2.1, 7.2 and 12.3. Organophosphates (esters of phosphoric acid) are highly 
prevalent in biological systems. Nucleic acids (DNA and RNA) are polymers of 
nucleotides connected by phosphodiester linkages. Phosphates are also prevalent in 
nature as organic monophosphates, glucose-6-phosphate, isopentenyl diphosphate, and 
nucleoside triphosphates. Phosphatases are also found on amino acid side chains as post-
translational modifications. In several chemical reactions involving phosphoryl transfer, 
metal cations like magnesium (Mg2+) are present to stabilize the negative charge on 
oxygen and make the phosphorous more electrophilic.55  
DNA catalysts have shown tremendous promise with phosphoryl transfer 
reactions. For instance, nucleoside triphosphate, triphosphorylated RNA or nucleoside 
cyclic phosphate have been used as electrophilic donors for ligation chemistry.42 
Substantial success has been achieved in phosphodiester hydrolysis and 
transesterification reactions.29 Furthermore, non-nucleotide substrates such as 
phosphopeptides can be tagged to RNA oligonucleotides using 5′-triphosphorylated RNA 
transcript as the electrophilic donors.56 DNA has had substantial success in catalyzing 
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reactions involving phosphoryl substrates. This earlier success is suggestive that the 
chances for identifying DNA catalysts with the ability to perform phosphoryl transfer or 
phosphorylation-dependent reactions are high, even for non-nucleotide substrates. 
1.4 Peptide/Protein Post-Translational Modifications 
Protein post-translational modifications (PTMs) are covalent modifications on 
amino acid side chains installed by enzymes following the synthesis of protein by the 
ribosome. Formally, any of the standard 20 amino acids in a protein that get modified 
following the ribosomal synthesis are considered to by post-translationally modified 
amino acids. Some of the common modifications include addition of phosphate, acetate, 
methyl group, lipid group, monosaccharide and oligosaccharides. PTMs play an 
important role in biology by modulating the function of several proteins. Some of such 
important functions include protein folding, stabilization, enzyme-cascade regulation, 
cellular localization and protein degradation.57  
1.4.1 Kinases and Phosphatases 
Protein phosphorylation is one of the most abundant PTMs. Phosphoserine, 
phosphothreonine and phosphotyrosine are some of the most extensively observed 
PTMs.57 Addition or removal of phosphates on peptide side chains are known to regulate 
cellular pathways, mainly those involved in signal transduction. Most kinases 
phosphorylate both serine and threonine whereas tyrosine-specific kinases function 
specifically on tyrosine. Dual-specificity kinases act on all three amino acids.58  
Conversely, phosphatases remove the phosphate group from the amino acid 
residue. Protein phosphatases are subdivided into groups based on their substrate 
specificity or requirement. They can be classified as tyrosine-specific phosphatases,59 
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serine/threonine-specific phosphatases,60 dual-specificity phosphatases,61 and histidine 
phosphatases.62 Chemically, phosphatase activity is a phosphoryl transfer reaction 
involving transfer of the phosphate from a peptidic side chain to an external water 
molecule.  
1.4.2 Phosphoserine Lyases 
Phosphorylated peptidic side chains such as phosphoserine (pSer) or 
phosphothreonine (pThr) can undergo a β-elimination of the phosphate, leading to 
formation of dehydroalanine (Dha) and dehydrobutyrine (Dhb) respectively. Dha and 
Dhb are rare electrophilic sites on peptide/protein side chains. In three specific classes of 
lantibiotic synthetases, serine/threonine are phosphorylated followed by a lyase activity 
that involves β-elimination of the phosphorylated residues.63 Separately, there are 
examples of pThr lyases that irreversibly inactivate the dual-phosphorylated host MAPKs 
through β-elimination leading to pathogenic activity.64 Although pSer/pThr lyase activity 
is a rare PTM, they are highly important both chemically and biologically.  
1.5 Thesis Research Focus 
This thesis focuses on my efforts to identify DNA catalysts for two important 
chemical reactions, phosphatase activity and phosphoserine lyase activity. Chapter 2 
focuses on catalytic DNA with phosphatase activity. A robust in vitro selection procedure 
was established to identify phosphatase deoxyribozymes. The starting material is a 
phosphorylated peptide and the product is the dephosphorylated hydroxyl group. A 
chemoselective method is required to separate the hydroxyl product, which is covalently 
linked to the active deoxyribozyme, from the inactive sequences connected to the 
phosphorylated starting material. This method of separating the active sequences is 
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formally called a capture method. A know deoxyribozyme forming nucleopeptide linkage 
with the dephosphorylated product was used as the chemoselective capture method. This 
capture method allowed for a size-based gel separation. Phosphatase deoxyribozymes 
were successfully identified. The DNA catalysts increase the reaction rate of 
phosphomonoester hydrolysis substantially, functioned with free phosphopeptides with 
multiple turnovers, were robust in the presence of cell lysate and externally added 
proteins, and functioned with larger protein substrates. 
Chapter 3 focuses on three different efforts to identify deoxyribozymes with 
sequence-selective phosphatase activity. The first effort involved using phosphopeptides 
with “extreme” (highly functionalized) biophysical/biochemical properties to encourage 
selectivity. In the second effort, competitive ligands were supplemented in buffer as an 
external selection process to inspire sequence selectivity. The third approach involved the 
use of reverse complement oligonucleotides to inhibit the sequence-general DNA 
catalysts. However, all three efforts failed to provide DNA enzymes with sequence 
selectivity. Chapter 4 focuses on efforts to deliver DNA enzymes inside live mammalian 
cells and establish intracellular phosphatase activity. LNCaP cells are known to 
differentiate to neuroendocrine cells when a known protein-tyrosine phosphatase, PTP1B, 
is overexpressed.65 We hope that phosphatase DNA catalysts can serve as a PTP1B 
mimic. 
Chapter 5 focuses on DNA catalysts with pSer lyase activity. In this effort, the 
substrate was a phosphoserine-containing hexapeptide. The final product Dha, a Michael-
like acceptor, was separated by addition of a thiol oligonucleotide to enable a size-based 
separation on denaturing polyacrylamide gel electrophoresis (PAGE), which was 
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subsequently enriched by PCR. DNA catalysts were successfully identified and applied in 
the chemoenzymatic synthesis of a cystathionine-containing cyclic peptide. The chapter 
also discusses additional efforts to identify sequence-general pSer/pThr lyase 
deoxyribozymes. Additionally, this chapter focuses on long-term applications of such 
deoxyribozymes in the synthesis of complex lanthipeptides and utility in 
phosphoproteomics. 
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Chapter 2: Catalytic DNA with Phosphatase Activity
1
 
2.1 Introduction 
In this chapter, catalytic DNA with phosphatase activity is discussed. Phosphatase 
reaction is hydrolysis of the phosphomonoester bond by an external water molecule to 
release the hydroxyl group and an inorganic phosphate. Phosphatase activity is discussed 
in the context of two phosphorylated amino acid side chains, phosphotyrosine (YP) and 
phosphoserine (SP). Development of catalysts is a major impetus for much of modern 
chemical research. Nature’s biomolecular protein and RNA catalysts are responsible for a 
wide range of chemical reactions, and protein enzymes in particular can achieve large 
rate enhancements.1 Although DNA catalysts are unknown in nature, in vitro selection 
(first pioneered for RNA)2 is readily applied to identify catalytically active artificial DNA 
sequences.3-4 Importantly, DNA (and RNA) catalysts can be identified by starting with 
entirely random sequence pools, whereas directed evolution of proteins typically requires 
a known, catalytically active starting point.5-6 A growing range of chemical reactions has 
been shown to be catalyzed by DNA.7 For DNA phosphodiester hydrolysis, the 
uncatalyzed (spontaneous) half-life for P–O bond cleavage of ~30 million years is 
reduced to as little as 0.5 min by a DNA catalyst.8,9 However, in this reaction the DNA 
catalyst interacts with its DNA substrate by extensive Watson-Crick base pairing, and 
such an approach cannot be generalized to non-oligonucleotide substrates such as 
peptides and proteins. With the exception of the ribosome, the natural ribozymes catalyze 
                                                 
 
 
1
 This research has been published: Chandrasekar, J.; Silverman, S. K. Catalytic DNA with phosphatase 
activity. Proc. Natl. Acad. Sci. USA 2013, 110, 5315-5320. 
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RNA cleavage and ligation, and they generally have more modest rate enhancements,10-12 
limited in part by the relatively high uncatalyzed half-lives of these reactions.  
2.1.1 Mechanism and Role of Protein Phosphatases 
Natural protein phosphatases13-14 function either by a double-displacement 
mechanism (cysteine-dependent phosphatases15-16 and haloacid dehalogenase (HAD) 
superfamily aspartate-dependent phosphatases17-19) or via direct metal-bound water attack 
using cofactors such as Mn2+ and Fe2+ (Figure 2.1).20 Both phosphomonoester dianion21 
and monoanion22-23 substrates have been implicated.24  
 
Figure 2.1. Catalytic mechanism of natural protein phosphatases. A) Protein-tyrosine phosphatase PTP1B. 
B) Direct metal-bound water attack using cofactors such as Mn2+ and Fe2+. C) Haloacid dehalogenase 
(HAD) superfamily aspartate-dependent phosphatases (figure from reference 17). 
2.1.2 Capture Strategy to Identify DNA Catalysts 
To identify DNA catalysts with (peptide/protein) phosphatase activity, we need to 
achieve chemoselective isolation of the product (dephosphorylated tyrosine or serine) 
from the initially phosphorylated starting material. As discussed in chapter 1, this 
separation of product (attached to active DNA) from the starting material (attached to the 
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inactive DNA pool) is formally called a capture reaction. An ideal capture reaction would 
involve a clean size-based separation of the desirable components by denaturing 
polyacrylamide gel electrophoresis (PAGE). 
The capture strategy has to be amenable to a typical in vitro selection pipeline. To 
enable size-based PAGE separation of the product, it is necessary to attach a secondary 
tag on tyrosine-OH or serine-OH product, but not YP or SP. Few chemical or enzymatic 
options exist for such chemoselective separation of Y from YP (Figure 2.2). A) Tyrosine 
alkylation using π-allylpalladium complexes.25 B) Tyrosine conjugation through an 
aqueous ene-type reaction.26 C) Deoxyribozyme that forms a nucleopeptide linkage of 
tyrosine with a 5′-triphosphorylated RNA.3 The enzymatic technique using a DNA 
catalyst forming nucleopeptide linkage with tyrosine-OH group is the most promising 
approach amenable to a typical in vitro selection procedure. 
 
Figure 2.2. Chemical and enzymatic techniques to attach chemoselective tag to tyrosine (YOH) and not 
phosphotyrosine (YP). A) Pd-based technique developed by Francis and co-workers.25 B) Aqueous-ene 
method developed by Barbas and co-workers.26 C) DNA catalyst utilized for tyrosine nucleopeptide 
conjugation developed by the Silverman laboratory (figure from reference 3). 
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2.1.3 Capture Strategy for Phosphoserine Modification 
Analogous chemoselective conjugation techniques are required to isolate Serine 
from SP. Chemical oxidation of N-terminal serine to an aldehyde using periodate 
oxidation followed by capture of the resulting electrophilic aldehyde is a well-known bio-
conjugation technique.27 DNA catalysts have also been identified to perform 
nucleopeptide linkage with an internal serine-OH embedded in a tripeptide (Figure 2.3).7 
However, it should be noted that phosphatase DNA catalysts identified by N-terminal 
serine oxidation may have limited utility. Phosphatase deoxyribozymes identified from 
such selection may be programmed to function merely with N-terminal phosphoserine 
instead of an internal phosphoserine. DNA catalysts with nucleopeptide-linkage forming 
ability with an internal serine-OH group would be the ideal choice for serine capture. 
 
Figure 2.3. Techniques to capture dephosphorylated serine SOH. A) Capture step involves oxidation of the 
N-terminal serine using sodium periodate. The resulting aldehyde is capture as a hydrazone using a 
hydrazide DNA. B) DNA catalyst is used to perform nucleopeptide linkage on the dephosphorylated serine.  
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2.2 Results 
DNA catalysts that covalently modify peptide and protein substrates are 
fundamentally interesting and have likely practical value, especially for biologically 
relevant chemical modifications. We have initiated studies into DNA-catalyzed 
modifications of amino acid side chains of peptide substrates, such as nucleopeptide 
linkage formation involving tyrosine and serine. 7, 28-29 A major challenge in such studies 
is to achieve catalysis even though the DNA catalyst cannot engage in any 
preprogrammable Watson-Crick binding interactions with the substrate. In this chapter, it 
is shown that DNA can catalyze Zn2+-dependent hydrolysis of tyrosine and serine 
phosphomonoesters of peptide substrates, i.e., have phosphatase activity. The half-life for 
spontaneous phosphoserine hydrolysis at ~37 °C is approximately 4 × 1010 years as 
estimated on the basis of the half-life for methyl phosphate dianion,13 which emphasizes 
the difficulty of catalyzing this reaction. 
2.2.1 Design for Serine and Tyrosine Capture 
The selection strategy requires a capture enzyme to separate the active DNA 
sequences from the inactive ones. Several DNA enzymes are capable of forming 
nucleopeptide linkage with tyrosine or serine and 5′-triphosphorylated RNA.29 These 
deoxyribozymes were tested for the “capture” purpose. Hexapeptide substrates 
AAAYPAA and AAASPAA that incorporate internal phosphoserine (SP) or 
phosphotyrosine (YP) were appended to a DNA anchor oligonucleotide (as discussed in 
Materials and Methods). 
Among deoxyribozymes 15MZ30, 15MZ36, 15MZ49, 9NG14, 10KC3, and 
11MN5, 15MZ36 was determined to have the best capture yield with the DNA-anchored 
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hexapeptide AAAYPAA (~65-70%). However, for the serine-containing peptide 
AAASPAA, the capture yield was relatively weak (~10%). The yield was substantially 
low to be useful as a capture method for serine phosphatase selections. Hence, 
reselections were performed to identify capture deoxyribozymes for AAASPAA. 
For selections involving AAAYPAA, we aimed to utilize Mg2+, Mn2+, and Zn2+ 
(40 mM, 20 mM and 1 mM respectively) as the metal cation co-factors. Previous efforts 
with DNA hydrolysis selections strongly suggested that Zn2+ plays an important role in 
phosphodiester hydrolysis.8,9 We hypothesized that Zn2+ would most likely be an 
important co-factor in phosphomonoester hydrolysis (phosphatase activity). When the 
capture reaction with 15MZ36 was tested in the presence of Zn2+, the nucleopeptide 
linkage yield dropped from ~70% to 35%. Zn2+ was determined to be a poisoning 
cofactor for the capture enzyme 15MZ36. Using 15MZ36 directly after the selection step 
(containing 1 mM Zn2+) would lead to a sub-optimal capture yield (even if phosphatase 
activity were to require Zn2+). To address this situation, all divalent metal cations 
(Mg/Mn/Zn) were removed by ethanol precipitation before the capture step. This was 
immediately followed by addition of 15MZ36, 5′-triphosphorylated RNA, and fresh 
Mg2+/Mn2+ co-factors for the capture reaction. However, this procedure is time 
consuming with the possibility of precipitation errors. Noting that Zn2+ has the highest 
affinity to EDTA in comparison to either Mg2+ or Mn2+, 2 equivalents of EDTA were 
added to selectively chelate the 1mM Zn2+. Without any precipitation, the 15MZ36 
enzyme and the 5′-triphosphorylated RNA were added to the reaction mixture (see 
Materials and Methods for capture details). The capture yield for this chelation procedure 
was similar to the precipitation technique (Figure 2.4). Because the selective chelation 
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was a more time efficient procedure, we used this modified capture method for the in 
vitro selection procedure.  
 
Figure 2.4. Capture yield of nucleopeptide linkage with a 5′-triphosphorylated RNA using 15MZ36.  
A) Blue filled circle, AAAYOHAA capture after precipitation and adding fresh Mg/Mn. B) Red filled 
triangle, capture after selective chelation of Zn2+ using 2 eq. of EDTA. C) Red open triangle, AAAYPAA 
capture after selective chelation with 15MZ36. 
2.2.2 In Vitro Selection Process for Phosphotyrosine 
Our strategy to identify phosphatase deoxyribozymes by in vitro selection has key 
steps depicted in Figure 2.5. A hexapeptide substrate AAAYPAA that incorporates an 
internal phosphotyrosine (YP) residue was covalently appended to a DNA anchor 
oligonucleotide (Figure 2.6), which was itself ligated to the deoxyribozyme pool. After 
each key selection step that used incubation conditions of 70 mM HEPES, pH 7.5, 1 mM 
ZnCl2, 20 mM MnCl2, 40 mM MgCl2, and 150 mM NaCl at 37 °C for 14 h, active DNA 
catalyst sequences were “captured” with the aid of the 15MZ36 deoxyribozyme that 
selectively uses dephosphorylated tyrosine (YOH) as the nucleophile to attack 5′-
triphosphorylated RNA, resulting in a PAGE shift for the corresponding deoxyribozyme 
sequence (Figure 2.7). 30 The active DNA sequences were amplified by PCR and joined 
by T4 DNA ligase to the DNA-anchored hexapeptide substrate for entering the next 
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selection round. After 14 rounds of selection, the phosphatase activity of the DNA pool 
reached 35% (Figure 2.8), and individual deoxyribozymes were cloned and characterized. 
 
Figure 2.5. In vitro selection strategy to identify DNA catalysts with phosphatase activity. Illustrated are 
the key selection and capture steps of each round. Each final deoxyribozyme has 40 particular nucleotides 
in its originally random N40 region. The covalent loop on the left side (dashed) was required for the 
selection process but was dispensable for catalysis by individual deoxyribozymes. The loop was absent for 
all assays of individual deoxyribozymes. 
 
Figure 2.6. Synthesis of DNA-anchored hexapeptides. A) Synthesis by attachment of the DNA anchor to 
the N-terminal α-amino group, with the linkage created by reductive amination. B) Synthesis by attachment 
of the DNA anchor to the N-terminal cysteine side chain, with the linkage created by disulfide formation. 
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Figure 2.7. Validating use of the 15MZ36 deoxyribozyme for capture of catalytically active DNA 
sequences that have dephosphorylated the YP residue of their covalently attached AAAYPAA hexapeptide 
substrate. A) Illustration of the 15MZ36-catalyzed capture reaction to attach the 5′-triphosphorylated RNA 
to the dephosphorylated AAAYOHAA substrate. Note that the substrate molecule is physically connected to 
the deoxyribozyme sequence that catalyzed its dephosphorylation (denoted as N40). The 15MZ36 catalytic 
region (41 nt) is 5′-CAAGGAGAGTTGTACAAGCTCGGGTCGTGTTCAAAGGGATC-3′. 29 B) PAGE image, illustrating 
selectivity for AAAYOHAA over AAAYPAA of the 15MZ36-catalyzed capture reaction. t = 30 s, 5 min, 10 
min, 15 min, 30 min, 1 h, 2 h, 4 h, 12 h. The open arrowhead marks the reactant, and the filled arrowhead 
marks the product. Incubation conditions: 50 mM HEPES, pH 7.5, 20 mM MnCl2, 40 mM MgCl2, 100 mM 
NaCl, 37 °C. C) Kinetic plot to quantify the PAGE image. 
 
Figure 2.8. Progression of the in vitro selection experiment. In each round, “control” refers to the yield for 
the 15MZ36-catalyzed capture reaction using the DNA-anchored dephosphorylated AAAYOHAA substrate, 
and “selection” refers to the yield for the 15MZ36-catalyzed capture reaction using the deoxyribozyme 
pool for that round. Round 1 pool yield was not measured because the pool was not radiolabeled. 
Five distinct deoxyribozyme sequences were identified (Figure 2.9). Of these five 
DNA catalysts, one — named 14WM9 — had substantial phosphatase activity not only 
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with the initially used YP hexapeptide that is connected rather closely to the DNA anchor 
oligonucleotide, but also with a YP hexapeptide that is attached to the DNA anchor 
through a PEG-type tether that includes 60 ethylene glycol units. The distinct 14WM27 
deoxyribozyme also showed a small amount of activity with the PEG-linked YP 
hexapeptide. We focused our attention primarily on 14WM9, because its substantial 
activity with the PEG-tethered hexapeptide suggested the possibility of catalysis with 
entirely free peptides as well. 
 
Figure 2.9. Sequences of the new phosphatase deoxyribozymes. Only the enzyme region (N40) sequences 
are shown. For single-turnover intramolecular (in cis) reactions, each enzyme region was surrounded by 
additional DNA nucleotides as shown in Figure 2.7A. For multiple-turnover intermolecular (in trans) 
reactions, each enzyme region was surrounded by the two single-stranded binding arms (each 16 nt) as 
shown in Figure 2.7A. 
2.2.3 Single-Turnover Dephosphorylation by the 14WM9 Deoxyribozyme 
We found that 14WM9 catalyzes Zn2+-dependent single-turnover 
dephosphorylation of both phosphotyrosine (YP) and phosphoserine (SP) in DNA-
anchored hexapeptide substrates (Figure 2.10). The substrates were the same as those 
used during the selection process, but now the DNA-anchored hexapeptide was not 
covalently attached to the deoxyribozyme (the dashed loop on the far left side of Figure 
2.5 was absent). The identities of the phosphorylated and dephosphorylated DNA-
anchored hexapeptides (i.e., substrates and products) were verified by MALDI mass 
spectrometry analysis directly from the DNA-catalyzed reaction samples (all [M–H]–: YP 
substrate m/z calcd. 6705.6, found 6708.3, ∆ = +0.04%; YOH product m/z calcd. 6625.6, 
found 6628.0, ∆ = +0.04%; SP substrate m/z calcd. 6629.5, found 6633.6, ∆ = +0.06%; 
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SOH product m/z calcd. 6549.5, found 6554.3, ∆ = +0.07%). Mass spectrometry was also 
used to verify the identities of separately synthesized standards (Table 2.1). 
 
Figure 2.10. Single-turnover assays of the 14WM9 deoxyribozyme that dephosphorylates phosphotyrosine 
and phosphoserine side chains. A) PAGE assays of the 14WM9-catalyzed reactions, using DNA-anchored 
hexapeptide substrates and showing representative timepoints. The open arrowhead marks the 
phosphopeptide substrate; the filled arrowhead marks the dephosphorylated product. Each hexapeptide 
substrate was joined via its N-terminal Ala residue to the 3′-end of the DNA anchor by reductive amination. 
Assay conditions: 1 µM 14WM9, 12.5 nM 5′-32P-radiolabeled DNA-anchored hexapeptide, 70 mM 
HEPES, pH 7.5, 1 mM ZnCl2, 20 mM MnCl2, 40 mM MgCl2, and 150 mM NaCl at 37 °C. In the assays 
with Zn2+ alone, the Mn2+ and Mg2+ were omitted. Timepoints for YP substrate: 10 s, 1 min, 5 min, 1 h. 
Timepoints for SP substrate: 30 s, 15 min, 2 h, 12 h. B) Kinetic plots for the assays. The negative controls 
without deoxyribozyme or without Zn2+ all showed no detectable dephosphorylation activity (<0.5%). 
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Table 2.1. MALDI mass spectrometry data for DNA-anchored peptide standards. The DNA was either 
5′-GGATAATACGACTCACTAT-rA-3′ (for peptides with N-terminal Ala anchored by reductive amination; 
the rA was oxidized by NaIO4) or 5′-GGATAATACGACTCACTAT-C3-SS-C3-OH-3′ (for peptides with N-
terminal Cys anchored by disulfide bond formation; the disulfide linker was reduced by DTT). The HEG 
linker was hexa(ethylene glycol) as illustrated in Figure 4. The PEG linker was 10 consecutive HEG 
linkers. 
DNA-anchored 
peptide 
mass 
calcd. 
mass 
found 
error, % 
(found – calcd.) 
DNA-AAAY
P
AA 6705.6 6703.7 
a
 –0.03 
DNA-AAAY
OH
AA 6625.6 6625.3 
a
 –0.01 
DNA-AAAS
P
AA 6629.5 6627.2 
a
 –0.03 
DNA-AAAS
OH
AA 6549.5 6547.6 
a
 –0.03 
DNA-C3-CAAY
P
AA 6636.7 6637.2 +0.01 
DNA-HEG-CAAY
P
AA 6980.9 6977.9 –0.04 
DNA-HEG-CAAY
OH
AA 6901.0 6902.5 +0.02 
DNA-HEG-CAAS
P
AA 6904.8  6897.5 –0.11 
DNA-HEG-CAAS
OH
AA 6824.9 6825.5 +0.01 
DNA-HEG-CY
P
A 6767.7 6771.3 +0.05 
DNA-HEG-CS
P
A 6691.6 6693.8 +0.03 
DNA-HEG-CY
P
 6696.6 6697.5 +0.01 
DNA-HEG-CS
P
 6620.5 6618.9 –0.02 
DNA-HEG-CAFY
P
AA 7057.0 7059.9 +0.04 
DNA-HEG-CAEY
P
AA 7039.0 7040.6 +0.02 
DNA-HEG-CAKY
P
AA 7038.0 7039.2 +0.02 
DNA-HEG-CAAY
P
FA 7057.0 7057.7 +0.01 
DNA-HEG-CAAY
P
EA 7039.0 7039.8 +0.01 
DNA-HEG-CAAY
P
KA 7038.0 7038.5 +0.01 
DNA-PEG-CAAY
P
AA 10079.8 10080.4 +0.01 
DNA-C3-S
P
AAAAC 6518.6 6512.3 -0.10 
 
a The found values for these DNA-anchored peptides were observed by MALDI MS analysis directly from 
the DNA-catalyzed reaction samples, rather than by using separately synthesized standard samples as 
tabulated here. 
Substantial catalytic activity of 14WM9 with the YP substrate was observed not 
only using the initial selection conditions that included each of 1 mM Zn2+, 20 mM Mn2+, 
and 40 mM Mg2+ at pH 7.5 and 37 °C (single-turnover kobs = 0.65 ± 0.05 min
–1; n = 3), 
but also with 1 mM Zn2+ alone, albeit with 3-fold reduction in rate constant 
(kobs = 0.19 ± 0.03 min
–1; n = 3). Activity with the SP substrate was observed with Zn2+ in 
the presence or absence of Mn2+ and Mg2+, again with about 3-fold difference in rate 
constant (kobs = 0.79 ± 0.15 h
–1 and 0.31 ± 0.06 h–1, respectively; n = 3). For both YP and 
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SP substrates, no activity was observed in the absence of either the deoxyribozyme or 
Zn2+, and 1 mM Zn2+ was optimal; either decreasing or increasing the Zn2+ concentration 
reduced the activity. Using the YP substrate (SP was not tested in this regard), truncating 
the constant 5′-portion of 14WM9 (16 nt 5′-segment in Figure 2.5) did not substantially 
disrupt catalytic function. The rate constant did not decrease (krel = 1.6 for 5′-truncated 
versus full-length deoxyribozyme), and the final yield was essentially unchanged. 
However, using a random DNA sequence in place of the 40 nt catalytic region — 
functionally equivalent to performing the first selection round with the N40 pool — 
abolished all catalytic activity, demonstrating that the mere presence of nonspecific DNA 
and Zn2+ is insufficient to support dephosphorylation. 
2.2.4 Multiple-Turnover Dephosphorylation by the 14WM9 Deoxyribozyme 
Although our in vitro selection strategy inherently requires a covalent tether 
between the peptide and the DNA anchor oligonucleotide (Figure 2.5), we found that 
14WM9 also catalyzes efficient multiple-turnover Zn2+-dependent dephosphorylation of 
the entirely free (untethered) AAAYPAA peptide substrate, as assayed both by HPLC of 
the peptide mixture (Figure 2.11A) and by colorimetric detection of the released 
inorganic phosphate, Pi, using malachite green dye (Figure 2.11B).  
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Figure 2.11. Multiple-turnover assays of the 14WM9 deoxyribozyme with free phosphopeptide substrate. 
A) HPLC assay. Conditions: 100 µM 14WM9, 125 µM DNA anchor oligonucleotide, 500 µM free 
AAAYPAA, 70 mM HEPES, pH 7.5, 6 mM ZnCl2, and 150 mM NaCl at 37 °C. ~5 turnovers were 
observed in 24 h. B) Malachite green dye assay, in which Pi is observed colorimetrically upon binding to 
ammonium molybdate and malachite green dye. Conditions: 10 µM 14WM9, 12.5 µM DNA anchor 
oligonucleotide, 500 µM free AAAYPAA, 70 mM HEPES, pH 7.5, 2 mM ZnCl2, and 150 mM NaCl at 37 
°C. As calculated from A620 values, 6 turnovers in 24 h and 15 turnovers in 96 h were observed. In both the 
HPLC and malachite green assays, omission of Zn2+ rather than 14WM9 also led to no activity in 24 h. 
LC-ESI mass spectrometry of the reaction sample confirmed the identities of the 
phosphorylated substrate and dephosphorylated product hexapeptides (all [M+H]+: YP 
substrate m/z calcd. 616.2, found 616.2; YOH product m/z calcd. 536.3, found 536.2). 
These assays revealed 6 turnovers in 24 h and 15 turnovers in 96 h by 14WM9. The DNA 
anchor oligonucleotide, now unconnected to the free peptide substrate, was required for 
efficient reaction, presumably to sequester the corresponding deoxyribozyme binding arm 
(truncation of this binding arm led to 12-fold lower yield at 24 h). In all of these assays, 
the higher deoxyribozyme concentrations (100 µM or 10 µM, rather than 1 µM as in the 
single-turnover assays) required elevated Zn2+ concentration (6 mM or 2 mM, rather than 
1 mM) for maximal activity, apparently to compensate for nonspecific chelation of Zn2+ 
by the increased amount of DNA. The Km for AAAY
PAA was ≥1 mM (Figure 2.12; the 
assays of Figure 2.11 were performed at 0.5 mM peptide).  
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Figure 2.12. Determination of Km for the 14WM9 deoxyribozyme. Data points are n = 1 for peptide 
concentrations below 1.0 mM, n = 3 for 1.0 mM, n = 5 for 1.5 mM, and n = 6 for 2.0 mM (error bars for n 
> 1 are standard deviation). Each velocity determination was derived from a linear fit of product formation 
(µM) versus time (min) by HPLC. The fit value to the standard equation V = Vmax•(Km/([peptide] + Km) 
gave Vmax = 8.3 ± 1.1 µM/min and Km = 2.2 ± 0.5 mM. However, because the data points do not turn over 
at high peptide concentration (and >2 mM peptide was not practical), the safest assessment is that Km ≥ 1 
mM. 
The multiple-turnover activity of 14WM9 was not substantially inhibited by an 
excess of the dephosphorylated AAAYOHAA peptide product, but considerable inhibition 
by Pi was observed when over 2 equivalents was included (Figure 2.13). The sequence-
unrelated 14WM27 deoxyribozyme also exhibited multiple-turnover phosphatase activity 
with the free AAAYPAA substrate and Zn2+ (Figure 2.14), demonstrating that DNA-
catalyzed dephosphorylation of a free peptide substrate is not limited to a single 
deoxyribozyme. 
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Figure 2.13. Evaluating inhibition of the 14WM9 deoxyribozyme by the dephosphorylated AAAYOHAA 
peptide product and by inorganic phosphate (Pi). A) Evaluating inhibition by AAAY
OHAA, as determined 
by the malachite green dye assay for detection of released Pi. Each assay included 100 µM 14WM9, 125 
µM DNA anchor oligonucleotide, 500 µM AAAYPAA substrate, and up to 1.5 mM AAAYOHAA product 
in 70 mM HEPES, pH 7.5, 6 mM ZnCl2, 20 mM MnCl2, 40 mM MgCl2, and 150 mM NaCl at 37 °C. No 
inhibition was observed, even with 3 equivalents of product relative to substrate. B) Evaluating inhibition 
by Pi, as determined by HPLC assay. Each assay included 100 µM 14WM9, 125 µM DNA anchor 
oligonucleotide, 500 µM AAAYPAA substrate, and up to 1.5 mM Pi in 70 mM HEPES, pH 7.5, 6 mM 
ZnCl2, 20 mM MnCl2, 40 mM MgCl2, and 150 mM NaCl at 37 °C. Substantial inhibition was reproducibly 
observed, especially above 2 equivalents of Pi relative to substrate. 
 
Figure 2.14. Activity of the 14WM27 deoxyribozyme with the free AAAYPAA substrate. A) HPLC assay, 
under conditions of Figure 2.11A (either 6 mM Zn2+ alone, or 6 mM Zn2+ with 20 mM Mn2+ and 40 mM 
Mg2+). B) Malachite green assay for released Pi, under conditions of Figure 2.11B. 
2.2.5 Substrate Dependence of 14WM9 
To gain insight into the interactions between the DNA catalyst and the substrate, 
we examined the dependence of 14WM9’s single-turnover catalytic activity on the 
chemical structure of its phosphorylated substrate. When the DNA-anchored hexapeptide 
was shortened to as little as a dipeptide (CYP or CSP, where the cysteine sulfhydryl was 
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used to attach the dipeptide to the DNA anchor), 14WM9 retained substantial activity 
(Figure 2.15).  
 
Figure 2.15. Dependence of 14WM9 catalytic activity on the chemical structure of the phosphorylated 
substrate. A) Structures of the evaluated substrates. Note that for these experiments, the hexapeptide was 
connected via an N-terminal Cys, rather than an N-terminal Ala as in Figure 2.10. B) Single-turnover 
assays, under conditions of Figure 2.10 (Zn2+/Mn2+/Mg2+). kobs values from PAGE assays, top to bottom as 
listed in figure legends: 0.54, 0.93, 0.75 min–1; 0.39, 0.087, 0.11, 0.13 h–1 [6.5 × 10–3, 1.5 × 10–3, 1.8 × 10–3, 
2.2 × 10–3 min–1]. 
Consistent with this finding, substrates with sequence CAXYPAA and CAAYPXA 
(where X = F, E, or K) were dephosphorylated to similar extents by 14WM9 (Figure 
2.16). In contrast, when the substrate was non-peptidic and the phosphate group was 
instead connected to the DNA anchor through one or two triethylene glycol (TEG) units, 
14WM9 had no detectable dephosphorylation activity (<0.5%; Figure 2.15). When the 
phosphate group was attached directly to the 3′-hydroxyl of the DNA anchor, activity 
was comparable to that observed for the shorter CSP substrate, indicating that the 
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floppiness introduced by the TEG linkers contributes to the lack of activity with those 
substrates (Figure 2.15). From these data, we conclude that 14WM9 substantially prefers 
peptidic substrates, although only a relatively short peptide segment is required for 
optimal activity. 
 
Figure 2.16. Assays of 14WM9 with various hexapeptide substrate sequences in which one amino acid 
adjacent to the YP was altered, under conditions of Figure 2.10 (Zn2+/Mn2+/Mg2+). t = 0, 2, 12 h. Data were 
obtained in parallel with Figure 2.15. 
2.2.6 14WM9 Catalysis Under More Biologically Relevant Conditions 
To investigate the ability of 14WM9 to function under more biologically 
representative conditions, its activity was assayed in the presence of human cell lysate or 
bovine serum albumin (BSA), using the free AAAYPAA substrate. When up to 160 
µg/mL of H1299 human non-small-cell lung carcinoma lysate protein was supplemented 
into the same buffer and metal ion components as used for the previous experiments, 
substantial catalytic activity by 14WM9 was retained (Figure 2.17A). Separately, when 
14WM9 was assayed in the presence of BSA, substantial activity was maintained up to 
20 mg/mL BSA (Figure 2.17B and Figure 2.18). Multiple-turnover behavior for the 
14WM27 deoxyribozyme was also observed in the presence of lysate or BSA (Figure 
2.19). Collectively, these findings establish that robust DNA-catalyzed phosphatase 
activity is compatible with high concentrations of nonspecific proteins and other native 
cellular components. 
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Figure 2.17. Activity of the 14WM9 deoxyribozyme in presence of human cell lysate and BSA. A) HPLC 
multiple-turnover assay with free AAAYPAA peptide in the presence of human cell lysate (160 µg/mL of 
lysate protein), under conditions of Figure 2.11A. The asterisk denotes the pentapeptide AAYOHAA formed 
by nonspecific peptidase activity in the lysate, as validated by ESI-MS ([M+H]+ m/z calcd. 465.2, found 
465.2). B) HPLC multiple-turnover assay in the presence of 20 mg/mL BSA, under conditions of Figure 
2.11A except 10 mM Zn2+. Substantial activity was also observed at 6 and 8 mM Zn2+, but reduced 
presumably due to nonspecific chelation of Zn2+ by BSA (Figure 2.18). The dagger denotes a small amount 
(~14%) of dephosphorylation product formed in 24 h in the absence of 14WM9. In both panels, omission 
of Zn2+ rather than 14WM9 led to no activity in 24 h. This finding suggests for panel B that Zn2+ activates 
nonspecific phosphatases present in the BSA, and inclusion of the DNA suppresses this phosphatase 
activity. 
 
Figure 2.18. 14WM9 multiple-turnover activity with free peptide substrate assayed in the presence of 20 
mg/mL BSA and different Zn2+ concentrations. Data acquired as in Figure 2.17B (t = 24 h). 
42 
 
 
Figure 2.19. 14WM27 multiple-turnover activity assayed in the presence of human cell lysate and BSA. A) 
HPLC assay in the presence of human cell lysate (160 µg/mL lysate protein). Conditions: 100 µM 14WM9, 
125 µM DNA anchor oligonucleotide, 500 µM free AAAYPAA, 70 mM HEPES, pH 7.5, 6 mM ZnCl2, 20 
mM MnCl2, 40 mM MgCl2, and 150 mM NaCl at 37 °C. The asterisks denote shorter peptide fragments 
formed by nonspecific peptidase activity in the lysate. B) HPLC assay in the presence of 20 mg/mL BSA. 
Conditions: 10 µM 14WM9, 12.5 µM DNA anchor oligonucleotide, 500 µM free AAAYPAA, 70 mM 
HEPES, pH 7.5, 10 mM ZnCl2, 20 mM MnCl2, 40 mM MgCl2, and 150 mM NaCl at 37 °C. 
Finally, we assessed the ability of 14WM9 to dephosphorylate a YP residue when 
presented as part of a large 91-mer protein substrate rather than merely on a short 
hexapeptide. For this purpose, we used as substrate a 66-mer fragment of prochlorosin 
ProcA2.8, 31 fused to an N-terminal His6 tag and joined at its C-terminus by native 
chemical ligation to the CAAYPAA hexapeptide. The resulting 91-mer protein was 
incubated with 14WM9 and analyzed by MALDI mass spectrometry, revealing 
substantial dephosphorylation (94% in 36 h; Figure 2.20). 
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Figure 2.20. Dephosphorylation of a larger protein substrate by 14WM9. The 91-mer protein derived from 
prochlorosin ProcA2.8 and ending with ...CAAYPAA at its C-terminus was dephosphorylated by 14WM9, 
digested in-gel by Lys-C, and analyzed by MALDI mass spectrometry (see Materials and Methods for 
details). Dephosphorylation conditions: 100 µM 14WM9, 125 µM DNA anchor oligonucleotide, 20 µM 
protein, 70 mM HEPES, pH 7.5, 6 mM ZnCl2, 40 mM MgCl2, 20 mM MnCl2, and 150 mM NaCl at 37 °C 
for 36 h. YOH product Lys-C fragment [M+H]+ m/z calcd. 3751.725, found 3751.699, ∆ = –6.9 ppm. 
Difference between product and substrate due to dephosphorylation ∆(m/z) calcd. 79.966, found 79.993, 
∆ = +0.033%. 
2.2.7 In Vitro Selection Process for N-terminal Phosphoserine and Capture 
Deoxyribozymes for Serine 
A strategy to identify phosphatase deoxyribozymes for N-terminal phosphoserine 
was devised (Figure 2.21A). The hexapeptide substrate, SPAAAAC, was covalently 
appended to a DNA-anchored oligonucleotide (by disulfide linkage), which was then 
ligated to the deoxyribozyme pool. After each key selection step that used incubation 
conditions of 70 mM HEPES, pH 7.5, 1 mM ZnCl2, 20 mM MnCl2, 40 mM MgCl2, and 
150 mM NaCl at 37 °C for 14 h, active DNA sequences were precipitated and “captured” 
in a two-step chemical technique. The first step involved oxidation of the N-terminal 
serine by sodium periodate for 30 min to reveal an aldehyde. After desalting and 
removing the excess periodate, a secondary capture step was performed with a 5′-
hydrazide DNA to form the hydrazone resulting in an upward PAGE shift (Figure 2.21A) 
(see Materials and Methods for capture conditions). The active DNA sequences were 
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amplified by PCR and joined by T4 DNA ligase to the DNA-anchored hexapeptide 
substrate for entering the next selection round. After 7 rounds of selection, positive 
control yield gradually decreased from 25% to ~10% (Figure 2.21B). Because the 
positive control itself was giving unreliably low yields, these selections were 
discontinued.  
Separately, for serine-OH capture deoxyribozymes, reselections from 15MZ36 
(which exhibits trace activity with AAASAA), and redirection from 11MY (continuation 
from an earlier selection round that captures non-peptidic aliphatic OH) were initiated. 
The DNA-anchored AAASAA substrate was prepared by reductive amination (see 
Materials and Methods). Each selection step used incubation conditions of 70 mM 
HEPES, pH 7.5, 100 pmol of 5′-triphosphorylated RNA, 20 mM MnCl2, 40 mM MgCl2, 
and 150 mM NaCl at 37 °C for 14 h Activity was observed in round 6 for the reselection 
and round 17 for redirection. Individual sequences were cloned, and sequenced. The best 
deoxyribozyme from both selections, 17WK3, showed 37% serine capture activity and 
selective for serine-OH over phosphoserine (Figure 2.21C).  
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Figure 2.21. A) Selection scheme for N-terminal phosphoserine phosphatase activity. After the selection 
step, dephosphorylated serine is oxidized to reveal an aldehyde, which is captured by the hydrazide 
oligonucleotide (red). B) Selections were performed for 7 rounds and discontinued. C) The catalytic region 
for capture deoxyribozyme (40 or 41 nt) and PAGE image illustrating selectivity for AAASOHAA (red) 
over AAASPAA (black) of the 6WJ- and 17WK-catalyzed capture reactions. The open arrowhead marks 
the reactant, and the filled arrowhead marks the product. 
2.3 Summary 
In this study, we have established the fundamental ability of DNA to catalyze the 
challenging reaction of phosphomonoester hydrolysis in the context of peptide substrates. 
The best DNA catalysts function with entirely free peptides. We also observed multiple-
turnover behavior even in the presence of human cell lysate or high concentrations of 
BSA. In addition, substantial phosphatase activity with a larger protein substrate was also 
observed. 
We previously demonstrated DNA-catalyzed DNA phosphodiester hydrolysis, 
i.e., nuclease activity.8-9 Both reactions involve “phosphoester” substrates, but a 
phosphomonoester as used here is substantially more difficult to hydrolyze than is a 
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phosphodiester, considering the >3 orders of magnitude difference in uncatalyzed half-
lives (4 × 1010 years for an aliphatic phosphomonoester dianion, 32 versus 3 × 107 years 
for a phosphodiester).33 Regardless of the uncatalyzed reaction rate constants, the peptide 
substrate for phosphomonoester dephosphorylation cannot be bound by the DNA catalyst 
using any Watson-Crick base pairs, whereas the DNA substrate for phosphodiester 
hydrolysis inherently interacts with the deoxyribozyme by extensive preprogrammed 
base pairing. This means that a phosphatase deoxyribozyme has the much greater 
challenge to interact well with its substrate. The new DNA-catalyzed phosphatase activity 
has rate constant as fast as 0.7 min–1 for YP dephosphorylation, a value commensurate 
with many other in vitro selected deoxyribozymes for various catalytic activities.3, 7, 34 
From a fundamental perspective, we wish to understand the mechanism of DNA-
catalyzed dephosphorylation, in the context of broader studies of biological phosphoryl 
transfer.35 Such mechanistic studies will benefit greatly from future high-resolution 
structural information that is currently unavailable except for one deoxyribozyme.36,37 
Although we can speculate that 14WM9, 14WM27, and the other newly identified 
phosphatase deoxyribozymes activate Zn2+ for direct hydrolysis of the phosphorylated 
side chains, determining their detailed mechanisms requires considerable further 
experiments, especially without a sound structural basis for the catalysis. 
The marked preference of the 14WM9 deoxyribozyme for a peptidic substrate 
suggests direct interaction of this deoxyribozyme with some portion of the substrate’s 
polyamide backbone, although the efficient dephosphorylation of a dipeptide substrate 
means that any such contact is not very extensive.  
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2.4 Materials and Methods 
2.4.1 Oligonucleotides 
DNA oligonucleotides were obtained from Integrated DNA Technologies 
(Coralville, IA) or prepared by solid-phase synthesis on an ABI 394 instrument using 
reagents from Glen Research. 5′-Triphosphorylated RNA oligonucleotides were prepared 
by in vitro transcription using synthetic DNA templates and T7 RNA polymerase.38 All 
oligonucleotides were purified by 7 M urea denaturing PAGE with running buffer 1× 
TBE (89 mM each Tris and boric acid and 2 mM EDTA, pH 8.3) as described 
previously.39-40 
2.4.2  Synthesis of Peptides and DNA-Anchored Peptides 
Peptides were prepared by solid-phase synthesis on Fmoc Rink amide MBHA 
resin (AAPPTec). Each peptide was coupled to the DNA anchor oligonucleotide via 
either the N-terminal α-amino group (linkage created by reductive amination) or the N-
terminal cysteine side chain (linkage created by disulfide formation).  
2.4.2.1 Synthesis of peptides. Peptides were prepared by solid-phase synthesis using 
Fmoc Rink amide MBHA resin, with N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-
yl)uronium hexafluorophosphate (HATU) as coupling agent. Each synthesis was 
performed at 0.2 mmol scale, initiated using 308 mg of Rink amide resin with a loading 
capacity of 0.65 mmol/g (AAPPTec). All steps were monitored by ninhydrin test. For 
each coupling, 5 equivalents (1.0 mmol) of Fmoc-amino acid, 4.9 equivalents (373 mg, 
0.98 mmol) of HATU, and 10 equivalents (350 µL, 2.0 mmol) of N,N-
diisopropylethylamine (DIPEA) were mixed in 10 mL of anhydrous DMF. The coupling 
reaction was initiated by adding this mixture to the resin and agitating by bubbling with 
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nitrogen for 45 min, followed by washing with DMF (3  10 mL). The N terminus of the 
newly installed amino acid was deprotected by agitating the resin in 20% piperidine in 
DMF (5 mL) under nitrogen for 5 min a total of three times, each time washing with 
DMF (3  5 mL). Peptides with N-terminal cysteine were capped via acetylation of their 
N-terminus by agitating the resin in 50 equivalents (924 µL, 10 mmol) of acetic 
anhydride and 25 equivalents of DIPEA (870 L, 5 mmol) in 5 mL of DMF under 
nitrogen for 30 min. The peptide was cleaved from the solid support by stirring the resin 
in a separate vial with a solution containing 5 mL of trifluoroacetic acid (TFA), 125 µL 
of water, 125 µL of ethanedithiol, and 50 L of triisopropylsilane for 90 min. The liquid 
solution was separated from the resin by filtration. This solution was dried on a rotary 
evaporator, providing a solid (for hexapeptides) or an oily solid (for dipeptides). To this 
material 20 mL of cold diethyl ether was added, and the peptide was obtained as a white 
solid that was filtered and purified by HPLC. 
2.4.2.2 Synthesis of DNA-anchored peptides. Each peptide was coupled to the DNA 
anchor oligonucleotide via either the N-terminal α-amino group (linkage created by 
reductive amination) or the N-terminal cysteine side chain (linkage created by disulfide 
formation).  
Procedure for coupling to N-terminal α-amino group (Figure 2.6A): The DNA anchor 
oligonucleotide was 5′-GGATAATACGACTCACTAT-rA-3′, where the 3′-terminal 
ribonucleotide was oxidized by NaIO4. A 100 µL sample containing 1.0 nmol of DNA 
anchor oligonucleotide in 100 mM HEPES, pH 7.5, and 10 mM NaIO4 was incubated at 
room temperature for 1 h. The oxidized product was precipitated to remove excess NaIO4 
by addition of 10 µL of 3 M NaCl and 300 µL of ethanol. The precipitated product was 
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dissolved in 65 µL of water and used directly in the next step. A 100 µL sample 
containing the NaIO4-oxidized DNA anchor oligonucleotide and 100 nmol (100 
equivalents) of peptide in 100 mM NaOAc, pH 5.2, 50 mM NiCl2, and 10 mM NaCNBH3 
was incubated at 37 °C for 14 h. The DNA-anchored hexapeptide was precipitated by 
addition of 10 µL of 3 M NaCl and 300 µL of ethanol and purified by 20% PAGE. A 
typical yield was 200–400 pmol. See Table 2.1 for MALDI mass spectrometry values. 
Procedure for coupling to N-terminal cysteine side chain (Figure 2.6B): The DNA 
anchor oligonucleotide was 5′-GGATAATACGACTCACTAT-C3-SS-C3-OH-3′, where the 3′-
disulfide linker was introduced via standard solid-phase DNA synthesis and unmasked to 
a 3′-thiol by DTT treatment. In some cases, one or ten hexa(ethylene glycol), or HEG, 
spacer units were included immediately to the 5′-side of the disulfide linker; see 
structures in Figure 2.11. A 50 µL sample containing 2 nmol of DNA anchor 
oligonucleotide in 50 mM HEPES, pH 7.5, and 50 mM DTT was incubated at 37 °C for 2 
h. The reduced product was precipitated to remove excess DTT by addition of 50 µL of 
water, 10 µL of 3 M NaCl, and 300 µL of ethanol. The precipitated product (DNA-C3-
SH) was dissolved in 45 µL of water. Activation as the pyridyl disulfide was achieved by 
adding 5 µL of 100 mM 2,2′-dipyridyl disulfide in DMF and incubating at 37 °C for 2 h. 
The product (DNA-C3-SSPy) was precipitated by addition of 50 µL of water, 10 µL of 3 
M NaCl and 300 µL of ethanol and dissolved in 25 µL of water. Conjugation to the 
peptide was performed by adding 20 µL of 50 mM triethylammonium acetate, pH 7.0, 
and 5 µL of 20 mM peptide (100 nmol, 100 equivalents). The sample was incubated at 37 
°C for 2 h, and the DNA-anchored peptide was purified by 20% PAGE. A typical yield 
was 1.4–1.8 nmol. See Table 2.1 for MALDI mass spectrometry values. 
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2.4.3  Capture Strategy for Phosphotyrosine Capture using 15MZ36 
The DNA-anchored AAAYAA substrate ligated to the DNA pool was 5′-32P-
radiolabeled using γ-32P-ATP and PNK (Fermentas). 
Procedure for capture step using selective chelation of zinc with EDTA. A 10 µL sample 
containing 0.1 pmol radiolabeled ligated pool (with DNA-anchored AAAYAA or 
AAAYPAA) was annealed in 5 mM HEPES, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA 
by heating at 95 °C for 3 min and cooling on ice for 5 min. The selection reaction was 
initiated by bringing the sample to 20 µL total volume containing 70 mM HEPES, pH 
7.5, 1 mM ZnCl2, 20 mM MnCl2, 40 mM MgCl2, and 150 mM NaCl. To the 20 µL 
selection sample containing was added 0.8 µL of 50 mM EDTA, pH 8.0 (40 nmol). The 
sample was then brought to 25 µL total volume containing 40 pmol of 15MZ36 capture 
deoxyribozyme, 80 pmol of 5′-triphosphorylated RNA substrate, and 20 mM MnCl2, 40 
mM MgCl2, and incubated at 37 °C for 14 h. 
Procedure for capture step using ethanol precipitation. The 20 µL selection sample 
containing 0.1 pmol radiolabeled ligated pool (with DNA-anchored AAAYAA or 
AAAYPAA) in 70 mM HEPES, pH 7.5, 1 mM ZnCl2, 20 mM MnCl2, 40 mM MgCl2, and 
150 mM NaCl was precipitated in 75% ethanol after adding 2.5 µL of 500 mM EDTA, 
pH 8.0 (1.25 mmol) to remove all divalent metal cations. The sample was then brought to 
a 20 µL total volume containing 40 pmol of 15MZ36 capture deoxyribozyme, 80 pmol of 
5′-triphosphorylated RNA substrate, and 20 mM MnCl2, 40 mM MgCl2, and incubated at 
37 °C for 14 h. 
For both cases at the appropriate time points, 2 µL aliquots were quenched with 5 
µL stop solution (80% formamide, 1× TBE [89 mM each Tris and boric acid and 2 mM 
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EDTA, pH 8.3], 50 mM EDTA, 0.025% bromophenol blue, 0.025% xylene cyanol). 
Samples were separated by 20% PAGE and quantified with a PhosphorImager. 
2.4.4  In Vitro Selection Procedure for Tyrosine Phosphatase Activity 
The selection procedure, cloning, and initial analysis of individual clones were 
performed essentially as described previously,39, 41 but with a different ligation step as 
recently reported. 30 An overview of the key selection and capture steps of each round is 
shown in Figure 2.5. 
The selection procedure, cloning, and initial analysis of individual clones were 
performed essentially as described previously 39, 41, but with a different ligation step as 
recently reported 30. An overview of the key selection and capture steps of each round is 
shown in Figure 2.5. The random deoxyribozyme pool was 5′-CGAAGTCCGCCATCTCTTC-
N40-ATAGTGAGTCGTATTAAGCTGATCCTGATGG-3′. PCR primers were 5′-
CGAAGTCGCCATCTCTTC-3′ (forward primer) and 5′-(AAC)4XCCATCAGATCAGCT-3′, where X 
is the HEG spacer to stop Taq polymerase (reverse primer). In each round, the ligation 
step to attach the deoxyribozyme pool at its 3′-end with the 5′-end of the DNA-anchored 
hexapeptide substrate was performed using a DNA splint and T4 DNA ligase. The splint 
sequence was 5′-ATAGTGAGTCGTATTATCCTCCATCAGGATCAGCTTAATACGACTCACTAT-3′, 
where the underlined T is included to account for the untemplated A nucleotide that is 
added at the 3′-end of each PCR product by Taq polymerase. This T nucleotide was 
omitted from the splint used for ligation of the initially random N40 pool, which was 
prepared by solid-phase synthesis without the untemplated A. Nucleotide sequences of 
the DNA anchor oligonucleotide, the deoxyribozyme binding arms, the 5′-
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triphosphorylated RNA substrate for the capture reaction, and the full 15MZ36 capture 
deoxyribozyme are shown in Figure 2.7. 
Procedure for ligation step in round 1. A 34 µL sample containing 1 nmol of DNA pool, 
850 pmol of DNA splint, and 750 pmol of 5′-phosphorylated DNA-hexapeptide substrate 
was annealed in 5 mM Tris, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by heating at 95 
°C for 3 min and cooling on ice for 5 min. To this solution was added 4 µL of 10× T4 
DNA ligase buffer (Fermentas) and 2 µL of 5 U/µL T4 DNA ligase (Fermentas). The 
sample was incubated at 37 °C for 12 h and purified by 8% PAGE. 
Procedure for ligation step in subsequent rounds. A 16 µL sample containing the PCR-
amplified DNA pool (~5–10 pmol), 20 pmol of DNA splint, and 30 pmol of 5′-
phosphorylated DNA-hexapeptide substrate was annealed in 5 mM Tris, pH 7.5, 15 mM 
NaCl, and 0.1 mM EDTA by heating at 95 °C for 3 min and cooling on ice for 5 min. To 
this solution was added 2 µL of 10× T4 DNA ligase buffer (Fermentas) and 2 µL of 1 
U/µL T4 DNA ligase (Fermentas). The sample was incubated at 37 °C for 12 h and 
purified by 8% PAGE. 
Procedure for selection step in round 1. Each selection experiment was initiated with 200 
pmol of the ligated N40 pool. A 15 µL sample containing 200 pmol of ligated N40 pool 
was annealed in 5 mM HEPES, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by heating at 
95 °C for 3 min and cooling on ice for 5 min. The selection reaction was initiated by 
bringing the sample to 30 µL total volume containing 70 mM HEPES, pH 7.5, 1 mM 
ZnCl2, 20 mM MnCl2, 40 mM MgCl2, and 150 mM NaCl. The sample was incubated at 
37 °C for 14 h. 
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Procedure for selection step in subsequent rounds. A 10 µL sample containing ligated 
pool was annealed in 5 mM HEPES, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by 
heating at 95 °C for 3 min and cooling on ice for 5 min. The selection reaction was 
initiated by bringing the sample to 20 µL total volume containing 70 mM HEPES, pH 
7.5, 1 mM ZnCl2, 20 mM MnCl2, 40 mM MgCl2, and 150 mM NaCl. The sample was 
incubated at 37 °C for 14 h. 
Procedure for capture step in round 1. To the 30 µL selection sample was added 1.2 µL 
of 50 mM EDTA, pH 8.0 (60 nmol). The sample was then brought to 45 µL total volume 
containing 300 pmol of 15MZ36 capture deoxyribozyme, 400 pmol of 5′-
triphosphorylated RNA substrate, 20 mM MnCl2, and 40 mM MgCl2 and incubated at 37 
°C for 14 h. 
Procedure for capture step in subsequent rounds. To the 20 µL selection sample was 
added 0.8 µL of 50 mM EDTA, pH 8.0 (40 nmol). The sample was then brought to 25 µL 
total volume containing 40 pmol of 15MZ36 capture deoxyribozyme, 80 pmol of 5′-
triphosphorylated RNA substrate, and 20 mM MnCl2, 40 mM MgCl2, and incubated at 37 
°C for 14 h. 
Procedure for PCR. In each selection round, two PCR reactions were performed, 10-
cycle PCR followed by 30-cycle PCR. First, a 100 µL sample was prepared containing 
the PAGE-purified selection product, 200 pmol of forward primer, 50 pmol of reverse 
primer, 20 nmol of each dNTP, and 10 µL of 10× Taq polymerase buffer (1× = 20 mM 
Tris-HCl, pH 8.8, 10 mM (NH4)2SO4, 10 mM KCl, 2 mM MgSO4, and 0.1% Triton X-
100). This sample was cycled 10 times according to the following PCR program: 94 °C 
for 2 min, 10× (94 °C for 30 s, 47 °C for 30 s, 72 °C for 30 s), 72 °C for 5 min. Taq 
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polymerase was removed by phenol/chloroform extraction. Second, a 50 µL sample was 
prepared containing 1 µL of the 10-cycle PCR product, 100 pmol of forward primer, 25 
pmol of reverse primer, 10 nmol of each dNTP, 20 µCi of α-32P-dCTP (800 Ci/mmol), 
and 5 µL of 10× Taq polymerase buffer. This sample was cycled 30 times according to 
the following PCR program: 94 °C for 2 min, 30× (94 °C for 30 s, 47 °C for 30 s, 72 °C 
for 30 s), 72 °C for 5 min. Samples were separated by 8% PAGE. 
2.4.5  Single-Turnover Assay Procedure Using PAGE 
The DNA-anchored phosphopeptide substrate was 5′-32P-radiolabeled using γ-32P-
ATP and Optikinase (USB), which lacks the 3′-phosphatase activity that we have found 
also dephosphorylates tyrosine and serine side chains. A 10 µL sample containing 0.25 
pmol of 5′-32P-radiolabeled DNA-anchored phosphopeptide substrate and 20 pmol of 
deoxyribozyme was annealed in 5 mM HEPES, pH 7.5, 15 mM NaCl, and 0.1 mM 
EDTA by heating at 95 °C for 3 min and cooling on ice for 5 min. The DNA-catalyzed 
dephosphorylation reaction was initiated by bringing the sample to 20 µL total volume 
containing 70 mM HEPES, pH 7.5, 1 mM ZnCl2, 20 mM MnCl2, 40 mM MgCl2, and 150 
mM NaCl (Mn2+ and Mg2+ were omitted in assays that used Zn2+ alone). The sample was 
incubated at 37 °C. At appropriate time points, 2 µL aliquots were quenched with 5 µL 
stop solution (80% formamide, 1× TBE [89 mM each Tris and boric acid and 2 mM 
EDTA, pH 8.3], 50 mM EDTA, 0.025% bromophenol blue, 0.025% xylene cyanol). 
Samples were separated by 20% PAGE and quantified with a PhosphorImager. Values of 
kobs were obtained by fitting the yield versus time data directly to first-order kinetics; i.e., 
yield = Y•(1 – e–kt), where k = kobs and Y is the final yield. Each kobs value is reported with 
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error calculated as the standard deviation from the indicated number of independent 
determinations. 
2.4.6  Multiple-Turnover Assay using HPLC 
A 20 µL sample containing 2 nmol (100 µM) of deoxyribozyme, 2.5 nmol (125 
µM) of free DNA anchor oligonucleotide, and 10 nmol (500 µM) of free AAAYPAA 
hexapeptide in 70 mM HEPES, pH 7.5, 6 mM ZnCl2, and 150 mM NaCl was incubated at 
37 °C. At an appropriate time point (0–24 h), the sample was quenched with 5 µL of 50 
mM EDTA, pH 8.0 (250 nmol, versus 120 nmol Zn2+ present) and frozen at –80 °C until 
further processing. To remove the deoxyribozyme, a filtration step was performed (this 
step was confirmed not to distort substantially the ratio of phosphorylated to 
dephosphorylated peptide). An Amicon Ultra-0.5 mL 3 kDa centrifugal filter was washed 
with 300 µL of water by centrifugation at 14000 g for 10 min. The sample was diluted 
with water to 300 µL and transferred to the filter, which was centrifuged at 14000 g for 
15 min, and the filtrate was collected. Another 300 µL of water was passed through the 
filter. The combined filtrates were evaporated to dryness, redissolved in 25 µL of water, 
and analyzed by HPLC. Analysis was performed on a Beckman System Gold instrument 
with a Beckman Ultrasphere C18 column (5 µm, 2 × 150 mm). Samples were analyzed 
using a gradient of 1% solvent A (acetonitrile) and 99% solvent B (0.1% trifluoroacetic 
acid in water) at 0 min to 21:79 A:B at 25 min at flow rate 0.5 mL/min. 
For assays in the presence of H1299 human non-small-cell lung carcinoma lysate, 
the lysate (40 mg/mL of lysate protein) was a gift prepared by B. Parkinson in the P. 
Hergenrother laboratory [lysis in RIPA lysis buffer containing protease inhibitor, with 
cell debris removed by centrifugation at 16000 g for 5 min 42 and quantification by 
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Bradford and bicinchoninic acid (BCA) assays]. The 20 µL sample additionally 
contained 1/250 by volume of lysate (160 µg/mL of lysate protein). For assays in the 
presence of BSA, the 20 µL sample additionally contained 20 mg/mL of BSA (Sigma 
A4503), and the Zn2+ concentration was 10 mM. 
2.4.7  Multiple-turnover Assay Procedure Using Malachite Green Dye 
A 20 µL sample containing 200 pmol (10 µM) of deoxyribozyme, 250 pmol (12.5 
µM) of free DNA anchor oligonucleotide, and 10 nmol (500 µM) of free AAAYPAA 
hexapeptide in 70 mM HEPES, pH 7.5, 2 mM ZnCl2, and 150 mM NaCl was incubated at 
37 °C. At an appropriate time point (0–96 h), the sample was quenched with 5 µL of 50 
mM EDTA, pH 8.0 (250 nmol) and frozen at –80 °C until further processing. To the 
sample was added 75 µL of water and 20 µL of malachite green assay solution (BioAssay 
Systems POMG-25H). After incubation at room temperature for 30 min, the sample was 
diluted with 180 µL of water, and the absorbance at 620 nm was measured (NanoDrop 
2000c, Thermo Scientific). Standard curves for inorganic phosphate (Pi) were obtained 
using solutions containing known amounts of Pi and all other assay components except 
the free hexapeptide. Numbers of turnovers were calculated directly from the ratio of 
mole amounts of released Pi and deoxyribozyme. 
2.4.8 Mass Spectrometry of DNA-Anchored Peptides 
The DNA-anchored AAAYOHAA dephosphorylation product was prepared from a 
10 µL sample containing 50 pmol of DNA-anchored AAAYPAA substrate and 80 pmol 
of 14WM9 deoxyribozyme, which was annealed in 5 mM HEPES, pH 7.5, 15 mM NaCl, 
and 0.1 mM EDTA by heating at 95 °C for 3 min and cooling on ice for 5 min. The 
DNA-catalyzed dephosphorylation reaction was initiated by bringing the sample to 20 µL 
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total volume containing 70 mM HEPES, pH 7.5, 1 mM ZnCl2, 20 mM MnCl2, 40 mM 
MgCl2, and 150 mM NaCl. The sample was incubated at 37 °C for 5 min, quenched with 
5 µL of 50 mM EDTA, pH 8.0 (250 nmol), desalted by Millipore C18 ZipTip, and 
analyzed by MALDI mass spectrometry (matrix 3-hydroxypicolinic acid). 
2.4.9 Mass Spectrometry of Free Hexapeptides 
The free AAAYOHAA dephosphorylation product was prepared from 10 nmol of 
the free AAAYPAA substrate using 2 nmol of the 14WM9 deoxyribozyme and the 
multiple-turnover procedure described above (24 h incubation). Analysis was performed 
on a Waters 2795 LC-MS instrument with a Beckman Ultrasphere C18 column (5 µm, 2 × 
150 mm) and detection by ESI mass spectrometry (Q-Tof Ultima API in positive ion scan 
mode using the manufacturer’s suggested parameters). Samples were analyzed using a 
gradient of 1% solvent A (0.1% formic acid in acetonitrile) and 99% solvent B (0.1% 
formic acid in water) at 0 min to 21:79 A:B at 25 min. 
2.4.10 Large Protein Preparation and Analysis 
The 85-mer His6-ProcA2.8(1-66) MESNA thioester was overexpressed and 
partially purified. The procedure was followed essentially as reported, 43 with minor 
modifications. E. coli BL21(DE3) cells harboring the pTXB1 plasmid that encodes the 
His6-ProcA2.8(1-66)-intein-CDB fusion protein were grown in 2 L LB with 100 µg/mL 
ampicillin at 37 °C until an OD600 of 0.6-0.7 was reached. Protein expression was 
induced by the addition of 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG), and 
the cells were grown for an additional 12 h at 18 °C. Cells were harvested by 
centrifugation at 5500 g for 20 min at 4 °C, and the cell pellet was resuspended in 30 mL 
of column buffer containing 100 mM sodium phosphate, pH 7.0, 500 mM NaCl, 1 mM 
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EDTA, and 1 mM TCEP. Cells were lysed by sonication on ice at an amplitude of 65% 
(3 s on, 9 s off) for 16 min. The lysate was centrifuged at 20000 g for 20 min, and the 
supernatant containing the fusion protein was loaded onto a chitin column (20 mL) that 
was pre-equilibrated with column buffer. The fusion protein was bound to the chitin 
column by shaking gently at 4 °C for 2 h. The column was mounted upright and washed 
with 200 mL (10 column volumes) of the column buffer. The column was washed with 
40 mL of buffer containing 100 mM sodium phosphate, pH 7.4, 500 mM NaCl, 1 mM 
EDTA, and 1 mM TCEP. To the column was added 20 mL of cleavage buffer containing 
100 mM sodium phosphate, pH 7.4, 500 mM NaCl, 1 mM EDTA, 1 mM TCEP, and 100 
mM MESNA. Intein-mediated cleavage of the 85-mer His6-ProcA2.8(1-66) thioester was 
performed by gentle shaking of the chitin resin for 12 h at 4 °C. The His6-ProcA2.8(1-66) 
thioester was eluted, concentrated using a 15 mL Amicon 3 kDa filter (Millipore), and 
lyophilized to dryness. 
A 100 µL sample containing 6 mg crude protein thioester (~0.6 mM thioester; 
most of the mass is salts) and 5 mM CAAYPAA hexapeptide in 100 mM HEPES, pH 7.5, 
1 mM TCEP, and 10 mM MesNa was incubated at 4 °C for 16 h.  To alkylate the 
cysteine side chain, 50 µL of 1 M iodoacetamide was added, and the sample was 
incubated at 25 °C for 45 min in the dark. The reaction mixture was acidified by adding 3 
µL of 5% trifluoroacetic to a final concentration of 0.1% trifluoroacetic acid. The ligated 
protein was purified by HPLC on a Beckman System Gold instrument with a Grace 
Vydac C4 column (5 µm, 4.6 × 250 mm) using a gradient of 2% solvent A (80% 
acetonitrile and 0.1% TFA in water) and 98% solvent B (0.1% trifluoroacetic acid in 
water) at 0 min to 100% solvent B at 45 min with flow rate of 1 mL/min. The ligated 
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protein eluted at 29 min and was collected, lyophilized, and redissolved in water. MALDI 
mass spectrometry [M+H]+ calcd. 9681.5, found 9681.7, ∆ = +0.002% (matrix 2,5-
dihydroxybenzoic acid). The final 91-mer protein sequence was 
GSSHHHHHHSSGLVPRGSHMSEEQLKAFLTKVQADTSLQEQLKIEGADVVAIA-
K^AAGFSITTEDLNSHRQNLSDDELEGVAGGAACAAYPAA, where the caret marks 
the Lys-C cleavage site closest to the YP position, and the single cysteine has been 
alkylated by iodoacetamide. 
To assay 14WM9-catalyzed dephosphorylation of the 91-mer protein, a 10 µL 
sample containing 1 nmol (100 µM) of deoxyribozyme, 1.25 nmol (125 µM) of free 
DNA anchor oligonucleotide, and 200 pmol (20 µM) of protein in 70 mM HEPES, pH 
7.5, 6 mM ZnCl2, 40 mM MgCl2, 20 mM MnCl2, and 150 mM NaCl was incubated at 37 
°C. The deoxyribozyme was omitted in the control experiment. After 36 h, 5 µL of the 
sample was added to 10 µL of solution containing 60 mM Tris, pH 6.8, 2% SDS, 0.1% 
bromophenol blue, and 10% glycerol. The sample was separated by SDS-PAGE (1 M 
Tris, pH 8.45, 0.1% SDS, 5% acrylamide stacking, 15% acrylamide + 10% glycerol 
resolving), run at 120 V for 75 min. The gel was stained with Imperial Protein Stain 
(Pierce 24615), and the band corresponding to the protein was excised. In-gel Lys-C 
digestion was performed as reported,44 except omitting treatment of the gel slice with 
DTT and iodoacetamide. For the Lys-C digestion step, the gel slice was treated with 40 
µL of a solution containing 100 mM Tris, pH 8.0, 40 mM DTT, and 0.6 ng/µL Lys-C 
(Roche 11420429001). The acidic extraction step used 5% formic acid in acetonitrile. 
The sample was concentrated by SpeedVac to 10 µL, desalted by Millipore C18 ZipTip, 
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and analyzed by MALDI mass spectrometry (matrix 2,5-dihydroxybenzoic acid). 
Monoisotopic m/z values were calculated using the PeptideMass calculator at ExPASy. 
2.4.11 Selection Procedure for N-terminal Phosphoserine Phosphatase Activity 
The in vitro selection process for N-terminal phosphoserine phosphatase activity 
is similar to the selection procedure described earlier with the following modifications in 
the capture steps. 
Procedure for capture step in round 1. To the 40 µL selection sample was added 10 µL 
of 500 mM EDTA, pH 8.0 (5 mmol). The sample was precipitated by adding 250 µL of 
water and 900 µL of ethanol. The sample was brought back to 150 µL total volume 
containing 200 mM HEPES, pH 7.5, 10 mM NaIO4 and incubated at 25 °C for 30 min to 
oxidize the N-terminal serine. Amicon Ultra-0.5 mL 3 kDa was used to desalt and 
remove the excess periodate by addition of 400 µL water followed by centrifugation at 
14000 × g for 20 min (twice). The desalted sample was dried and brought up to a 40 µL 
total volume containing 100 mM NaOAc, pH 4.6, 1 nmol of hydrazide capture 
oligonucleotide, 50 mM NiCl2 and incubated at 37 °C for 14 h. The sequence of 
hydrazide oligonucleotide was 5′- XGGAAGAGATGGCGACGGAACAACAACAACAACAAC-
3′, where X = 5′-carboxy-modifier C10 + hydrazine.  
Procedure for capture step in subsequent rounds. To the 20 µL selection sample was 
added 5 µL of 500 mM EDTA, pH 8.0 (2.5 mmol). The sample was precipitated by 
adding 275 µL of water and 900 µL ethanol. The sample was brought to 150 µL total 
volume containing 200 mM HEPES, pH 7.5, 10 mM NaIO4 and incubated at 25 °C for 30 
min. Excess periodate was removed using Amicon Ultra-0.5 mL 3 kDa (see above for 
procedure). The sample was dried and brought up to 20 µL total volume containing 100 
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mM NaOAc, pH 4.6, 400 pmol of hydrazide capture oligonucleotide, 50 mM NiCl2 and 
incubated at 37 °C for 14 h.  
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Chapter 3: Efforts to Identify Sequence-Selective Phosphatase 
Deoxyribozymes 
3.1 Introduction 
Sequence-selectivity is a key feature and a major goal of biocatalysis. Protein 
engineering is used to achieve this important objective of specificity/selectivity when 
nature does not have a preexisting protein enzyme as the starting point.1 Engineering 
protein to accomplish selectivity involves either a rational protein design or a directed 
evolution approach.2 Prior knowledge of the protein structure, including protein sequence 
homology, usually serves as an excellent starting point for protein engineering. For 
rational design, structural information of protein is exploited to make desirable mutations 
and changes. Site-directed mutagenesis is the most important tool used in rational protein 
design.3 A primary disadvantage of rational design is that unavailability of structural data 
makes progress with valuable mutations almost impossible. In contrast, directed 
evolution obviates the need for detailed understanding of the protein structure. Several 
random mutations are introduced and the proteins with the desirable traits are selected, 
isolated, and investigated. DNA shuffling is a commonly used technique to introduce 
semi-random mutations in the protein.4 Shuffling is widely considered as a human 
mimicry of the natural protein evolution process. This method involves preparation of 
recombinant variants of related homologous families. Other techniques such as staggered 
extension process (StEP), assembly PCR or synthetic shuffling, incremental truncation 
for the creation of hybrid enzymes (ITCHY), and non-homologous random 
recombination (NRR) exist for genetic recombination in protein evolution.5 Moreover, 
better techniques have been developed for introducing degenerate codons in the directed 
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evolution processes.6 With continuous advancements, protein engineering continues to 
remain a powerful field for the development of sequence-selective catalysts. 
However, several drawbacks exist with directed evolution (protein engineering). 
Firstly, proteins have long sequences. Only a limited set of variants can be created from a 
pre-existing starting point while maintaining the fundamental function of the initial 
enzyme. Secondly, selecting or screening for winners with desirable traits can be fairly 
tedious. Certain activities may require sophisticated robotics to screen through a huge 
number of variants. Not every activity can have a straightforward high-throughput 
screening readout. Separately, time intensive computational or bioinformatics analysis 
may be required to rationalize success of winners for subsequent evolution and 
mutations. Although protein engineering has achieved substantial success, practical 
considerations still limit the success of protein engineering to achieve  
sequence selectivity.  
In this chapter, efforts to identify DNA catalysts with sequence selectivity are 
elaborated. With phosphatase activity, we wish to expand our examination of peptide 
substrate sequences, seeking catalysts that have the selectivity to discriminate among 
varying phosphopeptides. Classical protein-tyrosine phosphatases have similar sequence 
amino acid preference for dephosphorylation of YP (acid over basic peptides).7 Protein 
enzymes like PTP1B are also highly proficient and can dephosphorylate majority of the 
YP substrates in the cytosol.7 Recombinant expression of protein-tyrosine phosphatases 
cannot achieve specific targeted catalysis. Tools like phosphatase deoxyribozymes can 
potentially address this problem. Three independent approaches to identify sequence-
selective catalysis in the context of phosphotyrosine phosphatase activity are discussed 
67 
 
here. A robust in vitro selection method to directly identify functional sequence-selective 
DNA catalysts starting from a library of 1014 molecules would be a milestone 
achievement in the biocatalytic endeavor, which will have the potential to strongly 
complement the protein engineering approach.  
3.1.1 Utility of Sequence Selective Enzymes in Biotechnology 
Engineering specificity and selectivity in proteases is of high importance in 
biotechnology (See Table 3.1). Proteases are often used in analytical and therapeutic 
applications.8 Directed evolution is used to allow identification of protease variants from 
randomized libraries. For instance, trypsin cleaves arginine and lysine residues at the C-
terminal portion.9 Using protein engineering trypsin was converted to chymotrypsin to 
cleave hydrophobic sites instead of the positively charged side chains.10-11 Native 
chymotrypsin found in pancreatic juices performs amide bond cleavage to the C-terminal 
portion of tyrosine, tryptophan and phenylalanine.12 Lysyl endopeptidase isolated from 
Achromobacter lyticus has a preference for lysine (positively charged residue).13 
Glutamyl endopeptidase catalyzes protease activity at the C-terminus of glutamate or 
aspartate (negatively charged amino acid).14 Although, few successes have been reported 
in obtaining specificity or selectivity from an initially different starting point, it is 
difficult to extensively fine-tune the activity without compromising the overall catalytic 
activity of the protease.15 
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Table 3.1. Proteases are listed with their sequence selectivity. Except Asp-N, all proteases shown here 
cleave at the C-terminal end of the specific amino acid residues.  
Protease Residues Notes 
Trypsin Lysine, Arginine Positively charged 
Chymotrypsin Tyrosine, Tryptophan, Phenyalanine Aromatic 
Lys-C Lysine Postively charged 
Glu-C Glutamate, Aspartate Negatively charged 
Asp-N Aspartate, Cysteine N-terminal cleavege 
Protein engineering has also been used for applications in organic synthesis as 
monooxygenases, ketoreductases, lipases or aldolases providing improved 
enantioselectivity and specificity.16 A good (catalytic active) starting point needs to be 
met with directed evolution, including negative selections for improved selectivity 
without losing initial activity. In vitro selection processes that directly help achieve 
identification of both activity and selectivity from an unknown starting point would be an 
important advancement in biotechnological research. 
3.1.2 Current Approaches for Achieving Selectivity in Nucleic Acid Catalysts 
Several research efforts have been devoted to establish selectivity with artificial 
nucleic acid catalysts. Negative selection is a process that is performed to remove DNA 
sequences that do not meet a specified selection criterion. Negative selections have been 
successfully used to identify selective catalytic DNA biosensors.17-18,19 Some examples 
include selective Co2+-, Na+-, Pb2+-, and uranyl-dependent DNA catalysts developed by 
Yi Lu and coworkers. Engineered molecular (ribo)switches have also been identified by 
negative selections.20 In spite of these documented successes, negative selection is not 
likely to be effective. Low or weak negative selection process allows several sequences 
with undesirable properties to survive, which eventually get amplified over and over.21 
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Developing a stringent negative selection procedure against phosphopeptide sequences 
(for selective phosphatase activity) is a not promising method to achieve 
 sequence selectivity.  
3.2 Results and Discussion 
Three independent approaches were tested for identification of DNA catalysts 
with sequence-selective phosphatase activity. A) Phosphopeptides with highly 
functionalized physical/chemical properties as the selection substrates. B) Apply 
selection pressure by spiking the reaction solution with free phosphopeptides (unrelated 
physical/chemical properties) as competitive ligands. C) Reverse complement inhibition 
to remove the undesirable sequence-general deoxyribozymes.  
3.2.1 Highly Functionalized Substrates with Varying Physical/Chemical Properties 
3.2.1.1 In vitro selection experiments 
New in vitro selection projects were initiated to identify sequence-selective DNA 
catalysts with phosphatase activity. The rationale was to use highly charged (positive and 
negative) and aromatic phosphopeptides as substrates for these new selections. Similar to 
natural and engineered proteases that function specifically with certain amino acid side 
chain residues, we hypothesized that phosphatase deoxyribozymes could be acquired 
with similar discriminatory properties. If highly functionalized peptidic substrates with 
varying chemical and physical attributes are provided, the odds of encouraging sequence 
selectivity increases. For positively charged peptide, we decided to use CAKKYPKKA, 
where YP is a phosphotyrosine. Similarly for negatively charged and aromatic 
phosphopeptides, we used CAEEYPEEA and CAFFYPFFA respectively.  
We also wished to explore phosphopeptide substrates of biological relevance. For 
that purpose, we utilized doubly phosphorylated fragment (8-18 residue) from Cyclic-
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Dependent Kinase 2 (CDK2).22 The kinase activity of CDK2 is dependent on the 
phosphorylation state of this fragment. Two positions, T14 and Y15, need to be in the 
dephosphorylated state for CDK2 to be enzymatically active. Even mutation of T14 and 
Y16 leads to increase in kinase activity of the CDK2.22 Hence the fragment containing 
T14 and Y15, CEKIGEGTPYPGVV with an extra cysteine handle at the N terminus, was 
used in our selection efforts. In addition, two phosphotyrosine-containing sequences from 
Insulin Receptor 1 and 2 (IRS1 and IRS2, see uniprot.org taxonomy ID 9606) were also 
utilized. The sequences were CIEEYPTEM (558-604 from IRS1) and CEGWYPRAL 
(133-139 from IRS2), both with an extra cysteine handle at the N terminus for 
conjugation to the DNA anchor. Each peptide was anchored as a disulfide through its N-
terminal Cys residue via a hexa(ethylene glycol) (HEG) tether to a DNA anchor 
oligonucleotide, which interacted with a fixed-sequence DNA segment by Watson–Crick 
base pairs.  
Contamination with generic enzymes is a major concern for selections efforts 
involving sequence selectivity. For instance phosphatases discovered in chapter 2 
(14WM9, 14M27) functioned promiscuously with a variety of phosphopeptides 
 (Figure 3.1).23 
 
Figure 3.1. Assays of 14WM9 with various hexapeptide substrate sequences in which one amino acid 
adjacent to the YP was altered, under selection conditions (figure from reference 23). 
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If independent selections were performed with different peptidic substrates, 
crossover of generic enzymes among every of these independent selections is a 
possibility. To prevent this contamination, new pools were designed and synthesized with 
different fixed constant binding arms flanking the random nucleotide region. This 
necessitates the use of different primers for every selection during polymerase chain 
reaction (PCR) amplification. However, crossover or contaminations among these 
selections are prevented (see Materials and Methods for details on pool, primers, splints 
and DNA anchors).  
The strategy to identify phosphatase deoxyribozymes was similar to the previous 
efforts described in chapter 2 (Figure 3.2). Phosphotyrosine-containing peptide substrate 
was covalently appended to a DNA anchor oligonucleotide (Figure 3.3), which was itself 
ligated to the deoxyribozyme pool. 
  
Figure 3.2. In vitro selection strategy is similar to that described in chapter 2 with a few key modifications. 
Each final deoxyribozyme has 40 particular nucleotides in its originally random N40 region. For each 
selection, different peptide was used as the substrate. The peptides are highly functionalized to have 
negative, positive or aromatic properties. 
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Figure 3.3. Conjugation of DNA anchor to the peptide. N-terminal cysteine of the peptide was conjugated 
to 3’-thiol oligonucleotide by dipyridyl disulfide activation. A model peptide (CAAYPAA) is shown as an 
example. Peptide sequences were varied according to the selection 
When the capture enzyme 15MZ36 was tested for all different peptides with 
tyrosine-OH, only slight variability in capture yield was observed. However, for peptide 
CAFFYFFA, the capture yield was insufficient to be useful for in vitro selection (<15%). 
All other peptides were efficiently captured by 15MZ36 (Figure 3.4). Selections were 
named FT1, FV1, FW1, FX1 and FY1 for E-rich, K-rich, CDK2, IRS1, and IRS2 
phosphotyrosine-containing peptidic fragments. 
After each key selection step that used incubation conditions of 70 mM HEPES, 
pH 7.5, 1 mM ZnCl2, 20 mM MnCl2, 40 mM MgCl2, and 150 mM NaCl at 37 °C for 14 
h, active DNA catalyst sequences were “captured” with the aid of the 15MZ36 
deoxyribozyme that selectively uses dephosphorylated tyrosine (YOH) as the nucleophile 
to attack 5′-triphosphorylated RNA, resulting in a PAGE shift for the corresponding 
deoxyribozyme sequence.23 The active DNA sequences were amplified by PCR and 
joined by T4 DNA ligase to the DNA-anchored peptide substrate for entering the next 
selection round. When the DNA pool reached considerable activity, individual 
deoxyribozymes were cloned and characterized. 
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Figure 3.4. Capture test with 15MZ36. Substantial capture yield was observed for all peptides. The capture 
method involved selective chelation of zinc (see chapter 2 and material and methods for more information). 
For peptide fragment from IRS2, 30% yield was observed (data not shown). PAGE image illustrating 
15MZ36-catalyzed capture for DNA-anchored CAAYOHAA, CAEEYOHEEA, CAKKYOHKKA, 
CEKIGETPYOHGVV and CIEEYOHTEM (left to right). Incubation conditions: 70 mM HEPES, pH 7.5, 20 
(40 and 60) mM MnCl2, 40 mM MgCl2, 100 mM NaCl, 37 °C. The capture yield is depicted at the bottom. 
 3.2.1.2 Cloning and sequences of the selection 
After several rounds of selection, activity was observed for at round 8 for FT1, 
round 10 FV1, and round 9 for FX1 (Figure 3.5). Individual sequences ere cloned and 
characterized. For FW1 and FY1, no activity was observed at round 14 and hence they 
were discontinued. 
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Figure 3.5. Progression of the in vitro selection experiment. In each round, “control” refers to the yield for 
the 15MZ36-catalyzed capture reaction using the DNA-anchored dephosphorylated CEGWYOHRAL 
substrate. Selection FT1, FV1 and FX1 were cloned at rounds 8, 10 and 9 respectively. 
Active sequences from FT1, FV1 and FX1 were aligned with phosphatases from 
earlier selections (14WM9 and 14WM27). If contamination were present, a strong 
similarity in sequence alignment would be observed in the N40 nucleotide region. 
Although a small portion of the 3’-end was conserved for sequences from both FT1 and 
FV1 selections with the 14WM9 and 14WM27 selections, no strong homology was 
otherwise observed. This was strongly indicative that none of the sequences were 
contamination products or relatives of the previous WM selections. FX1 selections shared 
no conserved region with WM selections at all. When all the sequences from FT1, FV1 
and FX1 were aligned together, no major homology was observed except for some 
conserved portion in the 3’-end among FT1 and FV1 (Figure 3.6).  
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Figure 3.6. Sequences of the new phosphatase deoxyribozymes. Only the enzyme region (N40) sequences 
are shown. For single-turnover intramolecular  reactions, each enzyme region was surrounded by additional 
DNA nucleotides (refer to Chapter 2 and Table 3.4). A) FT1 sequences with E-rich phosphopeptide were 
aligned with WM sequences show some conservation at the 3’ end. B) FV1 sequences with E-rich peptide 
show conservation at the 3’ end as well C) FX1 selections with the peptide CIEEYPTEM shows no 
homology. 
3.2.1.3 Single-Turnover dephosphorylation assay for selectivity 
FT1, FV1 and FX1 enzymes were tested for single-turnover dephosphorylation in 
the presence of Mg2+, Zn2+ and Mn2+ with the respective DNA-anchored phosphopeptide 
substrates for sequence selectivity. First, the FT1, FV1 and FX1 deoxyribozymes were 
tested for catalytic activity with DNA-anchored CAKKYPKKA. Even though selection 
FT1 and FX1 were performed with E-rich phosphopeptides, substantial 
dephosphorylation activity was observed with all enzymes for the K-rich phosphotyrosine 
substrate suggesting no sequence-selectivity with a K-rich substrate (Figure 3.7A). 
Similarly when all the FT1, FV1 and FX1 enzymes when tested with the DNA-anchored 
CAEEYPEEA substrate (negatively charged phosphopeptide), no selectivity was 
observed (Figure 3.7B). 
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Figure 3.7. DNA catalysts from selections FT1, FV1 and FX1 were tested for sequence selectivity with 
DNA-anchored K-rich phosphopeptide and E-rich phosphopeptide. A) Top panel shows the single-turnover 
test with DNA-anchored CAKKYPKKA. B) Lower panel shows the single-turnover assay with DNA-
anchored CIEEYPTEM. Note, same results were observed with CAEEYPEEA (data not shown). FT1, FV1 
and FX1 enzymes has different DNA anchor sequences (see Materials and Methods). 
This was rather surprising because we expected some degree of sequence 
selectivity. DNA is a negatively charged biopolymer. It is reasonable to expect some 
preference for the FV1 enzymes to have preference for the positively charged K-rich 
peptide over the E-rich counterpart. Nonetheless, empirical data suggests that no 
sequence selectivity was achieved. 
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3.2.2 Competitive Peptides for Sequence Selectivity
2
 
Although we had reasonable expectations for sequence-selectivity from the first 
approach, empirical data suggested that the new phosphatase deoxyribozymes were 
sequence general. Even so, selection pressure was not actively applied in the earlier effort 
to encourage sequence selectivity. There was no major incentive for DNA catalysts to 
recognize any specific sequence. To address this shortcoming in the previous approach, 
new selection efforts were initiated.  
In this approach, DNA-anchored phosphopeptide that is ligated to the pool is 
considered the actual substrate. In the selection buffer, free phosphotyrosine-containing 
peptides were unrelated physical and chemical properties were supplemented. These free 
phosphopeptides are expected to compete with the actual DNA-anchored phosphopeptide 
substrate. Only DNA catalysts that ignore the presence of free phosphopeptides and 
recognize the covalently tethered phosphopeptide for catalysis are expected to survive the 
selections (Figure 3.8). 
                                                 
 
 
2
 Prof. Silverman and I conceived and planned the project. University of Illinois undergraduate student 
Natalia Recko performed the in vitro selections with competitive peptides under my supervision.  
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Figure 3.8. In vitro selection in the presence of competitive ligands (or peptide) as an active selection 
pressure to encourage selectivity. DNA-anchored phosphopeptide is the actual substrate. Competitive 
phosphopeptides of unrelated properties are supplemented in the reaction solution. Only sequence-selective 
deoxyribozymes that are selective for the actual substrate and are not outcompeted by unrelated peptides 
will survive the selection. 
3.2.2.1 Testing selection conditions for competitive ligands 
To apply appreciable selection pressure, free peptide concentration needs to be 
substantially high to compete with the actual DNA-anchored phosphopeptide substrate. 
However, if the free peptide concentration is exceedingly high, non-specific inhibitory 
(or aggregation) effects will be observed leading to the failure of the in vitro selection 
efforts. To empirically determine a reasonable compromise in the concentration, 14WM9 
phosphatase deoxyribozyme was initially tested for catalytic activity in the presence of 
competitive phosphopeptides. 
DNA-anchored phosphopeptide (CAAYPAA), was tested with 14WM9 in 70 mM 
HEPES, pH 7.5, X mM ZnCl2 (where X is 1 mM, 1.5 mM, 2 mM and 3 mM), 20 mM 
MnCl2, 40 mM MgCl2, and 150 mM NaCl at 37 °C for 14 h in the presence of 2 mM free 
peptide peptides. The free peptides were systematically changed from A-rich, E-rich, K-
rich and F-rich phosphopeptides; i.e. AAAYPAAA, AEEYPEEA, AKKYPKKA and 
AFFYPFFA respectively (Figure 3.9). The F-rich peptide had the highest inhibitory effect 
79 
 
on DNA catalysis. This can be attributed to the hydrophobic property of AFFYPFFA. To 
minimize any such non-specific inhibition, the concentration of AFFYPFFA peptide was 
reduced from 2 mM to 0.5 mM. 
 
Figure 3.9. Single-turnover assays of the 14WM9 deoxyribozyme that dephosphorylates phosphotyrosine 
and phosphoserine side chains in the presence of competitive peptides. Assay conditions: 1 µM 14WM9, 
12.5 nM 5′-32P-radiolabeled DNA-anchored hexapeptide, 70 mM HEPES, pH 7.5, X mM ZnCl2(where X is 
1, 1.5, 2, 3), 20 mM MnCl2, 40 mM MgCl2, and 150 mM NaCl at 37 °C. In the assays with Zn
2+ alone, the 
Mn2+ and Mg2+ were omitted. Timepoints for CAAYPAA substrate is 12 h. Free peptides were 
supplemented in the selection buffer at the respective concentration. 
3.2.2.2 In vitro selections with competitive peptides  
Selections HM1, HN1, HP1 and HQ1 were initiated as depicted in Table 3.2. 
DNA-anchored peptides were prepared as mentioned in the earlier section via an N 
terminus cysteine handle. Peptides that lacking cysteines AXXYPXXA, where X = F, E, 
A, and K, were synthesized and purified by HPLC. These HPLC-purified peptides were 
used as competitive ligands. Based on the earlier results (Figure 3.9), 1mM of E-rich, K-
rich or A-rich phosphopeptides was a reasonable compromise between active selection 
pressure and disruptive non-specific inhibition. For F-rich peptide, a lower concentration 
of 0.5 mM was used because of the higher hydrophobic inhibition. The selection 
conditions were 70 mM HEPES, pH 7.5, 1 mM ZnCl2 (2 mM ZnCl2 for F-rich peptide), 
20 mM MnCl2, 40 mM MgCl2, and 150 mM NaCl at 37 °C for 14 h supplemented with 
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the respective HPLC-purified peptide at the appropriate concentration (0.5 or 1 mM). 
After 15 rounds of selection, no activity was observed and these selections were 
discontinued.  
Table 3.2 Selection HN1, HP1, HQ1, HM1 were designed with the following DNA-anchored 
phosphopeptides and HPLC-purified competitive peptides supplemented at the appropriate concentration. 
All peptides were spiked upto 1 mM in the selection step (except F-rich peptide, 0.5 mM) 
Selection DNA-anchored Substrate Competitive Peptide 
HN1 CAKKYPKKA AAAYPAAA (1mM) 
HP1 CAKKYPKKA AEEYPEEA ( 1 mM) 
HQ1 CAKKYPKKA AFFYPFFA (0.5 mM) 
HM1 CAAAYPAAA AKKYPKKA (1 mM) 
3.2.3 Reverse Complement Inhibition to Remove Undesirable Sequences
3
 
Because the two earlier efforts to identify sequence-selective deoxyribozymes 
were unsuccessful, a third approach was designed (Figure 3.10).  
 
Figure 3.10. Reverse complement selection involves inhibition of undesirable sequences A) Initial 
phosphatase pool contains sequence-general enzymes (blue) and sequence-selective enzymes (red). B) 
Sequence-general enzymes are inhibited as a double-stranded DNA by Watson-Crick base pairing. 
This approach relies on inactivation of undesirable sequence-general single-
stranded deoxyribozymes using the complementary reverse strand. Inactivation of 
                                                 
 
 
3
 Prof. Silverman and I conceived and planned the project for reverse complement inhibition. 
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undesirable sequences by Watson-Crick base pairing is expected to be a powerful 
alternative to performing a negative selection. 
3.2.3.1 In vitro selection strategy with reverse complement method 
A procedure was carefully devised to identify sequence-selective phosphatases 
with the reverse complement technique. Selections would be performed with the 
desirable substrate for a certain amount of rounds. A late-stage selection pressure would 
be applied when the pool is already enriched with phosphatase sequences, including both 
sequence-general and sequence-selective DNA catalysts. At this point, the selection 
would be split into two routes (Figure 3.11). The first portion of the pool would be passed 
through a selection process involving the undesirable substrate (red pathway). After the 
selection and capture, PCR amplification would be performed. However, instead of 
isolating the sense strand, the complementary (anti-sense) strand would be purified. The 
second portion of the pool will be passed through a selection process involving the 
desirable substrate (shown in green). During the selection step with the desirable 
substrate, the purified complementary (anti-sense) strands will be pooled together. This 
leads to specific inactivation of the single-stranded DNA that are functional with the 
undesirable substrate from the red pathway. Importantly, sequences that work selectively 
with the desirable substrate will be unaffected and survive the selection round. In 
summary, the overall process will lead to suppression of the sequence-general catalyst 
enabling the enrichment of the sequence-selective DNA catalysts. These selective DNA 
catalysts are expected to function specifically with the desirable used in the green 
pathway.  
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This selection process, if successful, gives a great degree of control on the desired 
selectivity. The desired and the undesired substrates can be fined tuned for a specific 
downstream biological application and is not limited to just phosphatase activity. 
 
Figure 3.11. Reverse complement inhibition is a selection pressure projected to strongly suppress the 
undesirable sequences. A) Green curve involves the steps with the desirable substrate. B) Red pathway 
involves a selection step with an undesirable substrate. The reverse complement is isolated after the PCR 
enrichment and used to inhibit the general sequences during the selection step with the actual substrate. 
3.2.3.2 Validation of the strategy 
It is important to validate the reverse complement inhibition strategy before 
initiating the new selection process. For that purpose, positive and negative controls were 
designed and performed with a catalytically active phosphatase pool (round 14WM 
selections mentioned in Chapter 2).  
Three test cases were investigated. A) No reverse complement, B) Random 
reverse complement, C) Exact reverse complement to the pool (see Materials and 
Methods for details). Selection step was performed with 70 mM HEPES, pH 7.5, 1 mM 
ZnCl2, 20 mM MnCl2, 40 mM MgCl2, and 150 mM NaCl at 37 °C for 14 h, in the 
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presence of respective reverse complement (anti-sense) sequences. The selection sample 
was then purified by an 8% denaturing PAGE to remove these additional reverse 
complement components. The solution was brought back to 20 µL with 50 pmol of 
15MZ36, 100 pmol of 5’-triphosphorylated RNA in 70 mM HEPES, pH 7.0, 20 mM 
MnCl2, 40 mM MgCl2, and 150 mM NaCl at 37 °C for 14 h. Only catalytically active 
DNA sequences should be captured. Results indicated that catalytic activity of the active 
pool was unaffected in the presence of random reverse complement. However, when the 
exact reverse complement was utilized, catalytic activity was suppressed because of the 
formation of a double-stranded DNA indicating that catalytic suppression was highly 
specific (Figure 3.12). These controls were strongly indicative that this reverse 
complement inhibition strategy is a viable pathway to allow enrichment of sequence-
selective DNA catalysts. 
 
Figure 3.12. Assay for validation of the reverse complement technique with 14WM phosphatase pool. This 
assay ensures that reverse complement inhibition is specific. A) Lane 1 shows that exact reverse 
complement leads to complete phosphatase inhibition. B) No reverse complement was added to the 
phosphatase pool. C) Capture activity with CAAYOHAA. D) Random reverse complement sequences led to 
negligible catalytic suppression (see Materials and Methods for details). 
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3.2.3.3 In vitro selection with the reverse complement strategy  
Because we are concerned about non-specific inhibition of DNA sequence in the 
initial rounds by random reverse complement sequences, we theorized that the best 
strategy is to apply a late-stage selection pressure when phosphatase deoxyribozymes 
already dominate the pool. If the sequence-selective DNA sequences are in lower copy 
number compared to the general sequences, we still expect the general sequences to get 
inhibited or suppressed by the reverse complement approach. The suppression of general 
phosphatases eventually enables the desirable sequence-selective deoxyribozymes to get 
enriched. This is a strong feedback approach for removing unwanted sequences. New 
selections involving the reverse complement approach were redirected from the later 
rounds of WM, FT1 and FV1. The plans for reverse complement selections are depicted 
in Table 3.3. 
Table 3.3. Selection MK1 to MS1. These selections were intiated from WM, FT1 and FV1 selections. The 
desirable, undesirable substrates, including the expected outcome are shown for each selection. 
Selection Desirable substrate 
(green pathway) 
Undesirabale substrate 
(red pathway) 
Expected outcome 
13WM → 14MK1 CAAAYPAAA None Sequence general 
13WM → 14ML1 CAAAYPAAA Random Sequence general 
13WM → 14MM1 CAAAYPAAA Exact No activity 
13WM → 14MN1 CAAAYPAAA CAFFYPFFA A-rich vs. F-rich 
7FT1 → 8MP1 CAEEYPEEA CAKKYPKKA E-rich vs. K-rich 
7FT1 → 8MQ11 CAEEYPEEA CAFFYPFFA E-rich vs F-rich 
7FV1 → 8MR1 CAKKYPKKA CAEEYPEEA K-rich vs. E-rich 
7FV1 → 8MS1 CAKKYPKKA CAFFYPFFA K-rich vs. F-rich 
These selections had properly designed controls MK1, ML1, MM1. The selection 
MK1 was continued from 13WM (active pool) without addition of any reverse 
complement. Selection ML1 had random reverse complements supplemented in the 
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selection process. Because random sequences are unrelated to the pool, no inhibitory 
activity by Watson-Crick base pairing is expected. For MM1 selections, the reverse 
complement from the same selection round was used for inhibition. Completely 
suppression by Watson-Crick base pairing is expected here between the sense and anti-
sense strand. Other selections were designed for specifically controlled desirable 
selectivity (see Table 3.3). For instance, MN1 was designed with the peptide 
CAAAYPAAA (in the green pathway) as the desirable substrate and CAFFYPFFA (red 
pathway) as the undesirable substrate. The likely outcome would be DNA catalysts with 
preferential activity for A-rich peptide over the F-rich peptide. Similarly, MP1, MQ1, 
MR1 and MS1 were designed for varied selectivity outcomes (Table 3.3).  
15MZ36 couldn’t function properly with CAFFYFFA as a “capture” enzyme. 
However another nucleopeptide-linkage forming deoxyribozymes 8HJ102,24 functioned 
with the F-rich peptide forming nucleopeptide linkage with YOH in a F-rich peptide as the 
nucleophile (see material and methods). Capture enzyme 8HJ102 was used in pathways 
involving F-rich peptides.  
The selections were pursued for 4 additional rounds. No activity was observed for 
the selections MN1 to MS1 even though the controls selections functioned normally as 
expected (Figure 3.13). Hence these selections were discontinued. 
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Figure 3.13. Capture step for selection with the reverse complement inhibition approach. Rounds 14MK1-
14MN1 and 8MP1-8MS1 are depicted here. The left lane denotes the capture control with CAAYOHAA. 
14MK1 (no reverse complement) and 14ML1 (random reverse complement) control selections show 
similar activity. For 14ML1 with the exact reverse complement, catalytic suppression of activity is 
observed. All the other selections showed background capture with little or no activity. The lower band is 
the DNA-anchored peptide ligated to the pool. The top band denotes capture with 15MZ36 and a 5’-
triphosphorylayted RNA/DNA chimera. 
3.3 Summary 
In summary, three different approaches were applied to enable identification of 
sequence-selective deoxyribozymes with phosphatase activity. The first approach utilized 
highly functionalized peptides (extreme physical or chemical properties) as the DNA-
anchored substrates (FT1-FY1). They were highly charged (positive or negative) or 
aromatic. The hypothesis was that, DNA catalysts arising from such selections would 
have a natural propensity to function superficially with closely related phosphotyrosine-
containing sequence. Unfortunately, the DNA catalysts identified from such selections 
were sequence general and functioned with any phosphotyrosine-containing sequence 
showing no noticeable discriminatory properties. In these efforts, DNA pools were 
synthesized with different primer-binding regions flanking the random nucleotide region. 
This was a pre-emptive measure to disallow general deoxyribozymes from contaminating 
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or crossing over to unrelated selections. However, no active pressure for selectivity was 
applied in this first effort to encourage selectivity. 
In the second effort, competitive peptides were utilized as an active selection 
pressure to enable selectivity. DNA-anchored phosphopeptide was formally the actual 
substrate for phosphatase activity. The selection buffer was supplemented with 
millimolar quantity of free phosphopeptide. The free peptides YP-containing peptides had 
physical and chemical properties unrelated to the DNA-anchored substrate (selections 
HM1-HQ1). Only selective deoxyribozymes that are capable of ignoring the presence of 
free phosphopeptides, but function specifically with the DNA-anchored phosphopeptides 
should survive the selections. Concentration of the free peptide was carefully optimized 
to overcome the effective molarity of the DNA-anchored peptide, but to not have non-
specific inhibition or aggregation on catalysis. However, these efforts failed to provide 
activity. We theorized that adding millimolar amounts of free phosphopeptides in 
solution are harsh conditions to enable DNA catalysis from the initially random pool, 
even though our preliminary design establishes that DNA phosphatases to be active under 
such conditions millimolar quantities of free peptide. 
In the third effort, a rational reverse complement approach was utilized to identify 
sequence-selective DNA catalysts. This approach involved splitting the selection process 
into two pathways. One pathway involved the undesirable substrate while the other 
involved the desirable one. The pool ligated to undesirable substrate was passed through 
a selection step followed by the enrichment and capture of the active sequences by PCR 
amplification. The reverse complement (or the anti-sense) sequences are isolated. These 
sequences are added in the selection step of the desirable pathway (where the correct 
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substrate is ligated to the pool). Specific inactivation or suppression by Watson-Crick 
base pairing is expected for the DNA catalysts in the pool that function with undesirable 
substrate. Only selective sequences that merely function with the desirable substrate on 
the other hand are expected to survive the process and get enriched. Although controls 
were establish, validated and carried in parallel with the actual selections (MK1-MM1), 
no activity was observed for actual selections. 
It is rather surprising that we have not been able to identify sequence-selective 
phosphatase deoxyribozymes. We expect DNA to show some preference for the adjacent 
peptide side chain residues. For instance, a DNA catalyst functioning with super 
positively charged phosphopeptide should get repelled by a super negatively charged 
peptidic substrate. Or DNA being a negatively charged molecule itself, should have 
preferential binding and catalysis for a positive charged (K-rich) phosphopeptide 
substrate. Likewise, we would expect a negatively charged biopolymer like DNA to have 
bias for positively charged phosphopeptides over the negatively charged peptides. In spite 
of having rational and well-controlled methods to improve enrichment of sequence-
selective deoxyribozymes, we haven’t been successful in such endeavors. On a promising 
note, DNA has shown its ability to be sequence-selective for other activities.25 This is 
suggestive that although sequence selectivity has not been achieved with phosphatase 
activity, DNA is capable of such sequence-selective catalysis in other processes.  
3.4 Materials and Methods 
3.4.1 Oligonucleotides and In vitro Selection 
DNA oligonucleotides were obtained from Integrated DNA Technologies 
(Coralville, IA) or prepared by solid-phase synthesis on an ABI 394 instrument using 
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reagents from Glen Research. 5′-Triphosphorylated RNA oligonucleotides were prepared 
by in vitro transcription using synthetic DNA templates and T7 RNA polymerase.26 All 
oligonucleotides were purified by 7 M urea denaturing PAGE with running buffer 1× 
TBE (89 mM each Tris and boric acid and 2 mM EDTA, pH 8.3) as described previously. 
The 5′-Triphosphorylated RNA/DNA chimera was synthesized as described in Walsh et 
al.27 A different 5′-Triphosphorylated RNA was used for capture reaction with the 
enzyme 8HJ102. The synthesis and sequence of the 5′-triphosphorylated RNA used for 
8HJ102 capture is described in Chu et al.24  
3.4.2 Synthesis of Peptides and DNA-Anchored Peptides 
Peptides were prepared by solid-phase synthesis on Fmoc Rink amide MBHA 
resin (AAPPTec). Each peptide was coupled to the DNA anchor oligonucleotide via the 
N-terminal cysteine side chain (linkage created by disulfide formation).  
3.4.2.1 Synthesis of peptides. Peptides were prepared by solid-phase synthesis using 
Fmoc Rink amide MBHA resin, with N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-
yl)uronium hexafluorophosphate (HATU) as coupling agent. Each synthesis was 
performed at 0.2 mmol scale, initiated using 308 mg of Rink amide resin with a loading 
capacity of 0.65 mmol/g (AAPPTec). All steps were monitored by ninhydrin test. For 
each coupling, 5 equivalents (1.0 mmol) of Fmoc-amino acid, 4.9 equivalents (373 mg, 
0.98 mmol) of HATU, and 10 equivalents (350 µL, 2.0 mmol) of N,N-
diisopropylethylamine (DIPEA) were mixed in 5 mL of anhydrous DMF. The coupling 
reaction was initiated by adding this mixture to the resin and agitating by bubbling with 
nitrogen for 60 min, followed by washing with DMF (3 × 10 mL). The N-terminus of the 
newly installed amino acid was deprotected by agitating the resin in 20% piperidine in 
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DMF (5 mL) under nitrogen for 5 min a total of three times, each time washing with 
DMF (3 × 5 mL). Peptides with N-terminal cysteine were capped via acetylation of their 
N-terminus by agitating the resin in 50 equivalents (924 µL, 10 mmol) of acetic 
anhydride and 25 equivalents of DIPEA (870 µL, 5 mmol) in 5 mL of DMF under 
nitrogen for 30 min. The peptide was cleaved from the solid support by stirring the resin 
in a separate vial with a solution containing 5 mL of trifluoroacetic acid (TFA), 125 µL 
of water, 125 µL of ethanedithiol, and 50 µL of triisopropylsilane for 90 min. The liquid 
solution was separated from the resin by filtration. This solution was dried on a rotary 
evaporator, providing a solid. To this material 15 mL of cold diethyl ether was added, and 
the peptide was obtained as a white solid that was filtered. Peptides with cysteine at the N 
terminus were used without HPLC purification (as crude substrates) for conjugating with 
the DNA anchor. All other peptides were purified by HPLC. 
3.4.2.2 Synthesis of DNA-anchored peptides. Each peptide was coupled to the DNA 
anchor oligonucleotide via the N-terminal cysteine side chain (linkage created by 
disulfide formation). The DNA anchor oligonucleotide (see Table 3.4 for sequence 
information for each selection) ended with a HEG-C3-SS-C3-OH-3′, where HEG stands 
for hexaethylene glycol linker.23 The HEG-3′-disulfide linker was introduced via standard 
solid-phase DNA synthesis and unmasked to a 3′-thiol by DTT treatment. A 50 µL 
sample containing 2-5 nmol of DNA anchor oligonucleotide in 50 mM HEPES, pH 7.5, 
and 50 mM DTT was incubated at 37 °C for 2 h. The reduced product was precipitated to 
remove excess DTT by addition of 50 µL of water, 10 µL of 3 M NaCl, and 300 µL of 
ethanol. The precipitated product (DNA-HEG-C3-SH) was dissolved in 45 µL of water. 
Activation as the pyridyl disulfide was achieved by adding 5 µL of 100 mM 2,2′-
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dipyridyl disulfide in DMF and incubating at 37 °C for 2 h. The product (DNA-HEG-C3-
SSPy) was precipitated by addition of 50 µL of water, 10 µL of 3 M NaCl and 300 µL of 
ethanol and dissolved in 25 µL of water. Conjugation to the peptide was performed by 
adding 20 µL of 50 mM triethylammonium acetate, pH 7.0, and 5 µL of 40 mM peptide 
(200 nmol). The sample was incubated at 37 °C for 2 h, and the DNA-anchored peptide 
was purified by 20% PAGE. A typical yield was 2-3 nmol. See Table 3.5 for MALDI 
mass spectrometry values. 
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Table 3.4. Different pools were used for each selection. Sequences are written 5′ to 3′. X denotes a HEG 
spacer to stop Taq polymerase from extending further. This enables separation of the single-stranded DNA. 
Sequence Y stands for the 40-nucleotide portion of 15MZ36, CAAGGAGAGTTGTACAAGCTCGGGTCGTGTTCAAAGG-
GATC 
oligonucleotide purpose oligonucleotide sequence 
Selection FT1 details (with CAKKY
P
KKA) 
DNA-HEG- substrate GGACTACCTTTATGCGTAT-HEG-C3-SH 
forward primer for selection CGAACGAAAGCCTCCTTC 
reverse primer for selection (AAC)4XCCATCAGGATCAGCT 
random pool for selection CGAACGAAAGCCTCCTTC-N40-ATACGCATAAAGGTAGAGCTGATCCTGATGG 
15MZ36 capture enzyme CCGTCGCCATCTCTTC-Y-ATACGCATAAAGGTAGTCCCCATCAGGATCAGC 
splint for ligation step during selection a ATAAGAAACGAGATATTCCTCCATCAGGATCAGCTATATCTCGTTTCTTAT 
Selection FV1 details (with CAEEY
P
EEA) 
DNA-HEG- substrate GGAATATCTCGTTTCTTAT-HEG-C3-SH 
forward primer for selection CGAATTAAGACTGAATTC 
reverse primer for selection (AAC)4XCCATCAGGATCAGCT 
random pool for selection CGAATTAAGACTGAATTC -N40-ATAAGAAACGAGATATAGCTGATCCTGATGG 
15MZ36 capture enzyme CCGTCGCCATCTCTTC-Y-ATAAGAAACGAGATATTCCCCATCAGGATCAGC 
splint for ligation step during selection a ATACCAATCAAGCCATTCCTCCATCAGGATCAGCTATGGCTTGATTGGTAT 
Selection FW1 details with (CEKIGEGT
P
Y
P
GVV) 
DNA-HEG- substrate GGAATGGCTTGATTGGTAT-HEG-C3-SH 
forward primer for selection CGAATTGAGTAAATATTC 
reverse primer for selection (AAC)4XCCATCAGGATCAGCT 
random pool for selection CGAATTGAGTAAATATTC -N40-ATACCAATCAAGCCATAGCTGATCCTGATGG 
15MZ36 capture enzyme CCGTCGCCATCTCTTC-Y-ATACCAATCAAGCCATTCCCCATCAGGATCAGC 
splint for ligation step during selection a ATATGTCTTTCAATAGTCCTCCATCAGGATCAGCTCTATTGAAAGACATAT 
Selection FX1 details (with CIEEY
P
TEM) 
DNA-HEG- substrate GGACTATTGAAAGACATAT-HEG-C3-SH 
forward primer for selection CGAAATGATGGCTATTTC 
reverse primer for selection (AAC)4XCCATCAGGATCAGCT 
random pool for selection CGAAATGATGGCTATTTC -N40-ATATGTCTTTCAATAGAGCTGATCCTGATGG 
15MZ36 capture enzyme CCGTCGCCATCTCTTC-Y-ATATGTCTTTCAATAGTCCCCATCAGGATCAGC 
splint for ligation step during selection a ATAATTAGTAACCTGATCCTCCATCAGGATCAGCTTCAGGTTACTAATTAT 
Selection FY1 details (with CEGWY
P
RAL) 
DNA-HEG- substrate GGATCAGGTTACTAATTAT-HEG-C3-SH 
forward primer for selection CGAAATAGATTATCATTC 
reverse primer for selection (AAC)4XCCATCAGGATCAGCT 
random pool for selection CGAAATAGATTATCATTC -N40-ATAATTAGTAACCTGAAGCTGATCCTGATGG 
15MZ36 capture enzyme CCGTCGCCATCTCTTC-Y-ATAATTAGTAACCTGATCCCCATCAGGATCAGC 
splint for ligation step during selection a ATATCATCAGTGGCTCTCCTCCATCAGGATCAGCTGAGCCACTGATGATAT 
Selection HQ1 details  
DNA-HEG- substrate GGATCCTGGATACAAATAT-HEG-C3-SH 
forward primer for selection CGAAGTATAAACCTGTTC 
reverse primer for selection (AAC)4XCCATCAGGATCAGCT 
random pool for selection CGAAGTATAAACCTGTTC -N40-ATATTTGTATCCAGGAAGCTGATCCTGATGG 
15MZ36 capture enzyme CCGTCGCCATCTCTTC-Y-CCGTCGCCATCTCTTCCCATCAGGATCAGC 
splint for ligation step during selection a ATATTTGTATCCAGGATCCTCCATCAGGATCAGCTTCCTGGATACAAATAT 
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a The underlined T in the splint was absent in the round 1 ligation step because the DNA pool in this 
step was prepared by solid-phase synthesis and therefore did not have an untemplated A nucleotide at its 3′-
end. The underlined T was included in all other selection rounds to account for the untemplated A 
nucleotide that is added at the 3′-end of each PCR product by Taq polymerase. 
Table 3.5. MALDI-MS for the DNA-anchored peptide substrates are depicted in this table.
 a
 indicates that 
mass spec was not specifically obtained for this substrate, but we have high confidence because the MS of 
the oligonucleotide and peptide were independtly determined and simultaenous conjugations were 
performed in parallel with MS of the other conjugates validated. All masses are [M+H] in positive mode. 
Refer to Table 3.4 for sequence information about the DNA anchor. 
DNA-anchored 
peptide 
mass 
calcd. 
mass 
found 
error, % 
(found – 
calcd.) 
For selections WM, MK1, and ML1 
DNA-HEG-CAAAY
P
AAA 7125.1 7124.8  –0.004 
DNA-HEG-CAFFY
P
FFA 7429.4 7429.1  –0.004 
For selections FT1, MP1, and MQ1 
DNA-HEG-CAEEY
P
EEA 7355.2 7355.3 +0.001 
DNA-HEG-CAKKY
P
KKA 7351.4 7349.4 –0.027 
DNA-HEG-CAFFY
P
FFA 7427.4 7428.1 +0.009 
For selections FV1, MR1, and MS1 
DNA-HEG-CAEEY
P
EEA 7345.2 
a
 Na 
DNA-HEG-CAKKY
P
KKA 7341.4 7340.9 –0.007 
DNA-HEG-CAFFY
P
FFA 7417.4 7418.6 +0.016 
For selection FW1 and HM1 
DNA-HEG-CEKIGEGT
P
Y
P
GVV 7866.7 7868.3 +0.020 
DNA-HEG-CAAAY
P
AAA 7243.1 
a
 Na 
For selection FX1 and HN1 
DNA-HEG-CIEEY
P
TEM 7495.4 7494.0 –0.019 
DNA-HEG-CAKKY
P
KKA 7417.5 
a
 Na 
For selection FY1 and HP1 
DNA-HEG-CEGWY
P
RAL 7457.4 7459.1 +0.023 
DNA-HEG-CAKKY
P
KKA 7399.5 7398.2 –0.018 
For selection HQ1 
DNA-HEG-CAKKY
P
KKA 7434.5 7434.1 –0.005 
3.4.3 In Vitro Selection Procedure for FT1-FY1 Selections 
The selection procedure, cloning, and initial analysis of individual clones were 
performed essentially as described previously.23,28 The random deoxyribozyme pool, 
PCR primers (both forward and reverse) are shown in the Table 3.4. In each round, 
ligation step was used to attach the deoxyribozyme pool at its 3′-end to the 5′-end of the 
DNA-anchored phosphopeptide substrate using a DNA splint and T4 DNA ligase. The 
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splint sequence is shown in Table 3.4 as well. A nucleotide is added at the 3′-end of each 
PCR product by Taq polymerase. This T nucleotide was omitted from the splint used for 
ligation of the initially random N40 pool, which was prepared by solid-phase synthesis. 
Nucleotide sequences of the DNA anchor oligonucleotide, the deoxyribozyme binding 
arms and the full 15MZ36 capture deoxyribozymes are depicted in Table 3.4. 5’-
Triphosphorylated RNA sequence is the same as used previously in chapter 2.  
Procedure for ligation step in round 1. A 34 µL sample containing 1 nmol of DNA pool, 
850 pmol of DNA splint, and 750 pmol of 5′-phosphorylated DNA-peptide substrate was 
annealed in 5 mM Tris, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by heating at 95 °C for 
3 min and cooling on ice for 5 min. To this solution was added 4 µL of 10× T4 DNA 
ligase buffer (Fermentas) and 2 µL of 5 U/µL T4 DNA ligase (Fermentas). The sample 
was incubated at 37 °C for 12 h and purified by 8% PAGE. 
Procedure for ligation step in subsequent rounds. A 16 µL sample containing the PCR-
amplified DNA pool (~5–10 pmol), 20 pmol of DNA splint, and 30 pmol of 5′-
phosphorylated DNA-phosphopeptide substrate was annealed in 5 mM Tris, pH 7.5, 15 
mM NaCl, and 0.1 mM EDTA by heating at 95 °C for 3 min and cooling on ice for 5 
min. To this solution was added 2 µL of 10× T4 DNA ligase buffer (Fermentas) and 2 µL 
of 1 U/µL T4 DNA ligase (Fermentas). The sample was incubated at 37 °C for 12 h and 
purified by 8% PAGE. 
Procedure for selection step in round 1. Each selection experiment was initiated with 200 
pmol of the ligated N40 pool. A 15 µL sample containing 200 pmol of ligated N40 pool 
was annealed in 5 mM HEPES, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by heating at 
95 °C for 3 min and cooling on ice for 5 min. The selection reaction was initiated by 
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bringing the sample to 30 µL total volume containing 70 mM HEPES, pH 7.5, 1 mM 
ZnCl2, 20 mM MnCl2, 40 mM MgCl2, and 150 mM NaCl. The sample was incubated at 
37 °C for 14 h. 
Procedure for selection step in subsequent rounds. A 10 µL sample containing ligated 
pool was annealed in 5 mM HEPES, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by 
heating at 95 °C for 3 min and cooling on ice for 5 min. The selection reaction was 
initiated by bringing the sample to 20 µL total volume containing 70 mM HEPES, pH 
7.5, 1 mM ZnCl2, 20 mM MnCl2, 40 mM MgCl2, and 150 mM NaCl. The sample was 
incubated at 37 °C for 14 h. 
Procedure for capture step in round 1. To the 30 µL selection sample was added 1.2 µL 
of 50 mM EDTA, pH 8.0 (60 nmol). The sample was then brought to 45 µL total volume 
containing 300 pmol of 15MZ36 capture deoxyribozyme, 400 pmol of 5′-
triphosphorylated RNA substrate, 20 mM MnCl2, and 40 mM MgCl2 and incubated at 37 
°C for 14 h. 
Procedure for capture step in subsequent rounds. To the 20 µL selection sample was 
added 0.8 µL of 50 mM EDTA, pH 8.0 (40 nmol). The sample was then brought to 25 µL 
total volume containing 40 pmol of 15MZ36 capture deoxyribozyme, 80 pmol of 5′-
triphosphorylated RNA substrate, and 20 mM MnCl2, 40 mM MgCl2, and incubated at 37 
°C for 14 h. 
Procedure for PCR. In each selection round, two PCR reactions were performed, 10-
cycle PCR followed by 30-cycle PCR. First, a 100 µL sample was prepared containing 
the PAGE-purified selection product, 200 pmol of forward primer, 50 pmol of reverse 
primer, 20 nmol of each dNTP, and 10 µL of 10× Taq polymerase buffer (1× = 20 mM 
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Tris-HCl, pH 8.8, 10 mM (NH4)2SO4, 10 mM KCl, 2 mM MgSO4, and 0.1% Triton X-
100). This sample was cycled 10 times according to the following PCR program: 94 °C 
for 2 min, 10× (94 °C for 30 s, 47 °C for 30 s, 72 °C for 30 s), 72 °C for 5 min. Taq 
polymerase was removed by phenol/chloroform extraction. Second, a 50 µL sample was 
prepared containing 1 µL of the 10-cycle PCR product, 100 pmol of forward primer, 25 
pmol of reverse primer, 10 nmol of each dNTP, 20 µCi of α-32P-dCTP (800 Ci/mmol), 
and 5 µL of 10× Taq polymerase buffer. This sample was cycled 30 times according to 
the following PCR program: 94 °C for 2 min, 30× (94 °C for 30 s, 47 °C for 30 s, 72 °C 
for 30 s), 72 °C for 5 min. Samples were separated by 8% PAGE. 
3.4.4 Testing for Sequence Selectivity (FT1, FV1, and FX1) 
The DNA-anchored phosphopeptide substrate was 5′-32P-radiolabeled using γ-32P-
ATP and Optikinase (USB), which lacks the 3′-phosphatase activity that we have found 
also dephosphorylates tyrosine and serine side chains. A 10 µL sample containing 0.25 
pmol of 5′-32P-radiolabeled DNA-anchored phosphopeptide substrate and 20 pmol of 
deoxyribozyme was annealed in 5 mM HEPES, pH 7.5, 15 mM NaCl, and 0.1 mM 
EDTA by heating at 95 °C for 3 min and cooling on ice for 5 min. The DNA-catalyzed 
dephosphorylation reaction was initiated by bringing the sample to 20 µL total volume 
containing 70 mM HEPES, pH 7.5, 1 mM ZnCl2, 20 mM MnCl2, 40 mM MgCl2, and 150 
mM NaCl. The sample was incubated at 37 °C. At appropriate time points, 5 µL aliquots 
were quenched with 5 µL stop solution (80% formamide, 1× TBE [89 mM each Tris and 
boric acid and 2 mM EDTA, pH 8.3], 50 mM EDTA, 0.025% bromophenol blue, 0.025% 
xylene cyanol). Correctly matched DNA-anchored peptides were tested with the 
appropriate enzymes. For instance, when testing FT1 deoxyribozymes, the DNA anchor 
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used for FT1 selection (shown in Table 3.4) was used to attach and test the different 
peptidic substrates. The peptide sequences were varied from CAKKYPKKA, 
CAEEYPEEA and CIEEYPTEM. Using a 20% PAGE, single-turnover 
desphosphorylation was difficult to investigate for DNA-anchored CAEEYPEEA, 
because the substrate and the product migrated closely (data not shown). Hence peptide 
CIEEYPTEM was formally used as a surrogate for E-rich phosphopeptide in the 
selectivity assay although CAEEYPEEA was confirmed for dephosphorylation as well. 
3.4.5 In Vitro Selection Procedure for HM1 to HQ1 
For selections involving competitive ligands, the procedure was similar to that 
described in section 3.4.3 with the following modification; free peptides (with properties 
different to the actual DNA-anchored substrate) were supplemented in the buffer as an 
active selection pressure to encourage sequence selectivity. Details for the pool, primers, 
ligation splint, 15MZ36 capture enzyme, and DNA anchor can be found in Table 3.4. 
HM1 selection was similar to FW1 selection with DNA-anchored CAAAYPAAA as the 
actual substrate and 1 mM AKKYPKKA (free peptide) supplemented in the selection 
buffer as a selection pressure. HN1 mimicked FX1 selection with CAKKYPKKA as 
DNA-anchored peptide and 1 mM AAAYPAAA supplemented in the selection buffer. 
HN1 mimicked the FX1 selection with CAKKYPKKA as DNA-anchored peptide and 1 
mM AAAYPAAA supplemented in the selection buffer. 
For HQ1 selection, information for the sequences is provided in Table 3.4. The actual 
substrate was CAKKYPKKA and the competitive substrate was AFFYPFFA (0.5 mM). 
The selection condition used 2 mM of ZnCl2 instead of the conventional 1 mM Zn
2+ 
during the capture step. For the 15MZ36 capture step, the amount of EDTA was 
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increased twice to selectively quench the excess zinc followed by addition of the 
15MZ36 capture enzyme and the 5’-triphosphorylated DNA. 
3.4.6 In Vitro Selection Procedure for MK1-MN1 
Selections 14MK1, 14ML1, 14MM1 and 14MN1 were continued from 13WM 
(WM selections discussed in chapter 2). For a general overview of the reverse 
complement inhibition selections, please refer to Figure 3.11. Information about primers, 
pool, ligation splint, and capture deoxyribozyme 15MZ36 is provided in chapter 2. The 
pool was divided into two portions, one for the undesirable substrate and the other for the 
desirable substrate. Details about the desirable and undesirable substrates are discussed in 
Table 3.3. 
3.4.6.1 Procedure for the undesirable substrate (Red pathway) 
For MK1 and ML1 were control selections with no undesirable substrates. For 
MM1, DNA-anchored CAAAYPAAA was the substrate. For MN1, the substrate was 
DNA-anchored CAFFYPFFA. Ligation, selection and capture steps were performed with 
15MZ36 for MM1. However, the capture enzyme for MN1 (F-rich peptide) was 8HJ102 
with the following sequence, 5’-CCCGAAAGCCTCCTTCGGGAGATGTCTCTCAGACGGAAACTTTC-
AGTACGGAATGGATAGTGAGTCGTATTATCCCCATCAGGATCAGC-3’, and a different 5’-
triphosphorylated RNA sequence specific to 8HJ102.24 Addition of EDTA for selection 
chelation in the capture step was omitted because 8HJ102 is a zinc-dependent enzyme 
that functions optimally with 40 mM Mg2+, 20 mM Mn2+ and 1 mM Zn2+.  
After the capture step, 10-cycle PCR was performed. Second, a 50 µL sample was 
prepared containing 1 µL of the 10-cycle PCR product, 25 pmol of forward primer, 100 
pmol of modified long reverse primer (5’-(AAC)12XCCATCAGGATCAGCT-3’), 10 nmol of 
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each dNTP, and 5 µL of 10× Taq polymerase buffer. This sample (scaled up to 6 times) 
was cycled 30 times according to the following PCR program: 94 °C for 2 min, 30× (94 
°C for 30 s, 47 °C for 30 s, 72 °C for 30 s), 72 °C for 5 min. The PCR sample was 
combined to 300 µL and precipitated by adding 30 µL of 3M NaCl, and 990 µL of 
ethanol. The anti-sense reverse complement strand was separated by 8% PAGE and 
isolated. 
3.4.6.2 Procedure for the desirable substrate 
The desirable substrates for MK1, ML1, MM1 and MN1 were CAAAYPAAA. In 
the selection step, 15 pmol of the quantified reverse complement (anti-sense) 
oligonucleotide was added. In addition, 30 pmol of binding arm primers were provided to 
prevent the constant binding arm portion of the reverse complement from interacting non-
specifically with the deoxyribozyme pool (Figure 3.14). Selection step was performed 
with these added components and incubated at 37 °C for 14 h. After this step, the pool 
was separated by 8% PAGE to remove the additional components, including the reverse 
complement. For MK1, no components were added in the selection step. For ML1, 
reverse complement prepared from a random oligonucleotide pool was supplement in the 
selection, including the binding arms described above. 
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Figure 3.14. Once the reverse PCR primer with a long 5’ tail is isolated (shown in purple), 15 pmol of this 
component was added to the selection step in the desirable pathway. In addition, two binding arms for the 
pool shown in light green and brown were added in (30 pmol) to prevent the reverse strand (purple) from 
engaging with non-specific interactions with the pool. Watson-Crick base pairing is exclusively favored at 
the N40 region for the sense and anti-sense strands. 
Capture step is performed by bringing the reaction solution to 20 µL total volume 
containing 50 pmol of 15MZ36 (sequence provided in chapter 2), 100 pmol of  5’-
triphosphorylated RNA/DNA chimera (check Walsh et al.),27 20 mM MnCl2, 40 mM 
MgCl2, and incubated at 37 °C for 14 h. 
3.4.7 In Vitro Selection Procedure for MP1-MS1 
Selections 8MP1, 8MQ1 were initiated from 7FT1 and 8MR1, 8MS1 were 
initiated from 7FV1. The information about primers, pool, splint for ligation, capture 
deoxyribozyme are also provided in Table 3.4. MP1/MQ1 correspond to FT1 and 
MR1/MS1 correspond to FV1. The pool was divided into two portions, one for the 
undesirable substrate and the other for the desirable substrate. Details about the desirable 
and undesirable substrates, including the desired outcome are discussed in Table 3.4 
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3.4.7.1 Procedure for the undesirable substrate: 
For MP1 and MQ1, the desired substrate was E-rich peptide and selectivity was 
pursued against K-rich peptide and F-rich peptides. Similarly for MR1 and MS1, K-rich 
peptide was the actual substrate with selectivity pressure against E-rich and F-rich 
peptides. 8HJ102 sequences used were 5’-CCCGAAAGCCTCCTTCGGGAGATGTCTCTCAGACGG-
AAACTTTCAGTACGGAATGGATACGCATAAAGGTAGTCCCCATCAGGATCAGC-3’ for MQ1 and 5’-
CCCGAAAGCCTCCTTCGGGAGATGTCTCTCAGACGGAAACTTTCAGTACGGAATGGATAAGA-
AACGAGATATTCCCCATCAGGATCAGC-3’ for MS1 Addition of EDTA in the capture step 
with 8HJ102 deoxyribozyme was omitted as discussed earlier. After the capture step, 
PCR was performed to isolate the corresponding anti-sense reverse complement strands. 
3.4.7.2 Procedure for the desirable substrate 
The desirable substrates for MP1/MQ1 were CAEEYPEEA and CAKKYPKKA 
for MR1/MS1. In the selection step, 15 pmol of the quantified reverse complement (anti-
sense) oligonucleotide was supplemented to inhibit the sequence-general 
deoxyribozymes. In addition, 30 pmol of binding arm primers (see Figure 3.14 and Table 
3.4 for the sequence information) were provided to sequester the constant binding region 
of the reverse complement. Selection step was performed with these added components 
and incubated at 37 °C for 14 h. After this step, the pool was separated by 8% PAGE to 
remove the reverse complement and other additional components.  
Capture step was performed by bringing the reaction solution to 20 µL total 
volume containing 50 pmol of 15MZ36 (sequence provided in chapter 2), 100 pmol of  
5’-triphosphorylated RNA/DNA chimera (check Walsh et al.),27 20 mM MnCl2, 40 mM 
MgCl2, and incubated at 37 °C for 14 h. 
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3.4.8 Mass Spectrometry Experiment Procedure 
DNA-anchored peptides were desalted by Millipore C18 ZipTip, and analyzed by 
MALDI mass spectrometry. Data were acquired on a Bruker UltrafleXtreme MALDI-
TOF mass spectrometer with matrix 3-hydroxypicolinic acid in positive ion mode at the 
UIUC School of Chemical Sciences Mass Spectrometry Laboratory (instrument 
purchased with support from NIH S10RR027109A). 
3.5 References 
(1) Brannigan, J. A.; Wilkinson, A. J. Protein engineering 20 years on. Nat. Rev. Mol. 
Cell Biol. 2002, 3, 964-970. 
(2) Bornscheuer, U. T.; Pohl, M. Improved biocatalysts by directed evolution and 
rational protein design. Curr. Opin. Chem. Biol. 2001, 5, 137-143. 
(3) Laible, M.; Boonrod, K. Homemade site directed mutagenesis of whole plasmids. 
J. Vis. Exp. 2009. 
(4) Joern, J. M. DNA shuffling. Methods Mol. Biol. 2003, 231, 85-89. 
(5) Packer, M. S.; Liu, D. R. Methods for the directed evolution of proteins. Nat. Rev. 
Genet. 2015, 16, 379-394. 
(6) Reetz, M. T.; Kahakeaw, D.; Lohmer, R. Addressing the numbers problem in 
directed evolution. ChemBioChem 2008, 9, 1797-1804. 
(7) Selner, N. G.; Luechapanichkul, R.; Chen, X.; Neel, B. G.; Zhang, Z. Y.; Knapp, 
S.; Bell, C. E.; Pei, D. Diverse levels of sequence selectivity and catalytic 
efficiency of protein-tyrosine phosphatases. Biochemistry 2014, 53, 397-412. 
(8) Li, Q.; Yi, L.; Marek, P.; Iverson, B. L. Commercial proteases: present and future. 
FEBS Lett. 2013, 587, 1155-1163. 
(9) Olsen, J. V.; Ong, S. E.; Mann, M. Trypsin cleaves exclusively C-terminal to 
arginine and lysine residues. Mol. Cell Proteomics 2004, 3, 608-614. 
(10) Hedstrom, L.; Szilagyi, L.; Rutter, W. J. Converting trypsin to chymotrypsin: the 
role of surface loops. Science 1992, 255, 1249-1253. 
103 
 
(11) Hedstrom, L.; Perona, J. J.; Rutter, W. J. Converting Trypsin to Chymotrypsin - 
Residue-172 Is a Substrate-Specificity Determinant. Biochemistry 1994, 33, 8757-
8763. 
(12) Appel, W. Chymotrypsin: molecular and catalytic properties. Clin. Biochem. 1986, 
19, 317-322. 
(13) Masaki, T.; Tanabe, M.; Nakamura, K.; Soejima, M. Studies on a New Proteolytic-
Enzyme from Achromobacter-Lyticus M497-1 .1. Purification and Some 
Enzymatic-Properties. Biochim. Biophys. Acta 1981, 660, 44-50. 
(14) Nemoto, T. K.; Ohara-Nemoto, Y.; Ono, T.; Kobayakawa, T.; Shimoyama, Y.; 
Kimura, S.; Takagi, T. Characterization of the glutamyl endopeptidase from 
Staphylococcus aureus expressed in Escherichia coli. FEBS J. 2008, 275, 573-587. 
(15) Pogson, M.; Georgiou, G.; Iverson, B. L. Engineering next generation proteases. 
Curr. Opin. Biotechnol. 2009, 20, 390-397. 
(16) Bottcher, D.; Bornscheuer, U. T. Protein engineering of microbial enzymes. Curr. 
Opin. Microbiol. 2010, 13, 274-282. 
(17) Lu, Y.; Liu, J.; Li, J.; Bruesehoff, P. J.; Pavot, C. M.; Brown, A. K. New highly 
sensitive and selective catalytic DNA biosensors for metal ions. Biosens. 
Bioelectron. 2003, 529-540. 
(18) Faulhammer, D.; Famulok, M. Characterization and divalent metal-ion dependence 
of in vitro selected deoxyribozymes which cleave DNA/RNA chimeric 
oligonucleotides. J. Mol. Biol. 1997, 269, 188-202. 
(19) Bruesehoff, P. J.; Li, J.; Augustine, A. J., 3rd; Lu, Y. Improving metal ion 
specificity during in vitro selection of catalytic DNA. Comb. Chem. High 
Throughput Screening 2002, 5, 327-335. 
(20) Breaker, R. R. Engineered allosteric ribozymes as biosensor components. Curr. 
Opin. Biotechnol. 2002, 13, 31-39. 
(21) Silverman, S. K. Pursuing DNA catalysts for protein modification. Acc. Chem. Res. 
2015, 48, 1369-1379. 
(22) Gu, Y.; Rosenblatt, J.; Morgan, D. O. Cell cycle regulation of CDK2 activity by 
phosphorylation of Thr160 and Tyr15. EMBO J. 1992, 11, 3995-4005. 
104 
 
(23) Chandrasekar, J.; Silverman, S. K. Catalytic DNA with phosphatase activity. Proc. 
Natl. Acad. Sci. USA 2013, 110, 5315-5320. 
(24) Chu, C.; Wong, O.; Silverman, S. K. A generalizable DNA-catalyzed approach to 
peptide-nucleic acid conjugation. ChemBioChem 2014, 15, 1905-1910. 
(25) Walsh, S. M.; Konecki, S. N.; Silverman, S. K. Identification of Sequence-
Selective Tyrosine Kinase Deoxyribozymes. J. Mol. Evol. 2015, 81, 218-224. 
(26) Milligan, J. F.; Groebe, D. R.; Witherell, G. W.; Uhlenbeck, O. C. 
Oligoribonucleotide synthesis using T7 RNA polymerase and synthetic DNA 
templates. Nucleic Acids Res. 1987, 15, 8783-8798. 
(27) Walsh, S. M.; Sachdeva, A.; Silverman, S. K. DNA catalysts with tyrosine kinase 
activity. J. Am. Chem. Soc. 2013, 135, 14928-14931. 
(28) Brandsen, B. M.; Velez, T. E.; Sachdeva, A.; Ibrahim, N. A.; Silverman, S. K. 
DNA-catalyzed lysine side chain modification. Angew. Chem. Int. Ed. 2014, 53, 
9045-9050. 
 
  
105 
 
Chapter 4: Intracellular Application of Phosphatase DNA Catalysts
4
 
4.1 Introduction 
In this chapter, strategy to achieve phosphatase activity with deoxyribozymes 
inside live mammalian is discussed. Some of the earliest in vivo efforts with DNA 
catalysts involved the use of 10-23 deoxyribozyme to cleave and silence mRNA.1,2 DNA 
enzymes with RNA cleaving activity have been explored in a few therapeutic avenues.2 
Additionally, DNA catalysts have been used for sensing and determining the 
concentration of  specific metal cation concentrations inside live cells.3,4 However, 
deoxyribozymes, so far, have never been utilized to serve as a protein (enzyme) 
substitutes inside live cells. Establishing the fundamental ability of single-stranded DNA 
to replace a functional protein inside cells would be an important accomplishment in the 
field of DNA catalysis. 
4.1.1 Techniques used in Gene Therapy 
Several techniques exist for delivering DNA into cells. A physical approach 
involves weakening of the cell membrane to enable penetration of external DNA through 
the cell membrane. Examples of such physical manipulation include electroporation, 
ultrasound/hydrodynamic treatment, and needle injection. Alternatively, chemical 
techniques such as viral and non-viral vectors can be used for nucleic acid delivery. 
Polycationic derivatives and cationic lipids can be used to coat the DNA and shield the 
negative charge. This helps the DNA pass through the electrostatically repulsive 
phospholipid cell membrane. Covalent conjugation to polycationic polymers such as 
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polyarginine also serves as excellent delivery agents.5 These delivery agents can be 
designed to be biodegradable to enable controlled spatial and temporal release of nucleic 
acids inside cells.6 Viral vectors have received substantial success in the field of gene 
therapy. The most popular viral vectors used for gene therapy are adenovirus, retrovirus, 
and vaccinia virus.7 Several therapeutic targets currently being addressed by gene therapy 
are under clinical trials (Figure 4.1).8 
 
Figure 4.1. Clinical targets currently addressed by gene therapy in clinical trials (figure from reference 8). 
Advances in gene therapy continue to offer better alternatives for delivery of 
deoxyribozymes inside cells. One of the earliest efforts to introduce DNA enzymes 
involved direct in vivo expression of single-stranded DNA in mammalian cells.9 More 
recently, gold nanoparticles3,4 and lipidoid-coated iron oxide nanoparticles10-11 have 
successfully introduced short DNA inside cell. Some of the promising features of 
nanomaterials include the ease of synthesis, efficient functionalization with nucleic acids, 
low toxic effects, and high delivery payload. Classical lipid transfection agents such as 
Lipofectamine also function as reliable delivery agents, albeit with lower payload 
efficiency in comparison to nano-particle based methods.11 Although Lipofectamine is 
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suitable for larger DNA constructs such as plasmids, better methods exist for delivery of 
short DNA strands. 
4.1.2 Choice of Cell System for DNA 
This chapter focuses on efforts to achieve dephosphorylation with phosphatase 
deoxyribozymes on full-length proteins inside live mammalian cells. Phosphatase 
deoxyribozymes identified so far (namely 14WM9 or 14M27), are zinc-dependent 
phosphomonoesterases.12 These enzymes function specifically with phosphotyrosine-
containing peptides and proteins. No free peptide activity is observed with 
phosphoserine.12 However, it is important to note that these DNA catalysts require up to 
millimolar (≥ 2 mM) concentration of Zn2+ for optimal enzymatic activity.12 This high 
dependence on zinc is a major concern for intracellular dephosphorylation. Cells lack 
millimolar quantity of zinc in cytosol, either in bound or unbound form. 
To address this concern, we first need to consider specific cells cell lines that can 
be maintained or cultured at high concentration of zinc. Secondly, these cells should have 
the ability to intake high amount of zinc in the cytosol when maintained in zinc-rich 
conditions. LNCaP cells (malignant human prostatic adenocarcinoma, androgen-
dependent) are suitable candidates for such purposes. These cells are known to 
accumulate the highest concentration of mobile zinc of all soft tissues in our body.13 
Additional of exogenous hormones such as testosterone or prolactin leads to 
overexpression of zinc-specific transporters on the cell membrane, which in turn 
increases the concentration of intracellular zinc.13 
Although the total amount of zinc in cells is easy to estimate, concentration of 
free (mobile or unbound) zinc is challenging to measure. Zinc can be in either free form 
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(available for catalysis) or strongly bound to proteins changing their effective free 
concentration. DNA enzymes need free (mobile) zinc for functioning. If the zinc is 
tightly bound to cellular components, deoxyribozymes may not function optimally. 
Lippard and co-workers calculated intracellular concentration of mobile (free) zinc using 
a zinc fluorescent biosensor, ZPP1.14-15 Based on their assessment, normal peripheral 
prostate cancer cell line, RWPE1, cultured in a zinc rich media contains free intracellular 
zinc of 12−16 fmol/cell.15 Assuming an average cell volume of 4.5 pL (adapted from 
Min6)14, the concentration of free zinc within a normal peripheral prostate cell is 
approximately 2.5 mM−3.5 mM. Analysis of LNCaP and DU145 (malignant human 
prostatic adenocarcinoma, androgen-dependent and androgen-independent) reveal 
negligible free zinc based on ZPPI fluorescence.14 However, Costello et al. suggest that 
treatment with hormones (testosterone or prolactin) leads to intake of zinc in the cytosol 
changing the free zinc concentration to greater than 2 fmol/cell.13 This implies that 
treatment with hormones can lead to a final concentration of ≥ 0.4 mM loosely-bound 
intracellular zinc in LNCaP cytosol. Because LNCaP is well studied and established in 
numerous prostate cancer studies, we pursued LNCaP as the test case. 
4.1.3 Downstream Investigation of Intracellular Activity 
To analyze the effect of phosphatase deoxyribozymes inside LNCaP cells, we 
need an appropriate positive control. Incidentally, PTP1B (Protein Tyrosine Phosphatase) 
was overexpressed in LNCaP cells in an earlier report, which led to cell differentiation of 
LNCaP to neuroendocrine (NE) cells.16 If phosphatase DNA catalysts function similar to 
PTP1B inside LNCaP cells, similar phenotypic outcome would be expected. 
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Protein tyrosine phosphatase PTP1B is a highly proficient enzyme with a kcat/Km 
of ~105 to 107M-1 s-1.17 PTP1B is predicted to dephosphorylate 50% of phosphotyrosine-
containing proteins in the cytosol within 5 s.18 The deoxyribozyme 14WM9 has kobs of 
0.65 min-1 and a Km greater than 1 mM, which equates to (at best) a kcat/Km of 100 M
-1 s-1. 
Under molecular crowding conditions of the cytosol (200 mg/mL), catalytic proficiency 
of 14WM9 can have a huge negative impact in the rate. Moreover, 14WM9 requires 
optimal zinc concentration for catalytic activity. For 14WM9 activity on larger protein 
substrates, kobs can be further reduced. Hence it is essential to introduce high amounts of 
DNA catalysts inside each cell to compensate for the high catalytic proficiency of 
PTP1B. This requires a highly proficient intracellular delivery of deoxyribozymes.  
When PTP1B was overexpressed in LNCaP cells by conventional lipid-based 
transfection, neuroendocrine phenotype were observed.16 The neuroendocrine-
differentiated cells are characterized by specific NE marker proteins. These proteins, 
neuron-specific enolase (NSE) and chromogranin A (CGA), can be conveniently tested 
by qRT-PCR or Western blot based on a previous report.16 
In conclusion, three important criteria need to demonstrate the proof-of-concept 
for intracellular dephosphorylation by phosphatase deoxyribozymes (Figure 4.2). 
• Cell line needs to intake high amounts of zinc in the cytosol. For that purpose we 
chose LNCaP cells as the most viable candidate 
• We should have an appropriate control where PTP1B has been previously over-
expressed in LNCaP. Fortunately previous studies have investigated this.  
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• We should have a proper downstream readout to verify the effectivity of phosphatase 
activity. PTP1B overexpression leads to neuroendocrine differentiation of LNCaP 
cells. Biomarkers such as NSE and CGA can be quantified by qRT-PCR: 
•  
Figure 4.2. Three important criteria need to be simultaneously satisfied to establish the ability of DNA 
catalysts to function as phosphatases inside cells. A) The cell line should be able to accommodate high 
concentration of zinc in the cytosol. B) Protein tyrosine phosphatase should already be overexpressed in the 
specific cell line. C) A convenient readout should exist for the downstream effect. 
4.2 Results and Discussion 
4.2.1 In Vitro Selection for More Proficient Phosphatase Deoxyribozymes  
4.2.1.1 Reselections FA1, FB1 and FC1 
In an effort to identify more proficient phosphatase deoxyribozymes, reselections 
were performed for 14WM9 and 14WM27 (Figure 4.3). Two partially randomized DNA 
pools were synthesized (each for 14WM9 and 14WM27) maintaining the same constant 
binding region, but randomizing the 40-nucleotide region by 25% at each position. These 
selections were name FA1 and FB1 respectively. An additional reselection with 14WM9 
called FC1 was initiated, which involved a DNA-anchored phosphopeptide 
CAKKYPKKA (K-rich peptide conjugated by disulfide linkage). Each pool was then 
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ligated to the DNA-anchored phosphopeptide. The selection strategy followed the same 
procedure discussed in chapter 2. Each selection step used incubation conditions of 70 
mM HEPES, pH 7.5, 1 mM ZnCl2, 20 mM MnCl2, 40 mM MgCl2, and 150 mM NaCl at 
37 °C for 14 h, active DNA catalyst sequences were “captured” with the aid of the 
15MZ36 deoxyribozyme that selectively uses dephosphorylated tyrosine (YOH) as the 
nucleophile to attack 5′-triphosphorylated RNA, resulting in a PAGE shift for the 
corresponding deoxyribozyme sequence. 
 
Figure 4.3. The 40-nucleotide region of 14WM9 and 14WM27 from WM selection is depicted here. Each 
position was partially randomized 25% for reselections FA1 and FC1 with 14WM9, and FB1 reselection 
with 14WM27. 
Active DNA sequences were amplified by PCR and joined by T4 DNA ligase to 
the DNA-anchored hexapeptide substrate for entering the next selection round. After 5 
rounds of selection, activity was observed for all selections (Figure 4.4). A two hour time 
pressure was applied at round 7 for FA1, FB1 and FC1 to enable enrichment of faster 
deoxyribozymes from the pool. However the activity at 2 h selection pressure was greater 
than 1/6th the activity at 12 h time point (Figure 4.4). This indicated that activity at 12 h 
was already dominated by fast deoxyribozymes and applying time pressure is redundant. 
Individual deoxyribozymes were cloned and characterized from round 6 for all selections. 
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Figure 4.4. Initial activity was observed for FA1, FB1 and FC1 at round 5. The blue plot indicates positive 
control with 15MZ36 capture yield. Cloning was performed at round 6 for FA1, FB1, and FC1. The green 
plot denotes a selection pressure of 2 h applied for enriching faster enzymes. However, fast sequences 
already dominated the pool and hence selections with 2 h time point were not pursued for cloning. 
Distinct deoxyribozyme sequences were identified for FA1-FC1 (Figure 4.5). 
Activities of these distinct catalysts were tested with a YP hexapeptide that is attached to 
the DNA anchor through a PEG-type tether that includes 60 ethylene glycol units (Figure 
4.6). As discussed in chapter 2, activity with PEG-tethered hexapeptide suggests the 
possibility of catalysis with entirely free peptides as well. Based on investigation of these 
newly identified enzymes and their activity with PEG-tethered substrate, it was evident 
that 14WM9 was still amongst the most proficient phosphatase deoxyribozymes 
enzymes. 
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Figure 4.5. 40 nucleotide portion of the active phosphatase sequences from 6FA1, 6FB1, and 6FC1. 
 
Figure 4.6. DNA-anchored CAAYPAA was tested with a PEG-type tether linkage (22 h time point). For 
more details on PEG-type tether, see chapter 2 (Materials and Methods). A) Hexapeptide CAAYPAA is 
conjugated to the DNA anchor via a PEG-type tether. B) Substantial activity was observed for 14WM9, 
6FA103, 6FB128 and 6FC113. However, 14WM9 was still amongst the fastest phosphatase enzymes. 
4.2.1.2 In vitro selection with different random region length
5
 
In vitro selection with different random region lengths were explored for 
improved phosphatase activity. HJ1 selections had 30 random nucleotides whereas HL1 
had 50. DNA-anchored CAAYPAA was used as the substrate. Each DNA pool was 
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ligated to the DNA-anchored phosphopeptide. Selection procedures are mentioned in 
(Materials and Methods). No activity was observed with HL1 selections with 50 random 
nucleotides. However, HJ1 (30-nucleotide region) gave activity at round 7. Round 8 was 
used for cloning. 
When assayed for free peptide activity with AAAYPAA substrate using malachite 
green inorganic phosphate assay, 8HJ102 deoxyribozyme was determined to be more 
proficient that 14WM9. At 24 h, 8HJ102 gave 22 turnovers (Figure 4.7) compared to 6 
turnovers by 14WM9 (see Materials and Methods for details).12  
 
Figure 4.7. 8HJ102 is a zinc-dependent phosphatase deoxyribozyme. Up to 22 turnovers are observed in 24 
h (2 mM Zn2+) as calculated by malachite green assay (see Materials and Methods for experimental 
details). 
4.2.2 Preparation of PTP1B Plasmid and the D181A Mutant 
Human PTP1B (PTPN1) encoded in pcDNA3.1 vector (Invitrogen) was a 
generous gift from the Steidl lab.19 Using the mutagenic primers 5′-ATACCACATGGCCT-
GCCTTTGGAGTCCCTGA-3′ and 5′-TCAGGGACTCCAAAGGCAGGCCATGTGGTAT-3′, the D181 
mutant was prepared (see Materials and Methods). T7 promoter sequence was used as a 
forward sequence primer to verify the sequences. 
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4.2.3 Cell Culture and Validation of the Positive Control 
LNCaP cells were maintained in RPMI 1640 media that was supplemented with 
10% FBS. 50,000 cells were transferred in a 24-well plate with 0.5 mL of media per well. 
jetPRIME (Polyplus) was mixed with the following DNA, 
a) pcDNA3.1-PTP1B (500 ng) 
b) pcDNA3.1-PTP1B-D181A (500 ng) 
c) 14WM9 with Cy3 at the 3′ end (500 ng) and 14WM9 helper oligonucleotide (750 ng) 
d) 8HJ102 with Cy3 at the 3′ end (500 ng) and 8HJ102 helper oligonucleotide (750 ng) 
Although the deoxyribozymes (14WM9, 8HJ102) were successfully transfected in 
LNCaP cells (Figure 4.8), the payload of deoxyribozymes is not projected to be as high 
as gold nanoparticle-based delivery. Following transfection, cells were grown for 0, 3 and 
6 days followed by detachment and isolation of the RNA. Investigation of NE genes NSE 
and CGA can be performed by qRT-PCR. 
 
Figure 4.8. 14WM9 and 8HJ102 with Cy3 at the 3′ end were transfected in LNCaP cells using jetPRIME 
transfection reagent. Left panel shows the bright field and the right panel shows the red fluorescence (RFP) 
window. 
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4.2.4 Synthesis of Gold Nanoparticles and their Conjugation to Deoxyribozymes 
Gold nanoparticles have been used to deliver high amounts of DNA inside cells. 
3′-thiol DNA can be linked to gold nanoparticles of diameter 13 nm.3 Each nanoparticle 
can carry up to 70 DNA enzymes based on previous reports.3 Up to 106 can be delivered 
inside cells, which accounts to 10-100 µM of DNA in a 2 pL cell.3 Both 14WM9 and 
8HJ102, with (HEG)3-C3-SH at the 3′ end were functionalized on gold nanoparticles. 
Appropriate helper (DNA anchor lacking HEG linker) oligonucleotides were hybridized 
(see material and methods). These gold-nanoparticle functionalized deoxyribozymes will 
be introduced to LNCaP cells and NSE and CGA levels will be investigated by qRT-PCR 
under different concentrations of zinc and testosterone. 
4.2.5 qRT-PCR Assay 
In the report by Wu et al.,16 overexpression of PTP1B in LNCaP cells leads to 
neuroendocrine differentiation of the cells. Biomarkers for neuroendocrine cells are NSE 
and CGA, These can be investigated using qRT-PCR. Primers and procedure for qRT-
PCR are already reported. 16 Preliminary test with qRT-PCR for a control GADPH gene 
indicates that the RNA integrity is maintained and qRT-PCR can be successfully 
performed (Figure 4.9).  
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Figure 4.9. Initial qRT-PCR for GADPH gene was performed with PTP1B transfected sample (day 6), 
PTP1B-D181A sample (day 6), and no transfection control (day 6). The Ct values were 28.32 (n = 3), 29.74 
(n = 3) and 27.95 (n = 3). No Ct value was obtained for a non-templated control (baseline). 
4.3 Summary and Future Directions 
The main goal of this chapter is to establish the fundamental ability of DNA 
catalysts to function as a full-length protein enzyme (PTP1B) inside cells (Figure 4.10). 
Tyrosine dephosphorylation plays a key role in cell signaling and signal transduction 
pathways. 
 
Figure 4.10. The main goal (vision) of this study is presented. PTP1B overexpression is known to impart 
neuroendocrine phenotype (or differentiation) to LNCaP cells. This can be verified by overexpression of 
the biomarkers CGA and NSE. We aim to achieve the NE phenotype using a phosphotyrosine phosphatase 
deoxyribozyme (14WM9 or 8HJ102) to establish the fundamental ability of deoxyribozymes to function as 
overexpressed full-length PTP1B enzyme inside cells. 
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Anomalous overexpression of protein tyrosine phosphatase (PTP1B) can lead to 
differentiation of cell types. In some cases, the overexpression might be beneficial, and 
conversely in detrimental in others. Gold nanoparticle-mediated delivery of phosphatase 
deoxyribozymes is a promising route for directly introducing enzymatic activity inside 
cells. The transfection efficiency is expected to be consistently high and reproducible 
when mediated by a gold nanoparticle-based delivery. 
Gold nanoparticles were successfully synthesized and functionalized with 
deoxyribozymes containing 3′-thiol. LNCaP cells have been determined to be alive and 
viable in up to 50 µM of external zinc and 10 nM of testosterone, which most likely 
enables uptake of high amount of zinc in the cytosol. Preliminary qRT-PCR with 
GADPH has established the integrity or RNA and successful cDNA synthesis. We hope 
to establish and the replicate overexpression of neuroendocrine biomarkers such as NSE 
and CGA using qRT-PCR with known primers for pcDNA3.1-PTP1B plasmid, and 
14WM9 and 8HJ102 deoxyribozymes. 
A major concern with future in vivo application is the high metal cation 
dependence of deoxyribozymes. Proficiency of deoxyribozymes will also greatly impact 
their future use in vivo. Deoxyribozymes are rarely known to function on full-length 
proteins and their efficiency can be substantially decreased under molecular crowding 
conditions. Modified nucleotides with protein-inspired functional groups can not only 
reduce the metal dependence, but also strongly complement the already high catalytic 
prowess of DNA with phosphomonoester hydrolysis. 
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4.4 Materials and Methods 
4.4.1 Oligonucleotides 
DNA oligonucleotides were obtained from Integrated DNA Technologies 
(Coralville, IA) or prepared by solid-phase synthesis on an ABI 394 instrument using 
reagents from Glen Research. 5′-Triphosphorylated RNA oligonucleotides were prepared 
by in vitro transcription using synthetic DNA templates and T7 RNA polymerase.20 All 
oligonucleotides were purified by 7 M urea denaturing PAGE with running buffer 1× 
TBE (89 mM each Tris and boric acid and 2 mM EDTA, pH 8.3) as described 
previously.12  
4.4.2 Synthesis of Peptides and DNA-Anchored Peptides 
Peptides were prepared by solid-phase synthesis on Fmoc Rink amide MBHA 
resin (AAPPTec). Each peptide was coupled to the DNA anchor oligonucleotide via N-
terminal cysteine side chain (linkage created by disulfide formation) as discussed in 
chapter 2.  
4.4.2.1 Synthesis of peptides. 
Peptides were prepared by solid-phase synthesis using Fmoc Rink amide MBHA 
resin, with N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexa-
fluorophosphate (HATU) as coupling agent. Each synthesis was performed at 0.2 mmol 
scale. The sequences of peptides were CAAYPAA and CAKKYPKKA. 
4.4.2.2 Synthesis of DNA-anchored peptides.  
Each peptide was coupled to the DNA anchor oligonucleotide via either the N-
terminal cysteine side chain (linkage created by disulfide formation). The DNA anchor 
oligonucleotide (see Table 4.1) ending with HEG-C3-SS-C3-OH-3′, where the 3′-disulfide 
linker was introduced via standard solid-phase DNA synthesis and unmasked to a 3′-thiol 
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by DTT treatment. A 50 µL sample containing 2-5 nmol of DNA anchor oligonucleotide 
in 50 mM HEPES, pH 7.5, and 50 mM DTT was incubated at 37 °C for 2 h. The reduced 
product was precipitated to remove excess DTT by addition of 50 µL of water, 10 µL of 
3 M NaCl, and 300 µL of ethanol. The precipitated product (DNA-HEG-C3-SH) was 
dissolved in 45 µL of water. Activation as the pyridyl disulfide was achieved by adding 5 
µL of 100 mM 2,2′-dipyridyl disulfide in DMF and incubating at 37 °C for 2 h. The 
product (DNA-HEG-C3-SSPy) was precipitated by addition of 50 µL of water, 10 µL of 
3 M NaCl and 300 µL of ethanol and dissolved in 25 µL of water. Conjugation to the 
peptide was performed by adding 20 µL of 50 mM triethylammonium acetate, pH 7.0, 
and 5 µL of 40 mM peptide (200 nmol). The sample was incubated at 37 °C for 2 h, and 
the DNA-anchored peptide was purified by 20% PAGE. A typical yield was 2-3 nmol.  
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Table 4.1. Different pools were used for each selection. Sequences are written 5′ to 3′. X denotes a HEG 
spacer to stop Taq polymerase from extending further. This enables separation of the single-stranded DNA. 
Sequence Y stands for CAAGGAGAGTTGTACAAGCTCGGGTCGTGTTCAAAGGGATC 
oligonucleotide purpose oligonucleotide sequence 
Selection FA1 and FB1 (with CAAY
P
AA) and FC1 with CAKKY
P
KKA 
DNA-HEG- substrate GGATAATACGACTCACTAT-HEG-C3-SH 
forward primer for selection CGAAGCGCTAGAACAT 
reverse primer for selection (AAC)4XCCATCAGGATCAGCT 
Partially randomized pool for selection CGAAGCGCTAGAACAT-N40-ATAGTGAGTCGTATTAAGCTGATCCTGATGG 
15MZ36 capture enzyme CCGTCGCCATCTCTTC-Z-ATAGTGAGTCGTATTATCCCCATCAGGATCAGCT 
splint for ligation step during selection a ATAGTGAGTCGTATTATCCTCCATCAGGATCAGCTTAATACGACTCACTAT 
Selection HJ1 (with CAAY
P
AA) 
DNA-HEG- substrate GGACTACCTTTATGCGTAT-HEG-C3-SH 
forward primer for selection CGAACGAAAGCCTCCTTC 
reverse primer for selection (AAC)4XCCATCAGGATCAGCT 
random pool for selection CGAACGAAAGCCTCCTTC –N30-ATACGCATAAAGGTAGAGCTGATCCTGATGG 
15MZ36 capture enzyme CCGTCGCCATCTCTTC-Z-ATACGCATAAAGGTAGTCCCCATCAGGATCAGC 
splint for ligation step during selection a ATAAGAAACGAGATATTCCTCCATCAGGATCAGCTATATCTCGTTTCTTAT 
Selection HL1 (with CAAY
P
AA) 
DNA-HEG- substrate GGAATATCTCGTTTCTTAT-HEG-C3-SH 
forward primer for selection CGAATTAAGACTGAATTC 
reverse primer for selection (AAC)4XCCATCAGGATCAGCT 
random pool for selection CGAATTAAGACTGAATTC -N50-ATAAGAAACGAGATATAGCTGATCCTGATGG 
15MZ36 capture enzyme CCGTCGCCATCTCTTC-Z-ATAAGAAACGAGATATTCCCCATCAGGATCAGC 
splint for ligation step during selection a ATACCAATCAAGCCATTCCTCCATCAGGATCAGCTATGGCTTGATTGGTAT 
 
a The underlined T in the splint was absent in the round 1 ligation step because the DNA pool in this step 
was prepared by solid-phase synthesis and therefore did not have an untemplated A nucleotide at its 3′-
end. The underlined T was included in all other selection rounds to account for the untemplated A 
nucleotide that is added at the 3′-end of each PCR product by Taq polymerase. 
4.4.3 In Vitro Selection Procedure for FA1-FC1 and HJ1 and HL1 
The selection procedure, cloning, and initial analysis of individual clones were 
performed essentially as described previously in chapter 2 and 3. The reselections 
FA1/FC1 and FB1 were partially randomized from the initial sequences 14WM9 and 
14WM27 respectively. The pools were 5′-CGAAGTCCGCCATCTCTTC-N40-
ATAGTGAGTCGTATTAAGCTGATCCTGATGG-3′ with 40-nucleotide region partially randomized 
25% at each position (see Figure 4.3 for 14WM9 and 14WM27). PCR primers are shown 
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in Table 4.1. In each round, the ligation step attached the deoxyribozyme pool at its 3′-
end with the 5′-end of the DNA-anchored phosphopeptide substrate using a DNA splint 
and T4 DNA ligase. Capture step was performed using 15MZ36 and 5′-triphosphorylated 
RNA. See information on selection and sequences in Table 4.1. The peptidic substrates 
for FA1 and FB1 were CAAYPAA. The substrate for FC1 was CAKKYPKKA. For 
different N30 and N50 random nucleotide region selections HJ1 and HL1, hexapeptide 
substrate CAAYPAA was used.  
Procedure for ligation step in round 1. A 34 µL sample containing 1 nmol of DNA pool, 
850 pmol of DNA splint, and 750 pmol of 5′-phosphorylated DNA-hexapeptide substrate 
was annealed in 5 mM Tris, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by heating at 95 
°C for 3 min and cooling on ice for 5 min. To this solution was added 4 µL of 10× T4 
DNA ligase buffer (Fermentas) and 2 µL of 5 U/µL T4 DNA ligase (Fermentas). The 
sample was incubated at 37 °C for 12 h and purified by 8% PAGE. 
Procedure for ligation step in subsequent rounds. A 16 µL sample containing the PCR-
amplified DNA pool (~5–10 pmol), 20 pmol of DNA splint, and 30 pmol of 5′-
phosphorylated DNA-hexapeptide substrate was annealed in 5 mM Tris, pH 7.5, 15 mM 
NaCl, and 0.1 mM EDTA by heating at 95 °C for 3 min and cooling on ice for 5 min. To 
this solution was added 2 µL of 10× T4 DNA ligase buffer (Fermentas) and 2 µL of 1 
U/µL T4 DNA ligase (Fermentas). The sample was incubated at 37 °C for 12 h and 
purified by 8% PAGE. 
Procedure for selection step in round 1. Each selection experiment was initiated with 200 
pmol of the ligated N40 pool. A 15 µL sample containing 200 pmol of ligated N40 pool 
was annealed in 5 mM HEPES, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by heating at 
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95 °C for 3 min and cooling on ice for 5 min. The selection reaction was initiated by 
bringing the sample to 30 µL total volume containing 70 mM HEPES, pH 7.5, 1 mM 
ZnCl2, 20 mM MnCl2, 40 mM MgCl2, and 150 mM NaCl. The sample was incubated at 
37 °C for 14 h. 
Procedure for selection step in subsequent rounds. A 10 µL sample containing ligated 
pool was annealed in 5 mM HEPES, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by 
heating at 95 °C for 3 min and cooling on ice for 5 min. The selection reaction was 
initiated by bringing the sample to 20 µL total volume containing 70 mM HEPES, pH 
7.5, 1 mM ZnCl2, 20 mM MnCl2, 40 mM MgCl2, and 150 mM NaCl. The sample was 
incubated at 37 °C for 14 h. 
Procedure for capture step in round 1. To the 30 µL selection sample was added 1.2 µL 
of 50 mM EDTA, pH 8.0 (60 nmol). The sample was then brought to 45 µL total volume 
containing 300 pmol of 15MZ36 capture deoxyribozyme, 400 pmol of 5′-
triphosphorylated RNA substrate, 20 mM MnCl2, and 40 mM MgCl2 and incubated at 37 
°C for 14 h. 
Procedure for capture step in subsequent rounds. To the 20 µL selection sample was 
added 0.8 µL of 50 mM EDTA, pH 8.0 (40 nmol). The sample was then brought to 25 µL 
total volume containing 40 pmol of 15MZ36 capture deoxyribozyme, 80 pmol of 5′-
triphosphorylated RNA substrate, and 20 mM MnCl2, 40 mM MgCl2, and incubated at 37 
°C for 14 h. 
Procedure for PCR. In each selection round, two PCR reactions were performed, 10-
cycle PCR followed by 30-cycle PCR. First, a 100 µL sample was prepared containing 
the PAGE-purified selection product, 200 pmol of forward primer, 50 pmol of reverse 
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primer, 20 nmol of each dNTP, and 10 µL of 10× Taq polymerase buffer (1× = 20 mM 
Tris-HCl, pH 8.8, 10 mM (NH4)2SO4, 10 mM KCl, 2 mM MgSO4, and 0.1% Triton X-
100). This sample was cycled 10 times according to the following PCR program: 94 °C 
for 2 min, 10× (94 °C for 30 s, 47 °C for 30 s, 72 °C for 30 s), 72 °C for 5 min. Taq 
polymerase was removed by phenol/chloroform extraction. Second, a 50 µL sample was 
prepared containing 1 µL of the 10-cycle PCR product, 100 pmol of forward primer, 25 
pmol of reverse primer, 10 nmol of each dNTP, 20 µCi of α-32P-dCTP (800 Ci/mmol), 
and 5 µL of 10× Taq polymerase buffer. This sample was cycled 30 times according to 
the following PCR program: 94 °C for 2 min, 30× (94 °C for 30 s, 47 °C for 30 s, 72 °C 
for 30 s), 72 °C for 5 min. Samples were separated by 8% PAGE. 
4.4.4 Multiple-Turnover Assay using Malachite Green Dye 
A 20 µL sample containing 200 pmol (10 µM) of deoxyribozyme 8HJ102, 250 
pmol (12.5 µM) of free DNA anchor oligonucleotide lacking the HEG linker, and 10 
nmol (500 µM) of free AAAYPAA hexapeptide in 70 mM HEPES, pH 7.5, X mM ZnCl2, 
and 150 mM NaCl was incubated at 37 °C. X was varied from 0.5 mM, 1 mM, 1.5 mM 
and 2 mM. At the 24 h time-point, 75 µL of water and 20 µL of malachite green assay 
solution (BioAssay Systems POMG-25H) was added to the solution. After incubation at 
room temperature for 30 min, the sample was diluted with 180 µL of water, and the 
absorbance at 620 nm was measured (NanoDrop 2000c, Thermo Scientific). Standard 
curves for inorganic phosphate (Pi) were obtained using solutions containing known 
amounts of Pi and all other assay components except the free hexapeptide. Numbers of 
turnovers were calculated directly from the ratio of mole amounts of released Pi and 
deoxyribozyme. 
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4.4.5 Cell Culture LNCaP 
LNCaP cells were grown and maintained in RPMI 1640, supplemented with 10% 
FBS. Cells were maintained in T75 Cell Culture flasks (Corning Plastic). For detachment 
from the flask, 5 mL of sterile Trypsin-EDTA (0.25% trypsin, 1mM EDTA) was treated 
with the cells at 37 °C for 5 min. 5 mL of cell media was added to stop the trypsin 
cleavage process. The cells were centrifuged at 250 g for 3 minutes to spin down the 
cells. The supernatant was aspirated and then 5 mL of fresh media was added to the 
centrifuged cells. Cells were resuspended in the media by a gentle vortex process. Cells 
were counted using a hemocytometer and an optical microscope.  
In a 24-well plate (Corning® Costar®), 50000 cells were transferred and 
additional media was supplemented to maintain a total volume of 0.5 mL per well. After 
24 h, appropriate plasmids were transfected in each well. jetPRIME (Polyplus) was used 
as the in vitro transfection agent. 50 µL of jetPRIME buffer was mixed with 0.5 µg of 
DNA. 0.5 µL of jetPRIME was then added to the buffered mixture. After vortexing for 
10 s, the sample was spun down and incubated at room temperature for 10 min. This was 
added dropwise to a single cell. Plasmids pcDNA3.1-PTP1B, pCDNA3.1-PTP1B-D181A 
and pEGFP were transfected to the LNCaP cells. Plasmid pEGFP was a generous gift 
from Jessie Peh from the Hergenrother laboratory. Transfection efficiency was 
investigated by verifying GFP expression using fluorescence microscopy (Figure 4.11). 
For downstream investigation with qRT-PCR, the cells were detached from the 
24-well using the following procedure. First, the media (after an appropriate time) were 
aspirated carefully with a pipette. Then 200 µL of trypsin was added to the well to detach 
the cells from the well. After 3 min, 200 µL of RPMI 1640 medium is added to arrest the 
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trypsinization. The detached cells were centrifuged at 1000 g for 3 min. The supernatant 
was aspirated. Cells will be investigated for gene expression using qRT-PCR. 
 
Figure 4.11. pEGFP transfection was successful using jetPRIME (Polyplus) transfection reagent. Left 
panel shows the bright field while the right panel indicates fluorescence field. 
4.4.6 Site-Directed Mutagenesis of PTP1B D181A 
QuikChange protocol was partially followed to perform site-directed mutagenesis. 
The PCR reactions were performed using the mutagenic primers 5′- ATACCACATGGCCT-
GCCTTTGGAGTCCCTGA-3′ (forward) and 5′-TCAGGGACTCCAAAGGCAGGCCATGTGGTAT-3′ 
(reverse). PCR was performed in 50 µL of 1× Pfu polymerase buffer with 100 pmol of 
each primer, 25 ng of pcDNA3.1-PTP1B plasmid, 0.5 µL of dNTPs, and 2.5 units of Pfu 
polymerase. The PCR was performed following the procedure: 95 °C for 30 s, 55 °C for 
1 min, 68 °C for 10 min for 30 cycles. The sample was then purified by 
phenol/chloroform extraction. The purified PCR sample was then digested with DpnI in a 
45 µL reaction with 1×NEB buffer 4 and 10 units of DpnI (New England Biolab). The 
DpnI digestion product was purified on 1% agarose gel. 
500 ng of of pcDNA3.1-PTP1B plasmid and the PCR sample were separately 
double digested in 20 µL reaction with 1×NEB buffer 2 and 10 units of EcoRI and 10 
units of BamHI (New England Biolab). Only the pCNDA3.1-PTP1B sample was further 
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treated with Calf Intestinal Alkaline Phosphatase (CIP). The reaction was brought to a 
volume of 30 µL with 1×CIP buffer and 10 units of CIP and incubated at 37 °C for 1 h. 
Both samples were purified by 1% agarose gel. The empty vector was isolated from the 
PCDNA3.1-PTP1B sample while the PTP1B-D181A fragment was purified from the 
other sample. The isolated fragments were mixed in 1:10 (vector to insert) ratio. Sample 
was ligated in a 30 µL containing 5 ng of vector, 50 ng of insert (PTP1B-D181A), 1× T4 
DNA ligase buffer (Fermentas) and 10 units of T4 DNA ligase (Fermentas) at 25 °C 
 for 16 h. 
DH5α cells were transformed with the ligated product. 5 µL of digestion reaction 
was mixed with 50 µL of chemically competent cells, and incubated on ice for 30 min. 
For transformation, the mixture was heat shocked at 42 °C for 1 min, and shaken 
horizontally in 500 µL of SOC medium at 220 rpm 37 °C for 1 h. The cells (200 µL) 
were spread on LB + ampicillin agar plates, and incubated at 37 °C overnight. Individual 
colonies were picked and cultured in 5 mL of LB medium containing 50 µg/mL of 
ampicillin overnight. Plasmids were harvested via mini-prep as described earlier in 
Chapter 2. Using T7 promoter the sequences mutant pcDNA3.1-PTP1B-D181A was 
confirmed.  
4.4.7 Synthesis of Gold Nanoparticles and Functionalization with Deoxyribozymes 
A 200 mL two-neck round-bottom flask was first cleaned with aqua regia for 30 
min. The flask was then washed multiple times with Millipore water. 98 mL of Millipore 
water and 2 mL of 50 mM of HAuCl4 solution were mixed in the clean flask. The flask 
was heated to reflux with a reflux condenser and a stopper. On refluxing, 10 mL of 38.8 
mM sodium citrate as quickly added to the reaction mixture. The color of the solution 
128 
 
changed to deep red within a minute. The reflux was continued for another 20 minutes. 
The solution was allowed to cool to room temperature while stirring. The size and shape 
of the resulting nanoparticles were characterized scanning transmission electron 
microscopy (TEM). 200 kV (JEOL 2100 Cryo TEM). (Figure 4.12) The diameter of the 
nanoparticles was consistent (approximately 13 nm). The concentration of the gold 
nanoparticle was 1.9 nM as determined by UV-Vis absorbance. Extinction coefficient of 
gold nanoparticles (AuNP) is 1.85 × 108 M-1cm-1. 
 
Figure 4.12. TEM image of gold nanoparticles. The particles were of consistent size 13 nm. 
14WM9 and 8HJ102 were prepared with two phosphorothioate modifications at 
both the 5′ and 3′ end to prevent exonuclease digestion in cytosol.21 14WM9 had the 
sequence: C*G*AAGCGCTAGAACATCGCAGCGAAATCGGTCTTTATAGGGGCTGTCCTCCGACGG-
ATAGTGAGTCGTAT*T*A-HEG3-C3-S-S-C3-OH and 8HJ102 had the sequence C*G*AACGAA-
AGCCTCCTTCCGCAGACCATGCATAGGGGCTGTCCCTCCGACATACGCATAAAGGTAGT*C*C-HEG3-C3-
S-S-C3-OH, where * indicates inter-nucleotide phosphorothioate modification.   
To reduce the disulfide linkage in the initial disulfide linkage 9 µL of 1 mM 
deoxyribozyme (9 nmol) was mixed with 1.5 µL of 10 mM TCEP (tris(2-
carboxyethyl)phosphine) in 500 mM sodium acetate buffer (pH 5.2). After 1 h, the 
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reduced deoxyribozyme was slowly added to 3 mL of gold nanoparticle solution in a 
clean vial while gently shaking. The glass vial was treated with 10% NaOH followed by 
several washing with Millipore water prior to adding the gold nanoparticle solution. The 
vial was stored in dark for 24 h. 30 µL of 500 mM Tris acetate (pH 8.2) and 300 µL of 
1M NaCl were added dropwise sequentially with gentle shaking. The vial was again 
stored in the dark for 24 h before the next step.  
Two buffer solutions were prepared; 25 mM Tris acetate (pH 8.2) with 100 mM 
NaCl called buffer A, and 20 mM MOPS (pH 7.0) with 100 mM NaCl called buffer B. 
Deoxyribozymes conjugated to gold nanoparticles (Drz-AuNP) were transferred to a low-
bind tube. 500 µL of Drz-AuNP was centrifuged at 16,100 g for 20 min. The supernatant 
containing unbound deoxyribozyme was removed. Particles were redispersed in 200 µL 
of buffer A and spun down twice (at 16,100 g) to remove the excess unbound DNA. The 
Drz-AuNP were then dispersed in 200 µL of buffer B. The supernatants containing the 
unbound DNA were combined and quantified. The amount of deoxyribozyme attached 
per gold nanoparticle was estimated. Gold nanoparticle concentration dispersed in 
solution B can be quantified by utilizing the extinction coefficient at 520 nm.    
Anchor (helper) oligonucleotides for 14WM9 [5′-G*G*ATAATACGACTCACT*A*T-3′] 
and 8HJ102, [5′-G*G*ACTACCTTTATGCGT*A*T-3′] were synthesized with internucleotide 
phosphorothioate modifications. .After estimating the amount of bound deoxyribozyme, 
helper oligonucleotides (desalted by PD-10 desalting column GE Healthcare) were added 
in 1:2 ratio excess. The mixture was heated at 65 °C for 5 min. The sample was allowed 
to cool down to room temperature for an hour. Immediately, the solution was stored at 4 
°C overnight to allow full hybridization (assumed to be 100% efficient). After the 
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overnight incubation, excess helper oligonucleotide was removed by centrifuging the 
sample with buffer B thrice with 200 µL buffer B at 16,100 g. Finally the sample was 
dispersed in 200 µL of 20 mM HEPES (pH 7.5) with 100 mM NaCl.  
4.4.8 qRT-PCR Plans 
GeneJET RNA Purification Kit (K0731) was used to isolate RNA from the cells 
Integrity of RNA was verified by a bleach agarose gel (Figure 4.13).  
RNA was reverse transcribed using the cDNA Syntehsis Kit (ThermoFisher 
Scientific K1671). Following primers will be used for qRT-PCR assay based on the 
report by Wu et al.16, all 5′ to 3′. 
PTP1B: GGAGATGGAAAAGGAGTTC (f), TGCTTTTCTGCTCCCACAC (r) 
NSE: AGCTGCCCCTGCCTTAC (f), AGCTGCCCCTGCCTTAC (r) 
CGA: GCGGTGGAAGAGCCATCAT (f), TCTGTGGCTTCACCACTTTTCTC (r) 
Β-Actin: GCGGGAAATCGTGCGTGACATT (f), GATGGAGTTGAAGGTAGTTTCGTG (r) 
GADPH: ACCACAGTCCATGCCATCAC (f), TCCACCACCCTGTTGCTGT (r) 
For the preliminary qRT-PCR test, a 20 µL reaction solution containing the 10 ng cDNA 
and PerfeCTa SYBR Green FastMix (Quanta Biosciences) was first subjected to UDG 
incubation at 50 °C for 2 min. Hot start PCR was initiated by heating the reaction 
solution at 95 °C for 10 min. A cycle containing 95 °C for 10s, 60 °C for 30s was 
performed for a total of a total 45 rounds, followed by a melt curve cycle of 95 °C for 15 
s, 55 °C for 15 s, and 95 °C for 15 s. Eco Real-Time PCR System (Illumina) was used for 
sample analysis.  
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Figure 4.13. The RNA integrity was checked on a 1% agarose gel with 1% v/v bleach. A) RNA standard-1 
1000 ng, B) RNA standard-2 1000 ng, C) LNCaP RNA 200 ng, D) LNCaP 400 ng, E) LNCaP with PTP1B-
D181A 200ng. 
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Chapter 5: Catalytic DNA with Phosphoserine and Phosphothreonine 
Lyase Activity
6
  
5.1 Introduction 
Peptides or proteins rarely form natural electrophilic sites.1-3 An important 
exception to this observation is dehydroalanine (Dha) and dehydrobutyrine (Dhb).1 
Dehydroalanine is formally created from serine (Ser) by a net elimination of water.4-5 
Dha and related functional groups are intermediates or products in the biosynthesis of a 
wide range of cyclic peptides, including lantibiotics,6-7 thiopeptides,8-10 microcystins,11-12 
and other natural products.11-12 When introduced synthetically into a peptide or protein, 
Dha enables preparation of many valuable natural and artificial modifications, usually via 
thiol addition.13-14 One biosynthetic pathway for generating Dha or Dhb involves 
activation of Serine or Threonine with a phosphate, followed by a secondary β-
elimination step to reveal Dha and Dhb. This secondary β-elimination step is also known 
as phosphoserine (pSer) and phosphothreonine (pThr) lyase activity.  
5.1.1 Comparison with Natural Phosphoserine/Phosphothreonine Lyases 
Proteins with pSer/pThr lyase activity in nature have important biological roles. 
For instance, the OspF family of pThr lyase (e.g. SpvC from Salmonella) inactivates the 
phosphorylated host MAPKs irreversibly through a β-elimination reaction.15 Families of 
lantibiotic synthetases (class III and IV) have specific lyase domains that are highly 
homologous to the OspF family pThr lyase.16 A genome-wide search in human proteins 
                                                 
 
 
6
 This research has been published: Chandrasekar, J.; Wylder, A. C.; Silverman, S. K. Phosphoserine Lyase 
Deoxyribozymes: DNA-Catalyzed Formation of Dehydroalanine Residues in Peptides. J. Am. Chem. Soc. 
2015, 137, 9575-9578. 
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for similar homology led to annotation of β-elimination function for the BLES03 protein 
whose function was initially unknown.17 Comparison with the crystal structure of the 
OsPF family lyase with lantibiotic VenL lyase is consistent with a mechanism that 
involves histidine stabilizing the phosphomonoester O-bond while lysine residue 
functions as the general base to abstract the proton from the peptide backbone to help 
perform the β-elimination (Figure 5.1).15,18,19  
 
Figure 5.1. Histidine, arginine and lysine stabilize the phosphate leaving group. Lysine (K80) serves as the 
general base to abstract the proton from the peptide backbone to enable β elimination (figure from 
reference 19). 
5.1.2 Bioactive Natural Products and Phosphoproteomics 
The β-elimination products of pSer/pThr are also known as α,β-dehydroamino 
acids. To date, about 37 different structural units are known of which Dha/Dhb is the 
main class.1 Typically isolated from bacteria, and less often from fungi, marine 
organisms or plants, these compounds often exhibit important biological activities 
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(Figure 5.2A). pSer/pThr lyase activity can also be achieved chemically via base-
catalyzed elimination of phosphate. However, such chemical methods are harsh with 
potential for substantial side reactions to be useful in a broader context. Nonetheless, 
base-treated chemical “pSer/pThr Lyase” reactions have received consideration as 
phosphopeptide enrichment tools in phosphoproteomics (Figure 5.2B).  
 
Figure 5.2. A) Pie charts illustrates the percentage of natural product containing α,β-dehydroamino acid, 
including their typical biological uses (figure from reference 1). B) Chemical β-elimination of phosphate 
from pSer and pThr is used as an enrichment tool in phosphoproteomics. The Dha or Dhb can be treated 
with ethanedithiol, followed by a reaction with biotin maleimide. Biotinylated peptides are captured using 
streptavidin beads. 
5.1.3 Limitations to Current Synthesis of Dha and Dhb 
Dha-containing peptides and proteins can be formed via base-catalyzed 
elimination of phosphate from pSer-containing substrates (Figure 5.2B); e.g., by 
treatment with strong base (~1 M hydroxide) for phosphoproteomics analysis.20-22 
However, such relatively harsh conditions lead to numerous side reactions and are not 
typically used to prepare Dha-containing products. Davis and coworkers have surveyed 
the use of various more sophisticated reagents for conversion of cysteine (Cys) to Dha, 
concluding that a bis-alkylation-elimination strategy is optimal.13-14, 23 However, any 
exposed Cys will react with such reagents, which therefore cannot readily be used when 
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the newly created Dha is intended for subsequent cyclization with a second Cys residue. 
Without a gentle and general route available, one must resort to difficult or lengthy 
synthetic approaches to install Dha or to obviate its need.13-14, 24 This is especially true 
considering that the Dha monomer for solid-phase peptide synthesis (SPPS) is—after 
nitrogen deprotection—a simple enamine that presents substantial difficulties for 
traditional SPPS, necessitating use of alternative Dha-related monomers (Figure 5.3).25-27 
Hence, this chapter focuses on a chemoenzymatic method to achieve synthesis of Dha 
from pSer utilizing deoxyribozymes. 
 
Figure 5.3. The Fmoc protecting group has to be deprotected using the base (20% piperidine). The next 
amino acid coupling is inefficient because of the low coupling efficiency of the unmasked enamine. 
Enamines are also easily hydrolyzed to aldehydes leading to peptide truncations. 
5.2 Results and Discussion 
5.2.1 In Vitro Selection Strategy for pSer Lyase Activity 
To perform in vitro selection for pSer lyase deoxyribozymes, we needed to 
develop a reliable “capture” reaction,28 by which specific DNA sequences that convert 
pSer to Dha are physically separable from the vast majority of catalytically inactive 
sequences. This capture was achieved with a simple 5′-thiol oligonucleotide that reacts 
via Michael-type addition with Dha, increasing the mass of only the catalytic DNA 
sequences and enabling their separation (Figure 5.4). The capture yield was ~40%, which 
was readily sufficient to enable the selection process. Using this strategy, in vitro 
selection was implemented using a DNA-anchored AAASPAA model peptide (SP = pSer) 
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that was attached via the DNA anchor’s remote 5′-end to the deoxyribozyme pool, which 
included an N40 region (40 random nucleotides). During each round’s key selection step, 
incubation conditions were 70 mM HEPES, pH 7.5, 1 mM ZnCl2, 20 mM MnCl2, 40 mM 
MgCl2, and 150 mM NaCl at 37 °C for 14 h. In many of our previous selection 
experiments, the ions Zn2+, Mn2+, and Mg2+ were each effective deoxyribozyme 
cofactors, sometimes alone and sometimes in combination. Following the selection and 
capture steps, PAGE-separated sequences were amplified by PCR and ligated to the 
DNA-anchored pSer peptide substrate for the next selection round. 
 
Figure 5.4. In vitro selection of pSer lyase deoxyribozymes. DNA-catalyzed elimination of phosphate from 
the pSer residue in the DNA-anchored peptide, forming Dha, is followed by DNA-splinted capture of Dha 
using a 5′-thiol oligonucleotide, which results in an upward PAGE shift for only the active DNA sequences. 
See Figure 5.12 for details, including depiction of the hexa(ethylene glycol) [HEG] tether connecting the 
DNA anchor to the peptide and validation of the capture reaction. The dashed loop on the left enables the 
selection process but is dispensable for catalysis. 
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DNA-catalyzed pSer lyase activity of the pool was 15% at round 9, which is 
relative to the maximum (control) capture yield of ~40% (Figure 5.5) and individual 
deoxyribozymes were cloned. In parallel, selection in 50 mM CHES, pH 9.0, 40 mM 
MgCl2, and 150 mM NaCl at 37 °C showed no activity through round 10, and this second 
selection experiment was discontinued. This experiment was performed because the 
higher pH could have fostered more efficient phosphate elimination, but catalysis was not 
observed (note that Zn2+ and Mn2+ cannot be used at the higher pH because of 
precipitation and elimination, respectively). From the round 9 pool, two unrelated 76 nt 
deoxyribozymes were identified (see Materials and Methods for sequences) and named 
DhaDz1 and DhaDz2, for Dha-forming Deoxyribozymes 1 and 2. 
 
Figure 5.5. Progression of the in vitro selection experiment. In each round, “control” refers to the yield for 
the splint capture reaction using the DNA-anchored AAA(Dha)AA substrate, and “selection” refers to the 
yield for the splint capture reaction using the deoxyribozyme pool for that round. The arrow marks the 
cloned round. Round 1 pool yield was not measured because the pool was not radiolabeled. 
5.2.2 Single-Turnover Assay with DhaDz1 and DhaDz2 
DhaDz1 catalyzed single-turnover Zn2+/Mn2+-dependent elimination of phosphate 
from the DNA-anchored AAASPAA substrate in high yield when this substrate was not 
attached to the deoxyribozyme (Figure 5.6). Although catalysis strictly required only 
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Zn2+ and Mn2+, optimal activity was observed only in the additional presence of Mg2+. 
DhaDz2 catalyzed the same elimination reaction, strictly requiring only Zn2+ but with 
greater activity in the additional presence of Mn2+, Mg2+, or both of these ions. For 
DhaDz1 in the presence of each of 1.5 mM Zn2+, 20 mM Mn2+, and 40 mM Mg2+, 
kobs = 0.28 ± 0.01 h
–1 (n = 3) with 80% yield, For DhaDz2 with 2.0 mM Zn2+, 20 mM 
Mn2+, and 40 mM Mg2+, kobs = 0.43 ± 0.07 h
–1 (n = 3) with 68% yield.  
 
Figure 5.6. Single-turnover pSer lyase activity of the DhaDz1 deoxyribozyme with DNA-anchored model 
peptide AAASPAA. S = pSer substrate; P = Dha product. Incubation conditions: 70 mM HEPES, pH 7.5, 
combinations of 1.5 mM ZnCl2, 20 mM MnCl2, and 40 mM MgCl2 as appropriate, and 150 mM NaCl at 37 
°C (10 nM 5′-32P-radiolabeled DNA-anchored peptide, 1 µM DhaDz1). The PAGE image shows timepoints 
at t = 30 s, 4 h, and 16 h. The Zn2+ concentration of 1.5 mM was optimal at 20 mM Mn2+ and 40 mM Mg2+. 
At 1.5 mM Zn2+ in the absence of Mg2+, a higher yield of 55% was observed at 10 mM Mn2+ (data not 
shown). Data for the DhaDz2 deoxyribozyme is in Figure 5.8A. 
MALDI mass spectrometry validated the pSer lyase activities of DhaDz1 and 
DhaDz2. For both DhaDz1 and DhaDz2, omitting the deoxyribozyme or using a random-
sequence oligonucleotide in place of the catalytic sequences led to no activity. Removal 
of the 18 nt fixed-sequence 5′-segment of DhaDz1 or DhaDz2 led to only ~10% yield in 
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16 h in both cases. This finding suggests that during the selection process, some portion 
of the fixed-sequence 5′-segment was recruited for folding or catalysis by the initially 
random N40 region. 
5.2.3  Multiple-Turnover Assay with DhaDz1 and DhaDz2 
DhaDz1 and DhaDz2 were assessed for multiple-turnover activity with the free 
(discrete; not DNA-anchored) model AAASPAA peptide substrate. Each deoxyribozyme 
was assayed both by colorimetric detection of the released inorganic phosphate using 
malachite green dye (Figure 5.7A) and by LC-MS of the peptide mixture (Figure 5.7B). 
DhaDz1 achieved up to 6–7 turnovers in 96 h as determined by both assays.  
 
Figure 5.7. Multiple-turnover pSer lyase activity of the DhaDz1 deoxyribozyme with free model peptide 
AAASPAA. The incubation conditions were as in Figure 5.6, except with 6 mM Zn2+ as optimized to 
accommodate the high DNA and peptide concentrations (100 µM DhaDz1, 4 mM peptide). A) Malachite 
green assay for released inorganic phosphate. At each timepoint, n = 3 (± sd); “ctrl DNA” refers to an 
inactive negative control of arbitrary sequence. B) LC-MS assay (TIC; ESI-MS of indicated peaks). The 
observed 18% yield is equivalent to 7.2 turnovers. The asterisks in the MS denote loss of ammonia from 
the peptide N-terminus.29 
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pSer lyase activity was observed only when the 19 nt fixed-sequence 3′-segment 
of DhaDz1 was part of a Watson-Crick duplex with the separate anchor oligonucleotide; 
either deletion of the 3′-segment or omission of the anchor led to no reaction (dye assay, 
40:1 peptide:DhaDz1, <0.1 turnovers). The single-turnover activity of DhaDz2 was also 
determined (Figure 5.8A). DhaDz2 also showed multiple-turnover activity (4 turnovers in 
96 h; Figure 5.8B). 
 
 
Figure 5.8. Single-turnover and multiple-turnover data for the DhaDz2 deoxyribozyme. A) Single-turnover 
pSer lyase activity of the DhaDz2 deoxyribozyme with DNA-anchored peptide AAASPAA. S = pSer 
substrate; P = Dha product. Incubation conditions: 70 mM HEPES, pH 7.5, combinations of 2.0 mM ZnCl2, 
20 mM MnCl2, and 40 mM MgCl2 as appropriate, and 150 mM NaCl at 37 °C (10 nM 5′-
32P-radiolabeled 
DNA-anchored peptide, 1 µM DhaDz2). The PAGE image shows timepoints at t = 30 s, 4 h, and 16 h. The 
Zn2+ concentration of 2.0 mM was optimal at 20 mM Mn2+ and 40 mM Mg2+. B) Multiple-turnover pSer 
lyase activity of the DhaDz2 deoxyribozyme with free peptide AAASPAA. LC-MS experiment as in Figure 
5.7B, but with 8 mM Zn2+. The observed 10% yield is equivalent to 4.0 turnovers. 
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5.2.4 Synthesis of Cystathionine-containing Compstatin Peptide using DhaDz1 
For practical utility, a pSer lyase deoxyribozyme must function with a realistic 
peptide substrate sequence, rather than the model peptide used during selection. 
Compstatin is a 13 amino acid cyclic peptide, identified by phage display, which inhibits 
the proteolytic activation of human complement component C3 and may have therapeutic 
value.30-33 Disulfide-containing cyclic peptides such as compstatin are stabilized by 
replacing the disulfide bond with a cystathionine bridge, i.e., –S–CH2– in place of –S–S–. 
This replacement is typically accompanied by minimal loss of bioactivity,34-35 including 
for compstatin.32 Here we used DhaDz1 to enable synthesis of a more stable 
cystathionine analogue of compstatin (Figure 5.9A). DhaDz1 was found to catalyze 
preparative-scale (nanomole) single-turnover formation of Dha within a compstatin-
derived linear peptide precursor that includes pSer and homocysteine (Hcy) in place of 
the two Cys in the native sequence (Figure 5.9B for LC-MS analysis). The linear 
Dha/Hcy intermediate was then efficiently cyclized by simple base treatment to the 
compstatin analogue in 70% two-step yield. Analysis of HPLC-purified intermediate and 
cyclic product after iodoacetamide treatment (to alkylate free cysteine thiol groups) by 
MALDI mass spectrometry confirmed their structures (Figure 5.9C). Because the 
cyclization step is not enzyme-catalyzed, both (R,S) and (S,S) diastereomers (i.e., epimers 
at the initially pSer residue) of the compstatin analogue are presumably formed. 
Formation of diastereomers upon thiol addition into Dha is well-recognized and not an 
inherent impediment to a wide range of experiments that exploit the products of such a 
reaction.13-14, 36-37 
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Figure 5.9. Application of the DhaDz1 pSer lyase deoxyribozyme for synthesis of a more stable compstatin 
analogue. A) Compstatin, and its stable cystathionine (thioether) analogue as prepared using DhaDz1. One 
of the two possible pSer/Hcy combinations is shown. B) HPLC analysis of the reaction process. The three 
traces show (top to bottom) the HPLC-purified linear precursor pSer/Hcy peptide, the crude linear 
intermediate Dha/Hcy peptide after treatment of the precursor with DhaDz1, and the crude cyclic product 
(compstatin thioether analogue) after subsequent base treatment of the HPLC-purified intermediate 
Dha/Hcy peptide. Single-turnover conditions for Dha formation: 100 µM DhaDz1, 125 µM untethered 
DNA anchor oligo, 50 µM precursor peptide, 70 mM HEPES, pH 7.5, 4 mM ZnCl2 (optimized), 20 mM 
MnCl2, 40 mM MgCl2, 150 mM NaCl, 37 °C, 96 h. Conditions for cyclization: 100 mM Tris, pH 8.0, 25 
°C, 4 h (shorter times not attempted). The two-step yield was 70%. For the intermediate, the asterisk 
denotes autocyclization product, the dagger denotes unreacted precursor, and unmarked peaks are side 
products not specifically identified. C) MALDI mass spectrometry of HPLC-purified precursor, 
intermediate, and product, each after iodoacetamide (IAA) treatment to modify any free thiol groups (+57; 
one free thiol in each of precursor and intermediate; no free thiol in product).38 For the precursor, the 
asterisks denote [M+Na]+ and [M+K]+, and the dagger denotes hydrolysis of pSer. For the intermediate, the 
double dagger denotes autocyclization product. 
5.2.5 Testing for Sequence Generality of DhaDz1 
To explore further the substrate generality of DhaDz1, deoxyribozyme conversion 
of pSer into Dha within four unrelated pSer-containing heptapeptides was tested. 
Specifically, heptapeptides derived from lantibiotic component cytolysin CylLL′′ (Val-
pSer-Leu),39-40 inhibitor of HIV replication T22 (Lys-pSer-Tyr),41 the α7 nAChR 
antagonist conotoxin ImI (Arg-pSer-Ala),34 and the lantibiotic lacticin 481 (Asn-pSer-
Trp) were used.3a For the first three peptides, single-turnover yields of approximately 
95%, 50%, and 30%, respectively, in 48 h were obtained on nanomole scale, after 
optimizing the Zn2+ concentration in the 2 to 5 mM range (MALDI-MS; Figure 5.10). For 
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the lacticin peptide, no yield (<5%) was observed, perhaps due to the Trp adjacent to 
pSer; further investigation is required. Separately, the other cystathionine variant of 
Compstatin was tested, but no activity was observed with this substrate (see Materials 
and Methods).  It is however important to note that these yields are determined based on 
MALDI-MS peak intensities. These MS signals can significantly differ from the actual 
ratio of substrate and product in the sample. Therefore, we should be cautious about the 
accuracy of yield determined on this basis. 
 
Figure 5.10. MALDI-MS for, A) Cytolysin (Val-Val-pSer-Leu-Lys-His). B) T22 (Tyr-Arg-Lys-pSer-Tyr-
Lys-Gly). C) Conopeptide (Asp-Pro-Arg-pSer-Ala-Trp-Arg). D) Lacticin (Asn-Met-Asn-pSer-Trp-Gln-
Phe). Conditions for Dha formation: 100 µM DhaDz1, 125 µM untethered DNA anchor oligo, 50 µM 
precursor peptide, 70 mM HEPES, pH 7.5, X mM ZnCl2 (optimized), 20 mM MnCl2, 40 mM MgCl2, 150 
mM NaCl, 37 °C, 96 h. Yield was found to be optimal with 5 mM Zn2+ (Val-pSer-Leu), 5 mM Zn2+ (Lys-
pSer-Tyr) and 3 mM Zn2+ (Arg-pSer-Ala). No activity was observed with the Asn-pSer-Trp peptide. For 
the precursor (brown), the asterisks denote [M+Na]+ and [M+K]+, and the double dagger denotes oxidation 
of methionine. For the product, the blue dagger denotes the hydrolysis peak (spontaneous MS product). See 
table 5.1 for the mass spectrometry values. 
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5.2.6 New Selections for Phosphothreonine Lyase Deoxyriboymes 
Although we have confined our attention here to conversion of pSer to Dha, 
analogous DNA-catalyzed reaction of pThr to form Dhb should be feasible. The new 
DhaDz1 and DhaDz2 deoxyribozymes do not function with a pThr substrate; the 
additional methyl group of pThr suppresses activity. This is unsurprising because the 
selection experiment that led to DhaDz1 and DhaDz2 was performed with pSer rather 
than pThr. Selections that directly use pThr-containing phosphopeptides are used to 
identify pThr lyase deoxyribozymes as well. We have validated that the capture approach 
of Figure 5.4 is successful with Dhb in place of Dha. (See Materials and Methods for 
synthesis of the Dhb standard) 
5.2.7 New Strategy for Long 5′-thiol Capture 
Higher capture yield was observed with the short 5′-thiol oligonucleotide (n = 0 in 
Figure 5.12B; 18-mer) as compared with the long 5′-thiol oligonucleotide (n = 6 in Figure 
5.12B; 54-mer). This outcome was attributed to some of the long 5′-thiol oligonucleotide 
lacking the intended 5′-thiol group, likely due to relatively inefficient coupling of the 
thiol phosphoramidite (due to partial hydrolysis) along with poor 12% PAGE resolution 
for such a lengthy oligonucleotide. After this selection experiment was concluded and 
individual deoxyribozymes were already identified, we prepared a sequence variant of the 
long 5′-thiol oligonucleotide by splint ligation starting with the 20% PAGE-purified short 
5′-thiol oligonucleotide. This variant of the long 5′-thiol oligonucleotide had capture 
yield equivalent to that of the short 5′-thiol oligonucleotide (ca. 40%). 
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5.2.8 Selection Strategy for Sequence General pSer/pThr Lyases
7
 
DhaDz1 couldn’t function promiscuously with each pSer-containing peptide we 
tested for generality (Section 5.2.6). This result is however not too surprising. Pressure 
was not applied during the selection process to encourage sequence-tolerant pSer lyase 
activity. Merely performing selections with DNA-anchored AAASPAA (alanine-rich 
peptide) is insufficient to achieve promiscuity. Applying a systematic strategic selection 
pressure may be necessary to obtain sequence generality.  
To address this situation, new selection efforts have been designed. Peptides 
AKKXKKA, AEEXEEA, AFFXFFA were synthesized (where X = SP or TP) and 
conjugated to the DNA anchor as by reductive amination (check Materials and Methods 
for lysine). In the new efforts to identify general DNA catalysts, we are imposing 
selection pressure by maintaining the pSer or pThr epitope while systematically changing 
the peptide identity every round of selection; also termed as the “alternation strategy” 
(Figure 5.11). 
When capture with thiol-containing oligonucleotide was tested with E-rich 
Dha/Dhb-containing peptide, suboptimal capture yield was observed (≤ 10%). This could 
be attributed to negative charges from the glutamate (E) repelling the “capture” thiolate 
and preventing Michael-type addition. With K-rich peptide however, high background 
activity was observed with even pSer or pThr (>15%, which would be a big headwind for 
selection processes). This can be hypothesized to be an SN1 displacement of pSer/pThr 
with a thiol oligonucleotide. For these reasons, selections utilizing E-rich and K-rich 
                                                 
 
 
7
 University of Illinois undergraduate Adam Wyler initiated the selection process for sequence generality 
under my supervision. 
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peptides have placed been on hold. However, alternation strategy is still viable with A-
rich and F-rich pSer/pThr-containing peptides. Separately, a biologically useful fragment 
from cytolysin, GITPPVAF,42 was also tested as a selection substrate. However, efforts to 
capture the Dhb standard of cytolysin fragment were unsuccessful. We hypothesize that 
the proline adjacent to Dhb may provide steric or directional inhibition to attack by a 5′-
thiol capture oligonucleotide (proline conformation).  
 
Figure 5.11. The strategy for identifying sequence-general deoxyribozymes involves changing the peptitic 
portion in the DNA-anchored peptide each selection round. The internal pSer/pThr amino acid is 
maintained constant every selection round, but the identity of the surrounding residues (X) is changed to F: 
aromatic, E: negatively charged, K: positively charged. 
5.2.9 Phosphoproteomics 
Although DhaDz1 and DhaDz2 exhibit much sequence tolerance, we can envision 
the use of such sequence-general pSer/pThr lyases in phosphoproteomics as enrichment 
tools. However, additional selections would be necessary to obtain powerful 
deoxyribozymes for such purpose. DNA has the following advantages, A) 
Deoxyribozymes can be used in high stoichiometric ratio (excess to the substrate). B) A 
mixture of DNA catalysts (cocktail) can be used to achieve a sequence-general even if a 
single deoxyribozyme doesn’t function as a universally general pSer/pThr lyase enzyme. 
C) Choice of metal cation cofactors is not a limitation for in vitro use. D) Acidic peptides 
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such as glutamates and aspartates will not be enriched, which is a disadvantage of IMAC 
(immobilized metal affinity chromatography) technology. DNA enzymes are expected to 
be chemoselective.  
DNA will have to overcome three fundamental challenges to be useful in 
phosphoproteomics. DNA catalysts are required to be sequence general. In addition, 
deoxyribozymes will require excellent catalytic proficiency, i.e. good values of kcat and 
Km. The more important factor would be Km because phosphorylated peptides are 
expected to be in lower abundance (pico-, femto-, atto-moles). kcat to some extent can be 
addressed by increasing the enzymatic incubation time.  
To demonstrate the proof-of-concept and applicability of deoxyribozymes, two 
proteins were chosen as test cases, chicken ovalbumin and β-casein. Both proteins serve 
as excellent source of pSer-containing proteins. Chicken ovalbumin has two pSer (mostly 
phosphorylated with 2 equivalents of phosphate) whereas β-casein can have about 5 
phosphorylated sites with substantial phosphorylation variability (0-5 phosphate 
equivalents relative to the protein). Bottom-up proteomics involves analysis of typtic 
digested fragments from protein. On the other hand, top-down approach involves analysis 
of intact proteins followed by mass-spectrometry induced fragmentation. Both proteins 
were separately digested with trypsin, desalted on a C18 column (solid-phase extraction). 
Known amounts of digested and full-length proteins were treated with alkaline 
phosphatase and analyzed by malachite green phosphate assay to quantify the amount of 
inorganic phosphate released. This would reveal the exact amount of phosphorylation in 
the protein or protein digest (assuming complete dephosphorylation of the protein by the 
alkaline phosphatase). Although β-elimination would lead to formation of Dha or Dhb, 
150 
 
inorganic phosphate can be quantified by the same technique. Relative quantification of 
inorganic phosphate will provide the yield of pSer/pThr Lyase for both the digested and 
full-length protein (see Materials and Methods). With DhaDz1 negligible activity was 
observed with either the full-length protein or the digested fragment. 
5.3 Summary and Future Directions 
In this chapter, we utilized enzymatic catalysis rather than reagent-based synthetic 
approaches to form Dha from a readily introduced precursor. The natural protein 
enzymes that create Dha residues proceed via an activated serine intermediate, such as 
phosphoserine (pSer)4-5 or glutamylated serine.43 Biosynthesis of lanthipeptides involves 
enzyme-catalyzed elimination reactions.44 However, these enzymes often require 
subsequently removed leader peptides on their substrates, and in general lanthipeptide 
dehydratases are not preparatively useful beyond their narrow natural sequence 
contexts.45 We therefore targeted de novo identification of entirely new enzymes for 
formation of Dha residues.   
Using in vitro selection, we identified DhaDz1 and DhaDz2, pSer lyase 
deoxyribozymes that eliminate phosphate from pSer in a peptide substrate to form Dha. 
This elimination is a fundamentally new DNA-catalyzed reaction, which expands the 
repertoire of reactions known to be catalyzed by DNA. DhaDz1 was used to synthesize a 
Dha-containing linear peptide intermediate to a cystathionine analogue of compstatin, a 
cyclic inhibitor of complement activation. With further development of pSer and pThr 
lyase deoxyribozymes to improve the elimination rate and yield and to establish peptide 
sequence generality beyond compstatin, we anticipate that such DNA catalysts will be 
useful for enzymatically converting pSer/pThr residues in peptide substrates into the 
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corresponding Dha/Dhb residues. This ability will enable a broad range of experiments in 
biological chemistry, both via study of natural products and their analogues as well as by 
site-specific labeling of peptides and proteins at readily and specifically engineered 
electrophilic sites. pSer/pThr lyase deoxyribozymes may also find utility in 
phosphoproteomics experiments.20-22  
For DNA to function with sequence generality, selections will involve an 
alternation strategy involving different DNA-anchored phosphopeptides in each selection 
round. To improve the catalytic proficiency of the pSer/pThr Lyase deoxyribozymes, 
modified nucleotides with protein-inspired functional groups can be used to augment the 
catalytic prowess of DNA. In protein OspF pThr lyases, lysine acts as a general base in 
proton abstraction. Histidine assists with β-elimination of the phosphate by making it a 
better leaving group. dUTPs with amino allyl and imidazole groups at the C5-
heterocyclic position can be can be used in future selection endeavors.46 Metal cation 
cofactors that bind tightly with phosphate, such as lanthanides, may also permit efficient 
DNA-catalyzed β-elimination of phosphate. For applications in phosphoproteomics, 
DNA catalysts will be required to have excellent Km values while turnover is not 
prohibitive for such applications. Ability of DNA to efficiently recognize the minimal 
epitope of pSer and pThr in any peptidic context/environment would be highly desirable. 
This should be further complemented by an efficient a proton abstraction from the 
peptidic backbone resulting in β-elimination. Two model proteins, chicken ovalbumin 
and β-casein, were arranged for preliminary phosphoproteomics analyses with DhaDz1 
with negligible activity. Newly identified pSer/pThr lyase deoxyribozymes in the future 
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will be directly tested on both full-length protein and digested tryptic fragments from 
these protein samples. 
5.4 Materials and Methods 
5.4.1 Oligonucleotide and Oligonucleotide Conjugates 
DNA oligonucleotides and oligonucleotide conjugates were obtained from 
Integrated DNA Technologies (Coralville, IA) or prepared by solid-phase synthesis on an 
ABI 394 instrument using reagents from Glen Research. All oligonucleotides and 
conjugates were purified by 7 M urea denaturing PAGE with running buffer 1× TBE (89 
mM each Tris and boric acid and 2 mM EDTA, pH 8.3), extracted from the 
polyacrylamide with TEN buffer (10 mM Tris, pH 8.0, 1 mM EDTA, 300 mM NaCl), 
and precipitated with ethanol as described previously.47-48 
Deoxyribozyme sequences were as follows (initially random N40 regions underlined): 
DhaDz1 5′-CGAATTAAGACTGAATTCACAGGTGGCGGATGTAGTTTACCCGTTTTCTGTAGAGCCATAA-
GAAACGAGATATTCC-3′ 
DhaDz2 5′-CGAATTAAGACTGAATTCACAGGATTCAAAGTGGCTGTCAGAAGTTGGTGAGGGAAGATAA-
GAAACGAGATATTCC-3′ 
5.4.2 Synthesis of Peptides and DNA-Anchored Peptides 
All amino acid monomers including those for phosphoserine (pSer, SP), 
homocysteine (Hcy), dehydrobutyrine (Dhb), trifluoroacetyl-lysine (KTfa) and S-
methylcysteine (CysMe, CMe) were obtained from Chem-Impex (Wood Dale, IL). Peptides 
were prepared by solid-phase synthesis using Fmoc Rink amide MBHA resin from 
Chem-Impex, with N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexa-
fluorophosphate (HATU) as coupling agent.49 
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Synthesis of the peptide AAASPAA was performed at 0.2 mmol scale, initiated 
using 260 mg of Rink amide resin with a loading capacity of 0.77 mmol/g. All steps were 
monitored by ninhydrin test. For each coupling, 5 equivalents (1.0 mmol) of Fmoc-amino 
acid, 4.9 equivalents (373 mg, 0.98 mmol) of HATU, and 10 equivalents (350 µL, 2.0 
mmol) of N,N-diisopropylethylamine (DIPEA) were mixed in 5 mL of anhydrous DMF. 
The coupling reaction was initiated by adding this mixture to the resin and agitating by 
bubbling with nitrogen for 60 min, followed by washing with DMF (3 × 10 mL). The N-
terminus of the newly installed amino acid was deprotected by agitating the resin in 20% 
piperidine in DMF (5 mL) under nitrogen for 5 min a total of three times, each time 
washing with DMF (3 × 5 mL). The peptide was cleaved from the solid support by 
stirring the resin in a separate vial with a solution containing 5 mL of trifluoroacetic acid 
(TFA), 125 µL of water, and 50 µL of triisopropylsilane for 90 min. The liquid solution 
was separated from the resin by filtration. This solution was dried on a rotary evaporator, 
providing a solid. To this material 20 mL of cold diethyl ether was added, and the peptide 
was obtained as a white solid that was filtered and purified by HPLC. 
Synthesis of each of the peptides AAACMeAA, AAA(Dhb)AA, Ac-
ISPVWQDWGAHR(Hcy)T (compstatin precursor 1), Ac-I(Hcy)VWQDWGAHRSPT 
(compstatin precursor 2) was performed as described above, with the following 
procedural modifications. Synthesis was performed at 0.1 mmol scale, initiated using 303 
mg of 0.33 mmol/g (Hcy) or 130 mg of 0.77 mmol/g (Dhb or CMe) Rink amide resin. For 
each coupling of a standard amino acid, 5 equivalents (0.5 mmol) of Fmoc-amino acid, 
4.9 equivalents (187 mg, 0.49 mmol) of HATU, and 10 equivalents (175 µL, 1.0 mmol) 
of DIPEA were mixed in 3 mL of anhydrous DMF and agitated with the resin for 60 min. 
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For Fmoc-S-trityl-L-homocysteine (Hcy), Fmoc-α,β-dehydro-2-aminobutyric acid or 
Fmoc-S-methyl-L-cysteine (CMe), 2 equivalents (0.2 mmol) of Fmoc-amino acid, 1.96 
equivalents (75 mg, 0.20 mmol) of HATU, and 4 equivalents (70 µL, 0.4 mmol) of 
DIPEA were mixed in 3 mL of anhydrous DMF and agitated with the resin for 120 min. 
For the step involving deprotection of Fmoc-α,β-dehydro-2-aminobutyric acid, extra care 
was taken to utilize dry solvent to avoid hydrolysis of the enamine.  The compstatin 
peptide was capped via acetylation of its N-terminus by agitating the resin in 50 
equivalents (462 µL, 5 mmol) of acetic anhydride and 25 equivalents of DIPEA (435 µL, 
2.5 mmol) in 5 mL of DMF under nitrogen for 30 min. The peptide was cleaved from the 
solid support by stirring the resin in a separate vial with a solution containing 3 mL of 
TFA, 100 µL of water, 100 µL of ethanedithiol (for compstatin), and 40 µL of 
triisopropylsilane for 90 min. 
The AAASPAA peptide was coupled to the DNA anchor oligonucleotide via the 
N-terminal α-amino group with a linkage created by reductive amination (Figure 5.12A). 
The DNA anchor oligonucleotide was 5′-GGAATATCTCGTTTCTTAT-HEG-rA-3′. This 
sequence includes a hexa(ethylene glycol) [HEG] spacer, which provides structural 
flexibility and may induce the emergent deoxyribozymes to function well with free 
(unanchored) peptide substrates, and a 3′-terminal ribonucleotide, which enables the 
reductive amination process. Coupling of peptide to DNA anchor was performed using 
the previously described procedure.49 pSer/pThr or Dhb-containing peptides were 
similarly coupled to a DNA anchor using reductive amination. For peptides containing 
lysines, the primary amines were protected as Lys-Tfa. After the N-terminal amine was 
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conjugated by reductive amination and purified on gel, Tfa was removed using ammonia 
at 55 °C for 4 h and evaporated to dryness. 
To prepare the DNA-anchored AAA(Dha)AA peptide, a precursor peptide 
incorporating S-methylcysteine, CysMe (CMe), was synthesized. The AAACMeAA peptide 
was conjugated to the 3′-terminal ribonucleotide of the DNA anchor oligonucleotide as 
described above. Then, a 50 µL sample containing 500 pmol of DNA-anchored 
AAACMeAA, 100 mM HEPES, pH 7.5, and 10 mM NaIO4 was incubated at room 
temperature for 1 h to oxidize the thioether to the sulfone. The sulfone product was 
precipitated by addition of 220 µL of water, 30 µL of 3 M NaCl, and 900 µL of ethanol. 
The sulfone product was dissolved in 20 µL of 10 mM NaOH, pH 12.0, and incubated at 
37 °C for 4 h to form the final elimination product, DNA-anchored AAA(Dha)AA. This 
final product was precipitated by addition of 250 µL of water, 30 µL of 3 M NaCl, and 
900 µL of ethanol. MALDI mass spectrometry for DNA-anchored AAACMeAA peptide 
m/z calcd. 6913.9, found 6915.5, ∆ = +0.02%. DNA-anchored AAA(Dha)AA elimination 
product m/z calcd. 6865.8, found 6864.8, ∆ = –0.01%. 
Procedure for validation of Dha capture reaction during in vitro selection process. The 
5′-terminus of the DNA-anchored AAACMeAA precursor peptide was ligated to the 3′-
terminus of the random deoxyribozyme pool using a DNA splint and T4 DNA ligase (see 
Procedure for ligation step, below). The ligated product was oxidized and eliminated as 
described above, forming DNA-anchored AAA(Dha)AA linked to the deoxyribozyme 
pool. A 10 µL sample containing 0.1 pmol of DNA-anchored AAA(Dha)AA linked to the 
pool, 20 pmol of capture splint, and 100 pmol of the short 5′-thiol capture oligonucleotide 
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(n = 0 in Figure 5.12B) in 100 mM Na2CO3, pH 9.2, was incubated at 37 °C for 12 h, 
with result shown in Figure 5.12C. 
5.4.3 In Vitro Selection Procedure 
The selection procedure, cloning, and initial screening of individual clones were 
performed essentially as described previously.49 An overview of the key selection and 
capture steps of each round is shown in Figure 5.4. A depiction of the capture step with 
nucleotide details and validation data is shown in Figure 5.12. The random 
deoxyribozyme pool was 5′-CGAATTAAGACTGAATTC-N40-ATAAGAAACGAGATATAGCTGATCC-
TGATGG-3′. PCR primers were 5′-CGAATTAAGACTGAATTC-3′ (forward primer) and 5′-
(AAC)4XCCATCAGATCAGCT-3′, where X is the HEG spacer to stop Taq polymerase (reverse 
primer). 
 
Figure 5.12. A) Synthesis of DNA-anchored AAASPAA peptide by attachment of the DNA anchor to the 
N-terminal α-amino group, with the linkage created by reductive amination. B) Capture step during in vitro 
selection. C) Validation of the capture reaction using the short 5′-thiol capture oligonucleotide 
(S = substrate, P = product). 
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In each round, the ligation step to attach the deoxyribozyme pool at its 3′-end with 
the 5′-end of the DNA-anchored hexapeptide substrate was performed using a DNA 
splint and T4 DNA ligase. The ligation splint sequence was 5′-
ATAAGAAACGAGATATTCCTCCATCAGGATCAGCTATATCTCGTTTCTTAT-3′, where the underlined 
T is included to account for the untemplated A nucleotide that is added at the 3′-end of 
each PCR product by Taq polymerase. This T nucleotide was omitted from the splint 
used for ligation of the initially random N40 pool, which was prepared by solid-phase 
synthesis without the untemplated A. The length of the capture oligonucleotide was 
alternated between shorter (odd-numbered rounds) and longer (even-numbered rounds), 
to avoid selection of particular DNA sequences that migrate aberrantly at a fixed position 
on the gel. Nucleotide sequences of the DNA anchor oligonucleotide, the deoxyribozyme 
binding arms, the splint oligonucleotide, and the two 5′-thiol capture oligonucleotides are 
shown in Figure 5.12B. 
Procedure for ligation step in round 1. A 34 µL sample containing 1 nmol of DNA pool, 
850 pmol of DNA splint, and 750 pmol of 5′-phosphorylated DNA-hexapeptide substrate 
was annealed in 5 mM Tris, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by heating at 95 
°C for 3 min and cooling on ice for 5 min. To this solution was added 4 µL of 10× T4 
DNA ligase buffer (Fermentas) and 2 µL of 5 U/µL T4 DNA ligase (Fermentas). The 
sample was incubated at 37 °C for 12 h and purified by 8% PAGE. 
Procedure for ligation step in subsequent rounds. A 16 µL sample containing the PCR-
amplified DNA pool (~5–10 pmol), 25 pmol of DNA splint, and 50 pmol of 5′-
phosphorylated DNA-hexapeptide substrate was annealed in 5 mM Tris, pH 7.5, 15 mM 
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NaCl, and 0.1 mM EDTA by heating at 95 °C for 3 min and cooling on ice for 5 min. To 
this solution was added 2 µL of 10× T4 DNA ligase buffer (Fermentas) and 2 µL of 1 
U/µL T4 DNA ligase (Fermentas). The sample was incubated at 37 °C for 12 h and 
purified by 8% PAGE. 
Procedure for selection step in round 1. The selection experiment was initiated with 200 
pmol of the ligated N40 pool. A 20 µL sample containing 200 pmol of ligated N40 pool 
was annealed in 5 mM HEPES, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by heating at 
95 °C for 3 min and cooling on ice for 5 min. The selection reaction was initiated by 
bringing the sample to 40 µL total volume containing 70 mM HEPES, pH 7.5, 1 mM 
ZnCl2, 20 mM MnCl2, 40 mM MgCl2, and 150 mM NaCl. The sample was incubated at 
37 °C for 14 h. 
Procedure for selection step in subsequent rounds. A 10 µL sample containing ligated 
pool was annealed in 5 mM HEPES, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by 
heating at 95 °C for 3 min and cooling on ice for 5 min. The selection reaction was 
initiated by bringing the sample to 20 µL total volume containing 70 mM HEPES, pH 
7.5, 1 mM ZnCl2, 20 mM MnCl2, 40 mM MgCl2, and 150 mM NaCl. The sample was 
incubated at 37 °C for 14 h. 
Procedure for preparation of 5′-thiol capture oligonucleotide. The 5′-thiol capture 
oligonucleotide (short or long version as appropriate; Figure 5.12B) was prepared by 
DTT reduction of the precursor oligonucleotide (prepared using the Glen Research thiol 
modifier C6 S-S) immediately prior to each use. A 50 µL sample containing 2 to 5 nmol 
of precursor oligonucleotide in 100 mM HEPES, pH 7.5, and 25 mM DTT was incubated 
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at 37 °C for 2 h. To remove excess DTT, the sample was precipitated by adding 220 µL 
of water, 30 µL of 3 M NaCl, and 900 µL of ethanol. 
Procedure for capture step in round 1. To the 40 µL selection sample was added 6 µL of 
0.5 M EDTA, pH 8.0 (3 µmol). The DNA was precipitated by adding 224 µL of water, 
30 µL of 3 M NaCl, and 900 µL of ethanol. The sample was then brought to 40 µL total 
volume containing 300 pmol of capture splint, and 500 pmol of short 5′-thiol capture 
oligonucleotide in 100 mM Na2CO3, pH 9.2 and incubated at 37 °C for 12 h. The sample 
was loaded directly on 8% PAGE. 
Procedure for capture step in subsequent rounds. To the 20 µL selection sample was 
added 3 µL of 0.5 M EDTA, pH 8.0 (1.5 µmol). The DNA was precipitated by adding 
247 µL of water, 30 µL of 3 M NaCl, and 900 µL of ethanol. The sample was then 
brought to 10 µL total volume containing 20 pmol of capture splint, and 100 pmol of the 
appropriate 5′-thiol capture oligonucleotide (long for even-numbered rounds, short for 
odd-numbered rounds) in 100 mM Na2CO3, pH 9.2 and incubated at 37 °C for 12–14 h. 
The sample was loaded directly on 8% PAGE. 
Procedure for PCR. In each selection round, two PCR reactions were performed, 10-
cycle PCR followed by 30-cycle PCR. First, a 100 µL sample was prepared containing 
the PAGE-purified selection product, 200 pmol of forward primer, 50 pmol of reverse 
primer, 20 nmol of each dNTP, and 10 µL of 10× Taq polymerase buffer (1× = 20 mM 
Tris-HCl, pH 8.8, 10 mM (NH4)2SO4, 10 mM KCl, 2 mM MgSO4, and 0.1% Triton X-
100). This sample was cycled 10 times according to the following PCR program: 94 °C 
for 2 min, 10× (94 °C for 30 s, 47 °C for 30 s, 72 °C for 30 s), 72 °C for 5 min. Taq 
polymerase was removed by phenol/chloroform extraction. Second, a 50 µL sample was 
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prepared containing 1 µL of the 10-cycle PCR product, 100 pmol of forward primer, 25 
pmol of reverse primer, 10 nmol of each dNTP, 20 µCi of α-32P-dCTP (800 Ci/mmol), 
and 5 µL of 10× Taq polymerase buffer. This sample was cycled 30 times according to 
the following PCR program: 94 °C for 2 min, 30× (94 °C for 30 s, 47 °C for 30 s, 72 °C 
for 30 s), 72 °C for 5 min. Samples were separated by 8% PAGE. The forward and 
reverse single-stranded PCR products were separable because formation of the reverse 
product was initiated using the reverse primer, which contains a nonamplifiable spacer 
that stops Taq polymerase. 
Procedure for cloning and initial screening. Using 1 µL of a 1:1000 dilution of the 10-
cycle PCR product from selection round 9, 25-cycle PCR was performed using the 
analogous procedure as described above for 30-cycle PCR, omitting α-32P-dCTP and 
using primers 5′-CGAATTAAGACTGAATTC-3′ (forward primer, 25 pmol) and 5′-
TAATTAATTAATTACCCATCAGGATCAGCT-3′ (reverse primer, 25 pmol), where the extensions 
with TAA stop codons in each frame were included to suppress false negatives in blue-
white screening.50 The PCR product was purified on 2% agarose and cloned using a 
TOPO TA cloning kit (Invitrogen). Initial screening of individual deoxyribozyme clones 
was performed using DNA strands prepared by PCR from miniprep DNA derived from 
individual E. coli colonies. The miniprep DNA samples were first assayed by digestion 
with EcoRI to ascertain the presence of the expected insert. The concentration of each 
PAGE-purified deoxyribozyme strand was estimated from the UV shadowing intensity 
relative to suitable standards. Each screening assay used ~0.1 pmol of 5′-32P-radiolabeled 
DNA-anchored AAASPAA substrate and at least 20 pmol of deoxyribozyme in the 
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single-turnover assay procedure described in a subsequent section of this document (here 
using 1.0 mM ZnCl2). 
5.4.4 Selection Progression 
In vitro selection was also performed with 30-nucleotide and 50-nucleotide 
random regions (JG1 and JK1 respectively). The DNA anchored oligonucleotide lacked 
the HEG-type tether. Activity was observed in round 8 for JG1. However, the sequences 
were inactive when individual clones were screened suggesting that the activity depends 
on the loop formed by the T4 DNA ligase. No activity was obtained for JK1 and both 
these selections were not pursued any further. 
5.4.5 Single-Turnover Procedure Assay 
The 5′-end of DNA-anchored AAASPAA was radiolabeled using γ-32P-ATP and 
Optikinase (USB), which lacks the 3′-phosphatase activity that we observed also 
dephosphorylates the pSer side chain. A 10 µL sample containing 0.1 pmol of 5′-32P-
radiolabeled DNA-anchored AAASPAA and 20 pmol of deoxyribozyme was annealed in 
5 mM HEPES, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by heating at 95 °C for 3 min 
and cooling on ice for 5 min. The DNA-catalyzed reaction was initiated by bringing the 
sample to 20 µL total volume containing 70 mM HEPES, pH 7.5, 1.5 or 2.0 mM ZnCl2 if 
included, 20 mM MnCl2 if included, 40 mM MgCl2 if included, and 150 mM NaCl, and 
the sample was incubated at 37 °C. Note that the Zn2+ concentration was carefully 
optimized for each deoxyribozyme. At appropriate time points, 2 µL aliquots were 
quenched with 5 µL stop solution (80% formamide, 1× TBE [89 mM each Tris and boric 
acid and 2 mM EDTA, pH 8.3], 50 mM EDTA, 0.025% bromophenol blue, 0.025% 
xylene cyanol). Samples were separated by 20% PAGE and quantified with a 
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PhosphorImager. Values of kobs were obtained by fitting the yield versus time data 
directly to first-order kinetics; i.e., yield = Y•(1 – e–kt), where k = kobs and Y is the final 
yield. Each kobs value is reported with error calculated as the standard deviation from the 
indicated number of independent determinations. 
5.4.6 Multiple-Turnover Assay Procedure with Malachite Green Dye 
A 20 µL sample containing 2 nmol of deoxyribozyme, 2.5 nmol of free DNA 
anchor oligonucleotide, and 80 nmol of AAASPAA hexapeptide in 70 mM HEPES, pH 
7.5, 6 or 8 mM ZnCl2 as appropriate, 20 mM MnCl2, 40 mM MgCl2, and 150 mM NaCl 
was incubated at 37 °C. Note that the Zn2+ concentration was carefully optimized for 
each deoxyribozyme. At each time point (0–96 h), 2 µL of the sample was frozen on dry 
ice and stored at –80 °C until further processing. To the sample was added 98 µL of 
water and 20 µL of malachite green assay solution (BioAssay Systems POMG-25H). 
After incubation at room temperature for 30 min, the sample was diluted with 180 µL of 
water, and the absorbance at 620 nm was measured (NanoDrop 2000c, Thermo 
Scientific). Standard curves for inorganic phosphate (Pi) were obtained using solutions 
containing known amounts of Pi and all other assay components with 2 nmol of an 
unrelated, catalytically inactive 74 nt DNA oligonucleotide instead of the 
deoxyribozyme. Numbers of turnovers were calculated directly from the ratio of mole 
amounts of released Pi and deoxyribozyme. 
5.4.7 Multiple-Turnover Assay Procedure with LC-MS 
A 20 µL sample containing 2 nmol of deoxyribozyme, 2.5 nmol of free DNA 
anchor oligonucleotide, and 80 nmol of peptide in 70 mM HEPES, pH 7.5, 6 or 8 mM 
ZnCl2 (optimized), 20 mM MnCl2, 40 mM MgCl2, and 150 mM NaCl was incubated at 
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37 °C for 96 h. To remove the deoxyribozyme before LC-MS analysis, a filtration step 
was performed. An Amicon Ultra-0.5 mL 3 kDa centrifugal filter (EMD Millipore) was 
washed with 400 µL of water by centrifugation at 14000 × g for 10 min. To the sample 
was added 400 µL water, and the combined solution was transferred to the filter, which 
was centrifuged at 14000 × g for 20 min. Another 400 µL of water was passed through 
the filter at 14000 × g for 20 min. Finally, 400 µL of 5% aqueous acetonitrile was passed 
through the filter at 14000 × g for 20 min. The combined filtrates were evaporated to 
dryness, and redissolved in 40 µL of water. The sample was analyzed by LC-MS on an 
Acquity UPLC instrument with a Phenomenex Jupiter C18 column (5 µm, 0.1 × 150 mm) 
attached to an electrospray ionization mass spectrometer (Q-TOF Synapt-G1 Waters in 
positive ion scan mode using the manufacturer’s suggested parameters) and an isocratic 
gradient of 1% solvent A (0.1% formic acid in acetonitrile) and 99% solvent B (0.1% 
formic acid in water) at 0.18 mL/min for 10 min. 
5.4.8 Procedure for Compstatin Peptide 
A 20 µL sample containing 2 nmol of deoxyribozyme, 2.5 nmol of free DNA 
anchor oligonucleotide, and 1 nmol of peptide in 70 mM HEPES, pH 7.5, 4 mM ZnCl2 
(optimized), 20 mM MnCl2, 40 mM MgCl2, and 150 mM NaCl was incubated at 37 °C 
for 96 h. The sample was quenched with 3 µL of 0.5 M EDTA, pH 8.0. To reverse 
formation of potential peptide disulfide dimers, 4 µL of 1 mM tris(2-
carboxyethylphosphine) (TCEP; 4 nmol) was added, and the sample was incubated at 25 
°C for 15 min. Because compstatin does not pass well through the Amicon filter, the 
deoxyribozyme was not removed by filtration. The sample was analyzed by HPLC on a 
Beckman System Gold instrument with a Phenomenex Kinetex C18 column (2.6 µm, 
164 
 
4.6 × 150 mm) and a gradient of 15% solvent A (acetonitrile) and 85% solvent B (0.1% 
trifluoroacetic acid in water) at 0 min to 30% solvent A and 70% solvent B at 60 min 
with flow rate of 0.5 mL/min. 
The HPLC-purified intermediate was cyclized by base treatment. The 
intermediate was evaporated to dryness, redissolved in 40 µL of 100 mM Tris, pH 8.0, 
and incubated at 25 °C for 4 h (shorter times not attempted). The sample was analyzed by 
HPLC as above. 
5.4.9 Mass Spectrometry Procedure 
To prepare the DNA-anchored AAA(Dha)AA using a deoxyribozyme, a 10 µL 
sample containing 50 pmol of DNA-anchored AAASPAA substrate and 100 pmol of 
DhaDz1 (or DhaDz2) was annealed in 5 mM HEPES, pH 7.5, 15 mM NaCl, and 0.1 mM 
EDTA by heating at 95 °C for 3 min and cooling on ice for 5 min. The DNA-catalyzed 
elimination reaction was initiated by bringing the sample to 20 µL total volume 
containing 70 mM HEPES, pH 7.5, 1.5 mM ZnCl2 (or 2.0 mM ZnCl2), 20 mM MnCl2, 40 
mM MgCl2, and 150 mM NaCl. The sample was incubated at 37 °C for 16 h and 
quenched with 5 µL of 0.5 M EDTA, pH 8.0 (2.5 µmol), desalted by Millipore C18 
ZipTip, and analyzed by MALDI mass spectrometry. Data were acquired on a Bruker 
UltrafleXtreme MALDI-TOF mass spectrometer with matrix 3-hydroxypicolinic acid in 
positive ion mode at the UIUC School of Chemical Sciences Mass Spectrometry 
Laboratory (instrument purchased with support from NIH S10RR027109A). 
For the MALDI mass spectrometry analyses of Figure 5.9C, the HPLC-purified 
precursor, intermediate, or product was evaporated to dryness, redissolved in a total 
volume of 40 µL containing 100 mM Tris, pH 8.0, 25 mM IAA, and 100 µM TCEP, and 
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incubated at 25 °C for 2 h in the dark. The sample was desalted and analyzed by MALDI 
mass spectrometry as described above, except with 2,5-dihydroxybenzoic acid as matrix. 
5.4.10 Addressing Long 5′-thiol Capture Yield 
A 34 µL sample containing 2 nmol of 5′-thiol capture oligonucleotide (short), 2.5 
nmol of the splint oligonucleotide 5′-TATCAGTATATGCGATGCTTCCGTCGCCATCTCTTCC-
3′, and 3 nmol of 5′-phosphorylated 5′-AGCATCGCATATACTGATAAACAACAACAACAACAAC-
3′ was annealed in 5 mM Tris, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by heating at 95 
°C for 3 min and cooling on ice for 5 min. To this solution was added 4 µL of 10× T4 
DNA ligase buffer (Fermentas) and 2 µL of 5 U/µL T4 DNA ligase (Fermentas). The 
sample was incubated at 37 °C for 12 h and purified by 12% PAGE to obtain the long 5′-
thiol capture oligonucleotide. The sample was treated with DTT (as mentioned earlier) 
prior to capture use.  
5.4.11 Procedure for Analysis of Heptapeptides by MALDI for Sequence Generality 
Heptapeptides used for studying sequence generality had the following sequences. 
Lantibiotic component cytolysin CylLL′′ was Val-Val-Val-pSer-Leu-Lys-His, inhibitor of 
HIV replication T22 was Lys-Tyr-Arg--pSer-Tyr-Lys-Gly, the α7 nAChR antagonist 
conotoxin ImI was Asp-Pro-Arg-pSer-Ala-Trp-Arg and the lantibiotic lacticin 481 was 
Asn-Met-Asn-pSer-Trp-Gln-Phe. These sequences were purified by HPLC. 
A 20 µL sample containing 2 nmol of deoxyribozyme, 2.5 nmol of free DNA 
anchor oligonucleotide, and 1 nmol of peptide in 70 mM HEPES, pH 7.5, X mM ZnCl2 
(optimized), 20 mM MnCl2, 40 mM MgCl2, and 150 mM NaCl was incubated at 37 °C 
for 96 h. An Amicon Ultra-0.5 mL 3 kDa centrifugal filter (EMD Millipore) was washed 
with 400 µL of water by centrifugation at 14000 × g for 10 min. To the sample was added 
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400 µL water, and the combined solution was transferred to the filter, which was 
centrifuged at 14000 × g for 20 min. Another 400 µL of water was passed through the 
filter at 14000 × g for 20 min. Finally, 400 µL of 5% aqueous acetonitrile was passed 
through the filter at 14000 × g for 20 min. The combined filtrates were evaporated to 
dryness. The samples were desalted by desalted by Millipore C18 ZipTip, and analyzed by 
MALDI mass spectrometry.  
5.4.12 Proof-of-concept for Phosphoproteomics 
Procedure for trypsin digestion. 5 mg of Chicken Ovalbumin (Sigma A5503) was re-
suspended in 500 µL solution containing  100 mM Tris, pH 8.0, 6 M urea, 5 M DTT and 
incubated at 37 °C for 60 min.  Similar procedure was carried separately for β-casein 
(Sigma C6905). The sequence identities of these proteins are well established (Figure 
5.13). After 60 minutes, a 3 mL solution containing 100 mM Tris, pH 8.0 was added to 
bring the final concentration of urea to 1 M. To this sample was added 2.5 µL of 100 ng/ 
µL of Trypsin (Promega V5111). The final protein:trypsin ratio has to be 20:1 (wt/wt) to 
for optimal digestion. The sample was incubated at 37 °C for 24 h. 200 µL of formic acid 
was added to bring the final pH ≤ 4.  
For trypsin-digested sample, Sep-Pak C18 (WAT023501) was used to remove the 
excess urea and DTT. The column was initially equilibrated with 1 mL of 50% 
acetonitrile (ACN). Then 5 mL of 1% ACN with 0.1% formic acid was passed through 
the column. Digested sample was introduced in the column and washed with additional 5 
mL of 1% ACN with 0.1% formic acid to enable complete removal of urea and DTT. 
Digested peptide sample was then eluted with 1 mL of 50% ACN in 0.1% TFA and 1mL 
of 90% ACN in 0.1% TFA. The elution sample was evaporated to dryness and 
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resuspended in 500 µ of water to prepare a solution of digested product containing 1 
mg/mL sample.   
Procedure for treatment with alkaline phosphatase and malachite green assay. 1 nmol of 
the full-length protein or the digested fragments was evaporated to dryness and incubated 
with 1 U of CIAP (Fermentas) in 10 µL of 1× CIAP buffer (10 mM Tris, pH 7.5, 10 mM 
MgCl2) at 37 °C for 12 h. The sample was heated at 95 °C for 5 min and cooled on ice 
for 10 min to inactivate the CIAP. The sample was investigated with malachite green 
assay (see malachite green assay procedure in section 5.4.6) to determine the amount of 
phosphorylation in nanomoles.  
A 20 µL sample containing 2 nmol of deoxyribozyme, 2.5 nmol of free DNA 
anchor oligonucleotide, and 1 nmol of tryptic peptides or the full-length protein (based on 
the amount of phosphorylation) in 70 mM HEPES, pH 7.5, X mM ZnCl2 (2, 3, 4, 5, 6, 7 
and 8 mM), 20 mM MnCl2, 40 mM MgCl2, and 150 mM NaCl was incubated at 37 °C for 
96 h. Negligible activity was observed with DhaDz1 by the malachite green assay. 
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Figure 5.13. Sequences of full-length proteins are depicted in this figure. Yellow region indicates 
phosphorylation sites. Blue highlight indicates glycosylation and green indicates N-terminal acetylation. A) 
Chicken ovalbumin. B) β-casein. 
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Table 5.1. Mass spectrometry of the peptides used in this study. A) MALDI data in black (monoisotopic). 
B) ESI-MS data in red (average). All the masses indicated as [M+H]+. 
 
Peptide mass 
calcd. 
mass 
found 
Cytolysin (pSer) 860.6 860.5 
Cytolysin (Dha) 762.7 762.6 
T22 (pSer) 981.0 981.0 
T22 (Dha) 893.0 893 
Conopeptide (pSer) 966.6 966.5 
Conopeptide (Dha) 868.6 868.5 
Lacticin (pSer) 1005.7 1005.4 
Lacticin (Dha) 987.7 na 
AAAS
P
AA 540.5 540.5 
AAAT
P
AA 554.5 555.2 
AKKS
P
KKA (Tfa-protected) 1224.0 1225.0 
AKKT
P
KKA (Tfa-protected) 1238 1237.4 
AEES
P
EEA 843.7 844.3 
AEET
P
EEA 857.7 857.3 
AFFS
P
FFA 915.9 915.4 
AFFT
P
FFA 929.9 929.4 
GIT
P
PVAF 783.8 783.4 
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